425

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

February 8, 2024

Date of Report (Date of earliest event reported)

Healthpeak Properties, Inc.

(Exact name of registrant as specified in its charter)

Maryland	001-08895	33-0091377
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

4600 South Syracuse Street, Suite 500

Denver, CO 80237

(Address of principal executive offices) (Zip Code)

(720) 428-5050

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

x Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $1.00 par value	PEAK	New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 2.02 Results of Operations and Financial Condition.

On February 8, 2024, Healthpeak Properties, Inc., a Maryland corporation (“Healthpeak”), issued a press release setting forth its financial results for the fourth quarter and year ended December 31, 2023. The press release refers to the Discussion and Reconciliation of Non-GAAP Financial Measures, which is available in the Investor Relations section of Healthpeak’s website, free of charge, at http://ir.healthpeak.com/quarterly-results. The press release and Discussion and Reconciliation of Non-GAAP Financial Measures are furnished herewith as Exhibits 99.1 and 99.3, respectively, and are incorporated by reference herein.

The information set forth in this Item 2.02 of this Current Report on Form 8-K and the related information in Exhibits 99.1 and 99.3 attached hereto are being furnished herewith, and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference in any filing with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference therein.

Item 7.01 Regulation FD Disclosure.

A supplemental report containing financial results and related information of Healthpeak for the fourth quarter and year ended December 31, 2023 is furnished as Exhibit 99.2 hereto and incorporated by reference herein. The supplemental report is also available in the Investor Relations section of Healthpeak’s website, free of charge, at http://ir.healthpeak.com/quarterly-results.

The information set forth in this Item 7.01 of this Current Report on Form 8-K and the related information in Exhibit 99.2 attached hereto is being furnished herewith, and shall not be deemed filed for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, and shall not be incorporated by reference in any filing with the Securities and Exchange Commission under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference therein.

Item 9.01 Financial Statements and Exhibits.

(d)         Exhibits.  The following exhibits are being furnished herewith:

No.	Description
99.1	Press Release dated February 8, 2024.
99.2	December 31, 2023, Supplemental Report.
99.3	December 31, 2023, Discussion and Reconciliation of Non-GAAP Financial Measures.
104	Cover Page Interactive Data File (embedded within the inline XBRL document and contained in Exhibit 101).

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: February 8, 2024
	Healthpeak Properties, Inc.
	By:	/s/ Peter A. Scott
		Peter A. Scott
		Chief Financial Officer

3

EX-99.1

Exhibit 99.1

Healthpeak Properties Reports Fourth Quarter and Year Ended 2023 Results

DENVER, February 8, 2024 - Healthpeak Properties, Inc. (NYSE: PEAK), a leading owner, operator, and developer of real estate for healthcare discovery and delivery, today announced results for the fourth quarter and full-year ended December 31, 2023.

FOURTH QUARTER 2023 FINANCIAL PERFORMANCE AND RECENT HIGHLIGHTS

– Net income of $0.13 per share, Nareit FFO of $0.48 per share, FFO as Adjusted of $0.46 per share, AFFO of $0.36 per share, and Total Same-Store Portfolio Cash (Adjusted) NOI growth of 3.6%

– Fourth quarter new and renewal lease executions totaled 1.1 million square feet:

· Outpatient Medical new and renewal lease executions totaled 743,000 square feet

· Lab new and renewal lease executions totaled 312,000 square feet

· Year-to-date 2024 Lab lease executions of 58,000 square feet with an additional 115,000 square feet under signed LOI

– Received entitlements for an additional 1.3 million square feet of lab development at the Vantage campus in South San Francisco

– Commenced two on-campus outpatient developments in our HCA Healthcare ("HCA") development program

– Entered into a new $236 million joint venture through the sale of a 65% interest in the Callan Ridge lab campus in the Torrey Pines submarket of San Diego in January 2024

– Net Debt to Adjusted EBITDAre was 5.2x for the quarter ended December 31, 2023

FULL-YEAR 2023 HIGHLIGHTS

– Net income of $0.56 per share, Nareit FFO of $1.79 per share, FFO as Adjusted of $1.78 per share, AFFO of $1.53 per share, and Total Same-Store Portfolio Cash (Adjusted) NOI growth of 4.8%

– Portfolio leasing summary:

· Full-year outpatient lease executions totaled 4.1 million square feet, with +4% cash releasing spreads on renewals

· Full-year lab lease executions totaled 985,000 square feet, with +23% cash releasing spreads on renewals

– Development highlights:

· 2023 completions and new starts:

· Nexus on Grand: Delivered the fully leased, 148,000 square foot, $161 million lab building in South San Francisco

· Vantage: Delivered the fully leased, 154,000 square foot, $201 million first building of Phase I in South San Francisco

· Callan Ridge: Completed core and shell work and delivered the space to the tenant for T.I. build out; the fully leased development in Torrey Pines totals 185,000 square feet with an expected total development cost of $146 million

· HCA Development Program: Commenced construction on two new outpatient developments totaling 192,000 square feet with total expected development costs of $90 million

· Land bank and future developments:

· In September 2023, the Cambridge City Council unanimously approved a comprehensive rezoning to allow for greater density and developable heights in the West Cambridge neighborhood of Alewife where Healthpeak owns a total of 39 acres

· In December 2023, Healthpeak received entitlements for an additional 1.3 million square feet of lab development at the Vantage campus

Page 1

– Issued $750 million of senior unsecured notes at blended yield of approximately 5.35% and weighted average initial maturity of approximately 10 years

– Sold $130 million of non-core properties at an average trailing cash yield of 5.4% and received $205 million of seller financing and other loan repayments

– 2023 sustainability and responsible business recognitions include:

· Received a Green Star rating from the Global Real Estate Sustainability Benchmark (GRESB) and named a constituent in the FTSE4Good Index for the twelfth consecutive year

· Named to CDP's Leadership band for the eleventh consecutive year, named a constituent in the S&P Global Dow Jones Sustainability N. America Index for the eleventh consecutive year and World Index for the fourth time; and named to the S&P Global Sustainability Yearbook for the ninth consecutive year

· Named an ENERGY STAR Partner of the Year for the third time

· Named to Newsweek’s America’s Most Responsible Companies list for the fifth consecutive year

· Named Winner for Best Proxy Statement (Mid Cap), and Finalist for Best ESG Reporting (Small to Mid Cap) by IR Magazine and Governance Intelligence

· Certified a Great Place to Work for the fourth consecutive year; included in The Tennessean Top Workplaces for the second consecutive year; and a Middle Tennessee Top Workplace for the first time

· Included in Fortune's Best Workplaces in Real Estate list for the second consecutive year

To learn more about Healthpeak's commitment to responsible business and view our 2022 ESG Report, please visit www.healthpeak.com/ESG.

FOURTH QUARTER COMPARISON

	Three Months Ended December 31, 2023				Three Months Ended December 31, 2022
(in thousands, except per share amounts)	Amount		Per Share		Amount		Per Share
Net income, diluted	$	70,787	$	0.13	$	6,388	$	0.01
Nareit FFO, diluted		263,810		0.48		192,158		0.35
FFO as Adjusted, diluted		252,639		0.46		238,744		0.44
AFFO, diluted		196,622		0.36		194,414		0.36

FULL-YEAR COMPARISON

	Year Ended December 31, 2023				Year Ended December 31, 2022
(in thousands, except per share amounts)	Amount		Per Share		Amount		Per Share
Net income, diluted	$	304,284	$	0.56	$	497,792	$	0.92
Nareit FFO, diluted		994,574		1.79		904,573		1.66
FFO as Adjusted, diluted		987,708		1.78		950,259		1.74
AFFO, diluted		847,358		1.53		790,296		1.45

Nareit FFO, FFO as Adjusted, AFFO, Same-Store Cash (Adjusted) NOI, and Net Debt to Adjusted EBITDAre are supplemental non-GAAP financial measures that we believe are useful in evaluating the operating performance and financial position of real estate investment trusts (see the "Funds From Operations" and "Adjusted Funds From Operations" sections of this release for additional information). See "December 31, 2023 Discussion and Reconciliation of Non-GAAP Financial Measures" for definitions, discussions of their uses and inherent limitations, and reconciliations to the most directly comparable financial measures calculated and presented in accordance with GAAP in the Investor Relations section of our website at http://ir.healthpeak.com/quarterly-results.

Page 2

SAME-STORE ("SS") OPERATING SUMMARY

The table below outlines the year-over-year three-month and full-year SS Cash (Adjusted) NOI growth.

Year-Over-Year Total SS Portfolio Cash (Adjusted) NOI Growth
	Three Month						Full Year
	SS Growth %			% of SS			SS Growth %			% of SS
Lab		2.7	%		47.1	%		3.7	%		46.6	%
Outpatient Medical		4.3	%		41.4	%		3.4	%		42.0	%
CCRC		4.7	%		11.5	%		15.6	%		11.5	%
Total Portfolio		3.6	%		100.0	%		4.8	%		100.0	%

Page 3

CALLAN RIDGE LAB CAMPUS JOINT VENTURE SALE

As previously announced, in January 2024, Healthpeak formed a new strategic joint venture with Breakthrough Properties (“Breakthrough”) through a sale of a 65% interest in Healthpeak’s fully leased Callan Ridge lab campus in the Torrey Pines submarket of San Diego.

The formation of the 65% Breakthrough / 35% Healthpeak joint venture values Callan Ridge at $236 million, or $1,275 per square foot, and represents a stabilized cash capitalization rate of 5.3% based on the initial annual rental rate of approximately $67 per square foot. At closing, net proceeds to Healthpeak were approximately $130 million. Additionally, the formation of the joint venture reduces Healthpeak's future tenant improvement funding by approximately $20 million.

Healthpeak began construction on the 185,000 square foot Callan Ridge campus in 2021. The two-building campus is fully leased to Turning Point Therapeutics, Inc., a subsidiary of Bristol-Myers Squibb Company (NYSE: BMY), through April 2035.

DEVELOPMENT UPDATES

VANTAGE ENTITLEMENTS

As previously announced, in December 2023, Healthpeak received entitlements for an additional 1.3 million square feet of lab space at the Vantage campus, bringing the combined campus to approximately 1.7 million square feet upon full build out. The additional entitlements represent double the allowable density compared to when Healthpeak originally acquired the land. The long-term nature of the entitlements offers flexibility to deliver the balance of the development in phases to align with market demand.

Strategically located in the heart of South San Francisco and at the doorstep of Genentech’s headquarters, the 20-acre purpose-built lab campus offers tenants a highly amenitized, world-class campus setting with access to multiple modes of transportation including direct access to the Rails-to-Trails pathway, which provides a pedestrian connection to downtown South San Francisco's restaurant and retail corridor, as well as the Caltrain station, which recently completed a multi-year renovation.

Healthpeak is South San Francisco's largest investor-owned landlord with a portfolio that encompasses 4.9 million square feet, including some the submarket's most desirable campuses including The Cove, Portside at Oyster Point, The Shore, Vantage, and Pointe Grand, among others.

OUTPATIENT DEVELOPMENT PROGRAM WITH HCA

During the fourth quarter, Healthpeak added two on-campus outpatient developments with total expected development costs of $90 million to its program with HCA.

· Galen Aurora: 72,000 square foot Class A medical training facility located on HCA’s Medical Center of Aurora hospital campus, a 325-bed acute care hospital in Denver, CO where Healthpeak currently owns three on-campus buildings totaling approximately 165,000 square feet. HCA nursing and professional education affiliates have pre-leased 100% of the development.

· McKinney Medical Center: 120,000 square foot Class A outpatient building on the campus of HCA's Medical City McKinney campus, a 281-bed acute care hospital in McKinney, TX where Healthpeak currently owns two on-campus buildings totaling approximately 120,000 square feet. HCA affiliates have pre-leased approximately 62% of the development for future outpatient services, including oncology, orthopedic, cardiology, wound care, imaging, and other services.

Since 2019, Healthpeak’s development program with HCA has delivered 9 outpatient buildings totaling 785,000 square feet with total development costs of approximately $235 million and is under construction on an additional three buildings totaling 262,000 square feet with total expected development costs of $121 million.

MERGER WITH PHYSICIANS REALTY TRUST AND TERM LOAN UPDATE

As previously announced on October 30, 2023, Healthpeak and Physicians Realty Trust entered into a definitive agreement to combine in an all-stock merger of equals. Each company will hold its respective special meeting of stockholders on February 21, 2024. Subject to Physicians Realty Trust's stockholders approving the proposed merger and Healthpeak's stockholders approving the issuance of Healthpeak common stock in connection with the proposed merger, among other matters, as well as the satisfaction or waiver of customary closing conditions, the transaction is expected to close on March 1, 2024.

Page 4

Additionally, Healthpeak expects to enter into a new $750 million 5-year unsecured term loan. Proceeds from the term loan are expected to fund the repayment of $210 million of Physicians Realty Trust private placement notes and to be used for general corporate purposes, including transaction costs and repayment of borrowings under Healthpeak's credit facility and commercial paper program. Healthpeak has entered into forward-starting swap agreements to fix the interest rate of the new term loan at approximately 4.5% for the full 5-year term of the loan.

DIVIDEND

On January 31, 2024, Healthpeak's Board declared a quarterly common stock cash dividend of $0.30 per share to be paid on February 26, 2024, to stockholders of record as of the close of business on February 14, 2024.

2024 OUTLOOK

For full year 2024, we have established the following outlook ranges, which are inclusive of the impact from the Physicians Realty Trust merger:

· Diluted earnings per common share of $0.07 – $0.13

· Diluted Nareit FFO per share of $1.54 – $1.60

· Diluted FFO as Adjusted per share of $1.73 – $1.79

· Diluted AFFO per share of $1.50 – $1.56

· Total Portfolio Same-Store Cash (Adjusted) NOI growth of 2.25% – 3.75%

This outlook assumes the merger with Physicians Realty Trust closes on March 1, 2024. These estimates are based on our view of existing market conditions, transaction timing, and other assumptions for the year ending December 31, 2024. Additionally, the outlook includes estimates for certain merger-related accounting adjustments, which will not be finalized until after the merger closes. For additional details and assumptions underlying this outlook, please see page 40 in our corresponding Supplemental Report and the Discussion and Reconciliation of Non-GAAP Financial Measures, both of which are available in the Investor Relations section of our website at http://ir.healthpeak.com.

Page 5

CONFERENCE CALL INFORMATION

Healthpeak has scheduled a conference call and webcast for Friday, February 9, 2024, at 8:00 a.m. Mountain Time.

The conference call can be accessed in the following ways:

· Healthpeak’s website: https://ir.healthpeak.com/news-events

· Webcast: https://events.q4inc.com/attendee/292488797. Joining via webcast is recommended for those who will not be asking questions.

· Telephone: The participant dial-in number is (800) 715-9871.

An archive of the webcast will be available on Healthpeak's website through February 7, 2025, and a telephonic replay can be accessed through February 15, 2024, by dialing (800) 770-2030 and entering conference ID number 58822.

ABOUT HEALTHPEAK

Healthpeak Properties, Inc. is a fully integrated real estate investment trust (REIT) and S&P 500 company. Healthpeak owns, operates and develops high-quality real estate for healthcare discovery and delivery.

FORWARD-LOOKING STATEMENTS

Statements contained in this release that are not historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, among other things, statements regarding our and our officers' intent, belief or expectation as identified by the use of words such as "may," "will," "project," "expect," "believe," "intend," "anticipate," "seek," "target," "forecast," "plan," "potential," "estimate," "could," "would," "should" and other comparable and derivative terms or the negatives thereof. Examples of forward-looking statements include, among other things: (i) statements regarding timing, outcomes and other details relating to current, pending or contemplated acquisitions, dispositions, transitions, developments, redevelopments, densifications, joint venture transactions, leasing activity and commitments, financing activities, or other transactions discussed in this release, including statements regarding our proposed merger with Physicians Realty Trust; (ii) the payment of a quarterly cash dividend; and (iii) the information presented under the heading "2024 Outlook." Pending acquisitions, dispositions, joint venture transactions, leasing activity, and financing activity, including those subject to binding agreements, remain subject to closing conditions and may not be completed within the anticipated timeframes or at all. Forward-looking statements reflect our current expectations and views about future events and are subject to risks and uncertainties that could significantly affect our future financial condition and results of operations. While forward-looking statements reflect our good faith belief and assumptions we believe to be reasonable based upon current information, we can give no assurance that our expectations or forecasts will be attained. Further, we cannot guarantee the accuracy of any such forward-looking statement contained in this release, and such forward-looking statements are subject to known and unknown risks and uncertainties that are difficult to predict. These risks and uncertainties include, but are not limited to: macroeconomic trends, including inflation, interest rates, labor costs, and unemployment; risks associated with the proposed merger transactions with Physicians Realty Trust (the “Mergers”), including, but not limited to, our ability to consummate the Mergers on the proposed terms or on the anticipated timeline, or at all, potential loss or disruption of current and prospective commercial relationships due to the uncertainties about the Mergers, and the outcome of legal proceedings instituted against us, our Board of Directors, and others related to the Mergers; our ability to integrate the operations of the Company and Physicians Realty Trust successfully and realize the anticipated synergies and other benefits of the Mergers or do so within the anticipated time frame; changes within the industries in which we operate; significant regulation, funding requirements, and uncertainty faced by our lab tenants; factors adversely affecting our tenants’, operators’, or borrowers’ ability to meet their financial and other contractual obligations to us; the insolvency or bankruptcy of one or more of our major tenants, operators, or borrowers; our concentration of real estate investments in the healthcare property sector, which makes us more vulnerable to a downturn in a specific sector than if we invested across multiple sectors; the illiquidity of real estate investments; our ability to identify and secure new or replacement tenants and operators; our property development, redevelopment, and tenant improvement risks, including project abandonments, project delays, and lower profits than expected; the ability of the hospitals on whose campuses our outpatient medical buildings are located and their affiliated healthcare systems to remain competitive or financially viable; our ability to develop, maintain, or expand hospital and health system client relationships; operational risks associated with third party management contracts, including the additional regulation and liabilities of our properties operated through RIDEA structures; economic conditions, natural disasters, weather, and other conditions that negatively affect geographic areas where we have concentrated investments; uninsured or underinsured losses, which could result in significant losses and/or performance declines by us or our tenants and operators; our investments in joint ventures and unconsolidated entities, including our lack of sole decision making authority and our reliance on our partners’ financial condition and continued cooperation; our use of fixed rent escalators, contingent rent provisions, and/or rent escalators based on the Consumer Price Index; competition for suitable healthcare properties to grow our investment portfolio; our ability to foreclose or exercise rights on collateral securing our real estate-related loans; any requirement that we recognize reserves, allowances, credit losses, or impairment charges; investment of substantial resources and time in transactions that are not consummated; our ability to successfully integrate or operate acquisitions; the potential impact on us and our tenants, operators, and borrowers from litigation matters, including rising liability and insurance costs; environmental compliance costs and liabilities associated with our real estate investments; ESG and sustainability commitments and requirements, as well as stakeholder expectations; epidemics, pandemics, or other infectious diseases, including Covid, and health and safety measures intended to reduce their spread; human capital risks, including the loss or limited availability of our key personnel; our reliance on information technology systems and the possibility of a cybersecurity incident or cybersecurity threat affect our information systems or the information systems of our tenants, operators or borrowers; volatility, disruption, or uncertainty in the financial markets; increased borrowing costs, including due to rising interest rates; cash available for distribution to stockholders and our ability to make dividend distributions at expected levels; the availability of external capital on acceptable terms or at all, including due to rising interest rates, changes in our credit ratings and the value of our common stock, bank failures or other events affecting financial institutions; our ability to manage our indebtedness level and covenants in and changes to the terms of such indebtedness; the failure of our tenants, operators, and borrowers to comply with federal, state, and local laws and regulations, including resident health and safety requirements, as well as licensure, certification, and inspection requirements; required regulatory approvals to transfer our senior housing properties; compliance with the Americans with Disabilities Act and fire, safety, and other regulations; laws or regulations prohibiting eviction of our tenants; the requirements of, or changes to, governmental reimbursement programs such as Medicare or Medicaid; legislation to address federal government operations and administrative decisions affecting the Centers for Medicare and Medicaid Services; our participation in the CARES Act Provider Relief Fund and other Covid-related stimulus and relief programs; our ability to maintain our qualification as a REIT; our taxable REIT subsidiaries being subject to corporate level tax; tax imposed on any net income from “prohibited transactions”; changes to U.S. federal income tax laws, and potential deferred and contingent tax liabilities from corporate acquisitions; calculating non-REIT tax earnings and profits distributions; ownership limits in our charter that restrict ownership in our stock; provisions of Maryland law and our charter that could prevent a transaction that may otherwise be in the interest of our stockholders; conflicts of interest between the interests of our stockholders and the interests of holders of Healthpeak OP common units; provisions in the operating agreement of Healthpeak OP and other agreements that may delay or prevent unsolicited acquisitions and other transactions; our status as a holding company of Healthpeak OP; and other risks and uncertainties described from time to time in our Securities and Exchange Commission filings. Except as required by law, we do not undertake, and hereby disclaim, any obligation to update any forward-looking statements, which speak only as of the date on which they are made.

Page 6

ADDITIONAL INFORMATION AND WHERE TO FIND IT

In connection with the proposed transaction, on December 15, 2023, Healthpeak and Physicians Realty Trust filed with the SEC a registration statement on Form S-4 containing a joint proxy statement/prospectus and other documents regarding the proposed transaction. The joint proxy statement/prospectus contains important information about the proposed transaction and related matters. The Form S-4 was declared effective, and each of Healthpeak and Physicians Realty Trust commenced mailing of the joint proxy statement/prospectus included as part of the Form S-4, on January 11, 2024.

STOCKHOLDERS ARE URGED AND ADVISED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS (INCLUDING ALL AMENDMENTS AND SUPPLEMENTS THERETO) AND OTHER RELEVANT DOCUMENTS FILED WITH THE SEC CAREFULLY BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT HEALTHPEAK, PHYSICIANS REALTY TRUST AND THE PROPOSED TRANSACTION.

Investors and security holders of Healthpeak and Physicians Realty Trust are able to obtain free copies of the registration statement, the joint proxy statement/prospectus and other relevant documents filed by Healthpeak and Physicians Realty Trust with the SEC through the website maintained by the SEC at www.sec.gov. Copies of the documents filed by Healthpeak with the SEC are also available on Healthpeak’s website at www.healthpeak.com, and copies of the documents filed by Physicians Realty Trust with the SEC are available on Physicians Realty Trust’s website at www.docreit.com.

PARTICIPANTS IN THE SOLICITATION

Healthpeak, Physicians Realty Trust and their respective directors, trustees and executive officers may be deemed to be participants in the solicitation of proxies from Healthpeak’s stockholders and Physicians Realty Trust’s shareholders in respect of the proposed transaction. Information regarding Healthpeak’s directors and executive officers can be found in Healthpeak’s definitive proxy statement filed with the SEC on March 17, 2023. Information regarding Physicians Realty Trust’s trustees and executive officers can be found in Physicians Realty Trust’s definitive proxy statement filed with the SEC on March 23, 2023.

Additional information regarding the interests of such potential participants is included in the joint proxy statement/prospectus and other relevant documents filed with the SEC in connection with the proposed transaction. These documents are available on the SEC’s website and from Healthpeak and Physicians Realty Trust, as applicable, using the sources indicated above.

Page 7

NO OFFER OR SOLICITATION

This communication is for informational purposes only and is neither an offer to purchase, nor a solicitation of an offer to sell, any securities or the solicitation of any vote in any jurisdiction pursuant to the proposed transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

CONTACT

Andrew Johns, CFA

Senior Vice President – Investor Relations

720-428-5400

Page 8

Healthpeak Properties, Inc.

Consolidated Balance Sheets

In thousands, except share and per share data

	December 31, 2023			December 31, 2022
Assets
Real estate:
Buildings and improvements	$	13,329,464		$	12,784,078
Development costs and construction in progress		643,217			760,355
Land and improvements		2,647,633			2,667,188
Accumulated depreciation and amortization		(3,591,951	)		(3,188,138	)
Net real estate		13,028,363			13,023,483
Loans receivable, net of reserves of $2,830 and $8,280		218,450			374,832
Investments in and advances to unconsolidated joint ventures		782,853			706,677
Accounts receivable, net of allowance of $2,282 and $2,399		55,820			53,436
Cash and cash equivalents		117,635			72,032
Restricted cash		51,388			54,802
Intangible assets, net		314,156			418,061
Assets held for sale, net		117,986			49,866
Right-of-use asset, net		240,155			237,318
Other assets, net		772,044			780,722
Total assets	$	15,698,850		$	15,771,229
Liabilities and Equity
Bank line of credit and commercial paper	$	720,000		$	995,606
Term loans		496,824			495,957
Senior unsecured notes		5,403,378			4,659,451
Mortgage debt		256,097			346,599
Intangible liabilities, net		127,380			156,193
Liabilities related to assets held for sale, net		729			4,070
Lease liability		206,743			208,515
Accounts payable, accrued liabilities, and other liabilities		657,196			772,485
Deferred revenue		905,633			844,076
Total liabilities		8,773,980			8,482,952
Commitments and contingencies
Redeemable noncontrolling interests		48,828			105,679
Common stock, $1.00 par value: 750,000,000 shares authorized; 547,156,311 and 546,641,973 shares issued and outstanding		547,156			546,642
Additional paid-in capital		10,405,780			10,349,614
Cumulative dividends in excess of earnings		(4,621,861	)		(4,269,689	)
Accumulated other comprehensive income (loss)		19,371			28,134
Total stockholders’ equity		6,350,446			6,654,701
Joint venture partners		310,998			327,721
Non-managing member unitholders		214,598			200,176
Total noncontrolling interests		525,596			527,897
Total equity		6,876,042			7,182,598
Total liabilities and equity	$	15,698,850		$	15,771,229

Healthpeak Properties, Inc.

Consolidated Statements of Operations

In thousands, except per share data

	Three Months Ended December 31,						Year Ended December 31,
	2023			2022			2023			2022
Revenues:
Rental and related revenues	$	412,332		$	392,245		$	1,631,805		$	1,541,775
Resident fees and services		136,341			125,873			527,417			494,935
Interest income		4,979			6,350			21,781			23,300
Income from direct financing leases		—			—			—			1,168
Total revenues		553,652			524,468			2,181,003			2,061,178
Costs and expenses:
Interest expense		52,784			49,413			200,331			172,944
Depreciation and amortization		188,544			179,157			749,901			710,569
Operating		224,401			220,492			902,060			862,991
General and administrative		21,556			57,872			95,132			131,033
Transaction and merger-related costs		14,417			3,217			17,515			4,853
Impairments and loan loss reserves (recoveries), net		(5,445	)		3,326			(5,601	)		7,004
Total costs and expenses		496,257			513,477			1,959,338			1,889,394
Other income (expense):
Gain (loss) on sales of real estate, net		—			(969	)		86,463			9,078
Other income (expense), net		2,600			(587	)		6,808			326,268
Total other income (expense), net		2,600			(1,556	)		93,271			335,346
Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures		59,995			9,435			314,936			507,130
Income tax benefit (expense)		11,842			650			9,617			4,425
Equity income (loss) from unconsolidated joint ventures		3,558			(156	)		10,204			1,985
Income (loss) from continuing operations		75,395			9,929			334,757			513,540
Income (loss) from discontinued operations		—			873			—			2,884
Net income (loss)		75,395			10,802			334,757			516,424
Noncontrolling interests’ share in continuing operations		(4,451	)		(4,274	)		(28,748	)		(15,975	)
Net income (loss) attributable to Healthpeak Properties, Inc.		70,944			6,528			306,009			500,449
Participating securities’ share in earnings		(157	)		(140	)		(1,725	)		(2,657	)
Net income (loss) applicable to common shares	$	70,787		$	6,388		$	304,284		$	497,792
Basic earnings (loss) per common share:
Continuing operations	$	0.13		$	0.01		$	0.56		$	0.92
Discontinued operations		—			0.00			—			0.00
Net income (loss) applicable to common shares	$	0.13		$	0.01		$	0.56		$	0.92
Diluted earnings (loss) per common share:
Continuing operations	$	0.13		$	0.01		$	0.56		$	0.92
Discontinued operations		—			0.00			—			0.00
Net income (loss) applicable to common shares	$	0.13		$	0.01		$	0.56		$	0.92
Weighted average shares outstanding:
Basic		547,091			537,992			547,006			538,809
Diluted		547,361			538,396			547,275			539,147

Healthpeak Properties, Inc.

Funds From Operations

In thousands, except per share data

	Three Months Ended December 31,						Year Ended December 31,
	2023			2022			2023			2022
Net income (loss) applicable to common shares	$	70,787		$	6,388		$	304,284		$	497,792
Real estate related depreciation and amortization		188,544			179,157			749,901			710,569
Healthpeak’s share of real estate related depreciation and amortization from unconsolidated joint ventures		6,723			8,642			24,800			27,691
Noncontrolling interests’ share of real estate related depreciation and amortization		(4,610	)		(4,709	)		(18,654	)		(19,201	)
Loss (gain) on sales of depreciable real estate, net		—			986			(86,463	)		(10,422	)
Healthpeak’s share of loss (gain) on sales of depreciable real estate, net, from unconsolidated joint ventures		—			45			—			134
Noncontrolling interests’ share of gain (loss) on sales of depreciable real estate, net		—			—			11,546			12
Loss (gain) upon change of control, net(1)		—			—			(234	)		(311,438	)
Taxes associated with real estate dispositions		—			—			—			29
Nareit FFO applicable to common shares		261,444			190,509			985,180			895,166
Distributions on dilutive convertible units and other		2,366			1,649			9,394			9,407
Diluted Nareit FFO applicable to common shares	$	263,810		$	192,158		$	994,574		$	904,573
Diluted Nareit FFO per common share	$	0.48		$	0.35		$	1.79		$	1.66
Weighted average shares outstanding - diluted Nareit FFO		554,635			543,879			554,559			546,462
Impact of adjustments to Nareit FFO:
Transaction and merger-related items(2)	$	10,842		$	3,215		$	13,835		$	4,788
Other impairments (recoveries) and other losses (gains), net(3)		(4,407	)		9,702			(3,850	)		3,829
Restructuring and severance-related charges(4)		—			32,749			1,368			32,749
Casualty-related charges (recoveries), net(5)		(3,424	)		298			(4,033	)		4,401
Recognition (reversal) of valuation allowance on deferred tax assets(6)		(14,194	)		—			(14,194	)		—
Total adjustments		(11,183	)		45,964			(6,874	)		45,767
FFO as Adjusted applicable to common shares		250,261			236,473			978,306			940,933
Distributions on dilutive convertible units and other		2,378			2,271			9,402			9,326
Diluted FFO as Adjusted applicable to common shares	$	252,639		$	238,744		$	987,708		$	950,259
Diluted FFO as Adjusted per common share	$	0.46		$	0.44		$	1.78		$	1.74
Weighted average shares outstanding - diluted FFO as Adjusted		554,635			545,704			554,559			546,462

(1) The year ended December 31, 2022 includes a gain upon change of control related to the sale of a 30% interest to a sovereign wealth fund and deconsolidation of seven previously consolidated lab buildings in South San Francisco, California. The gain upon change of control is included in other income (expense), net in the Consolidated Statements of Operations.

(2) The three months and year ended December 31, 2023 include costs related to the proposed merger with Physicians Realty Trust, which are primarily comprised of legal, accounting, tax, and other costs that were incurred prior to year-end, partially offset by termination fee income associated with Graphite Bio, Inc., for which the lease terms have been modified to accelerate expiration of the lease to December 2024. Termination fee income is included in rental and related revenues on the Consolidated Statements of Operations.

(3) The three months and year ended December 31, 2022 include $7 million of charges incurred in connection with the downsizing of the Company’s corporate headquarters in Denver, Colorado, which are included in general and administrative expenses in the Consolidated Statements of Operations. The year ended December 31, 2022 also includes the following, which are included in other income (expense), net in the Consolidated Statements of Operations: (i) $14 million of expenses incurred for tenant relocation and other costs associated with the demolition of an outpatient medical building and (ii) a $23 million gain on sale of a hospital under a direct financing lease. The three months and years ended December 31, 2023 and 2022 include reserves and (recoveries) for expected loan losses recognized in impairments and loan loss reserves (recoveries), net in the Consolidated Statements of Operations.

(4) The three months and year ended December 31, 2022 include $32 million of severance-related charges associated with the departures of our former Chief Executive Officer and former Chief Legal Officer and General Counsel in the fourth quarter of 2022. These expenses are included in general and administrative expenses in the Consolidated Statements of Operations.

(5) Casualty-related charges (recoveries), net are recognized in other income (expense), net and equity income (loss) from unconsolidated joint ventures in the Consolidated Statements of Operations.

(6) In conjunction with classifying the assets related to the Callan Ridge JV as held for sale as of December 31, 2023, we concluded it was more likely than not that we would realize the future value of certain deferred tax assets generated by the net operating losses of taxable REIT subsidiaries. Accordingly, during the three months and year ended December 31, 2023, we recognized the reversal of a portion of the associated valuation allowance and recognized a corresponding income tax benefit.

Healthpeak Properties, Inc.

Adjusted Funds From Operations

In thousands

	Three Months Ended December 31,						Year Ended December 31,
	2023			2022			2023			2022
FFO as Adjusted applicable to common shares	$	250,261		$	236,473		$	978,306		$	940,933
Stock-based compensation amortization expense		3,513			1,903			14,480			16,537
Amortization of deferred financing costs		3,088			2,812			11,916			10,881
Straight-line rents(1)		(1,677	)		(12,346	)		(14,387	)		(49,183	)
AFFO capital expenditures		(47,332	)		(33,407	)		(113,596	)		(108,510	)
Deferred income taxes		117			(355	)		(816	)		(4,096	)
Amortization of above (below) market lease intangibles, net		(5,525	)		(5,851	)		(25,791	)		(23,380	)
Other AFFO adjustments		(7,486	)		3,536			(9,335	)		520
AFFO applicable to common shares		194,959			192,765			840,777			783,702
Distributions on dilutive convertible units and other		1,663			1,649			6,581			6,594
Diluted AFFO applicable to common shares	$	196,622		$	194,414		$	847,358		$	790,296
Diluted AFFO per common share	$	0.36		$	0.36		$	1.53		$	1.45
Weighted average shares outstanding - diluted AFFO		552,810			543,879			552,734			544,637

(1) The year ended December 31, 2023 includes an $8.7 million write-off of straight-line rent receivable associated with Sorrento Therapeutics, Inc., which commenced voluntary reorganization proceedings under Chapter 11 of the U.S. Bankruptcy Code. This activity is reflected as a reduction of rental and related revenues in the Consolidated Statements of Operations.

EX-99.3

​-​ ! "# $ %&' ()(% *+ ,

​-​ - - ! "# $ % &'( ) * $ % &'( ) &+! () ( ,,- . / (- . ( +0 - 1 # (/ + (" - # + . / ,(#. / +/ + + (/ /) " (/ ,(# ! / + + , 0 +23'+- 4 0 (,,- 2("- * 5 !( + " () . / 2+/ ( / 2+! /(/ '( 1 + .( / ( / ( + . -( + $ % &'( ) &+! () (/ 2 ( /) () /2 - 6 . -( ( + / !(- ( /) (/ . / /) ' 2 ( /) +/ 2 ( / +0 + " / . / * $ % &'( ) &+! () " 2 + ' (. - . ( +/ (/ 1 (- 0 2( +/ ( (/ $ % &'( ) * ​-​ - 7- 8 9: 7 ;<​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​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`R​ 7- ​-​ - _[`R​ 4 + 0+ N (- ( 4 ( ,,- . / (- , 0+ .(/2 . ( 0 / "# ' a( +/(- +2 ( +/ +0 N (- ( /! . / AGa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a /2+. A-+ B ' .+ 2 -# 2+.,( ("- ]*M* ) / (--# (22 , (22+ / /) , /2 ,- AGO PHB . ( + (/ * 7 : R S &+/ +- ( " ,- + , + ( ( '( +0 + (- " 0 +. + /2+/ +- ( UV * / , " ( ,,- . / (- .. ( +0 + 0 /(/2 (- ,+ +/4 ?' 2' /("- "+ ' .(/() . / (/ /! + + (/(-#6 + - ! () (/ + 2+.,( + - ! () + '( +0 + ' 2+.,(/ * 5 , + ( ( '( +0 + (- " 0 +. + /2+/ +- ( UV /+ / / + 0- 2 + (2 (- - (" - # + (" - # + (22 ( '+ - ' " ( 0( - / (/# + (-- 2' -+(/ + ( - 1 ( +/ +0 ' UV * 7 : T ​ &+/ +- ( O + ,- + , + ( ( '( +0 + (- ) + ( 0 +. + /2+/ +- ( UV 4 (0 ( /) "(23 (22 . -( , 2 ( +/ (/ (.+ 6( +/* / , O + ( ,,- . / (- . ( +0 + 0 /(/2 (- ,+ +/4 ?' 2'4 ?' / bcdefegehfi j

​-​ - - ​ -​ ​ ​ ​ ​ - ​ ​ - - ​ - ​​- ​ ​ - ​ ​ ​ - ​ ​ ​ ​ ​ ​ ​ ​ ​ -​ ​​ ! "# ​$ %& '​( ) ​* - ​ ​+ ​, ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ - - ​ ​-. ​/- ​ ​ + ​, ​​ ​ ​ - ​ ​ ​ ​ ​- - ​ ​ ​ ​ - ​ ​ ​ - ​ ​ - - ​ - ​​- ​ ​ - ​ ​ ​ - ​ ​ ​ ​ ​ ​ ​ ​ ​ -​ ​0 ​ ​ ​ ​ ​/- ​ ​+ ​, ​ ​ ​ - - ​ ​-. ​​ ​- ​​- - ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ - ​ - ​ ​ ​ ​ - ​ ​ ​ ​1 ​ ​ -​ ​ ​-. ​ 2 % ​3 #​​* ​-​ ​ ​**4*​ -​ ​ ​ ​ ​ - ​ - ​ ​ ​ 1 ​ ​ ​ ​ - ​ ​ ​ -​ - ​ - - ​ ​ ​ ​ ​ 5​- ​ - ​ ​ ​ -​ ​6 ​- ​​- ​708 ​9 ​708 ​7 ​ ​660 ​660​ ​9 ​ - ​9660 ​ ​- - - ​ ​ -​ ​ ​ - - ​ ​​ ​ ​ ​ ​ - - ​ ​ - ​ - ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ - ​ ​ -​ -​ ​ ​ ​ - ​: ​ - ​ ​ -​ ​ ​ ​ - ; ​ - - ​ ​​ ​ - ​ - ​ ​ ​-​ ​ ​-​- ​ ​ - ​ ​ ​ ​- ​ - ​ ​- ​ -​ ​ -​ ​ ​ ​ ​ -​ ​9 ​ - ​ - ​ ​ ​ ​ - ​ ​ - ​ ​ ​​-​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 3" 2 %"2<​= > 2? ​/- ​ ​, ​ ​ ​ ​ ​/- ​ ​@ ​9 ​6​- - ​ ​A ​​ ​ ​ - ​ ​ ​ ​ ​- - ​ ​ ​ ​ - ​ ​ ​ - ​ ​ - - ​ - ​​- ​ ​ - ​ ​ ​ - ​ ​ ​ ​ ​ ​ ​ ​ ​ -​ ​0 ​ ​ ​ ​​- ​ -​​ ​ ​ ​ ​- ​ ​ ​ - ​ ​ - ​ ​ ​ ​ ​ - ​ B ​ ​ - ​ ​ ​ ​ ​-. ​0 ​ ​ ​ ​ ​ ​ ​ ​ ​ - - ​ ​-. ​​ ​- ​​- - ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ - ​ - ​ ​ ​ ​ - ​ ​ ​ ​1 ​ ​ -​ ​ ​-. 3"C '​DE2 ? #​: ​​- ​ B - ​ ​ ​ ​ ​​- ​ ​ ​ 5​ ​ ​ - ​F​ ​ ​ G ​6​B ​* ​ ​​- ​ ​ ​ ​ ​ ​ ​​- ​ B - ​ ​ ​ ​ ​​- ​ ​ ​ 5​ ​ ​ - ​F​ ​ ​ G​ ​ ​ - - ​ ​-. ​6​B ​* ​ ​ ​ ​ - ​ ​ ​ ​​- ​ - ​ -​ - ​- ​ ​ - ​ ​ ​ - ​ ​ ​ 5 ​ ​ ​ ​ - ​- ​ 6​B ​* ​* ​ - ​9 ​6​B ​* ​* ​6​B ​* ​​ ​ ​ ​ ​ ​ ​ - ​ - ​1 ​ ​ ​ - ​ ​ - ​ ​ ​- ​ ​ ​ ​- ​​- ​ ​ - ​ ​ ​ - ​​ 3& '#​3 HI​J! 2 "H #​KLM2 " ​33JNO​2 '​33J​2#​P'Q&# '​660​ - ​7 ​ ​660​ - ​660​ ​9 ​ ​ ​ ​ ​​ ​ ​ ​​-​ ​ ​ ​R ​ ​ ​660​ ​ ​ ​ -​ ​ ​ ​660​ ​ ​ ​ -​ ​ - ​ ​ ​660​ ​ -​ ​ ​​ - ​ - ​- - @99S​ ​ ​ ​- ​ - ​ ​ ​4/8: ​T ​ ​ ​ ​ ​ ​ - ​- ​ - - ​ -​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​- ​ ​ ​ -​F B ​ -​ - G ​ ​ - ​- ​ - ​ -​​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​-​ ​ ​ ​ ​ ​ ​+​- ​ ​ ​ ​​- ​ ​ ​ ​ ​ ​ -​ - ​ -​ ​ ​ 5 ​ - ​ ​ - ​ - ​ - ​ ​ ​- ​ ​ ​ ​4/8:​ ​ ​ ​ ​ ​ ​ - ​- ​ ​ ​ ​ -​ ​ ​ ​​- ​ ​: ​ ​660​ ​ ​ - ​ ​ ​4/8:​​- ​ ​ ​ ​ ​​ UVWXYZ​[[\ ​​660 ​ ​ ​- ​ ​ ​7 ​ - ​9 ​ ​ -​ ​4 ​/ ​8- - ​: ​F]7 ​ G ​​ ​- ​​- ​F G​ ​ ​ ​ -​ ​F ​​-​ - ​ ​ ​@99SG ​ B ​- ​ ​- ​ ​ ​ ​ ​ ​ ​ ​ ​​- ​- ​ - ​ - ​ - ​ ​ B ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​​ ​ - ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ - ​ ​ ​ ​ ​ ​ -​ - ​ ​ ​ - ​ - ​ - ​ ​ ​ ​ ​ ​7 ​ ​660​ - ​660​ ​9 ​F ​ G​ ​ ​- ​ - ​9 - ​ ​ ​- ​ - ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ - ​ ​ - ​ - - ​ ​ ​- ​ - ​ R ​ ​ ​ ​ ​7 ​ ​660​ ​ - - ​ ​ ​- ​ - ​ ​ ​- ​ ​ ​ - ​ ​ - ​ ​ ​ ​ ​ ​ ​ ​ ​ - ​ ​- ​​ ​ -​ -​ - ​ ​ ​ - ​ ​ ​ ​6 ​ - ​ ​ ​- ​ - ​​-​ ​ ​ ​ ​- ​ -​_``a ​ ​ ​ ​ ​ ​ ​ 1 ​ ​ ​ ​- ​ ​7 ​ ​660​ ​ ​ ​ ​ ​ ​ - ​ ​ ​ ​ ​ ​ ​ - ​ ​- ​​ ​ ​ -​ ​ - ​ ​ - ​ ​ ​ ​ ​ ​ ​0 ​ ​ ​ ​​- ​ -​​ ​ ​ -​ ​ ​ ​ - ​ - ​ ​ ​ ​ ​ - ​ ​ - ​​ ​​- - ​ ​ ​ ​ ​ - ​ - ​ ​​- ​​-​ ​ ​- ​ ​ ​ ​ ​​-​ ​ ​ ​ - ​​ ​ ​ ​ ​- ​ ​ ​ - ​ ​ - ​ ​ ​ ​ ​R ​ ​- ​ - ​ ​ - - ​ ​ ​- ​ - ​ - ​ ​ ​ ​ - ​ - ​ ​ - ​ ​- ​​ ​ ​- ​​-​7 ​ ​660​ ​- ​ - ​ ​ ​ ​ ​ ​ ​​ ​: ​ ​- ​ - ​ ​ ​ - ​ ​ - ​ ​ ​ ​ ​ ​ ​ ​ - ​ - ​ ​ ​ ​ - ​ ​ ​ ​ ​- ​ ​ ​ ​- ​ - ​ - ​ ​ ​ ​ ​ ​ ​ ​ - ​ - ​ ​- ​ ​ ​ ​​- ​ ​ ​ : ​ - ​ -​ ​ ​ ​​- ​ -​ ​ ​ ​ ​ - ​ ​ ​​- ​ ​ ​- ​ ​ ​ ​ ​ ​ ​- b​F​G​ ​ - ​ -​ -​ ​ ​- ​ ​ ​ ​- ​​ ​ ​ ​ ​ ​ ​- ​ ​ ​ - ​ ​ - ​ ​​- ​ - ​ ​- ​ -​ ​- ​ ​ 1 ​ ​ ​ ​ - ​- ​ - ​ ​- ​- ​ ​ - ​ ​ ​ ​ ​ ​ ​ ​ - ​ ​ ​ ​ ​ ​ ​ ​ - ​ - ​ B - ​ - ​F​​G​ ​ -​ ​​-​ ​​- ​ ​ ​ ​ ​ ​ ​​- ​ ​ - ​ ​ ​ ​- ​ ​ - ​ ​ ​ ​ ​ ​T ​ ​ ​ ​ ​ ​ - ​ ​ ​ ​ ​- - ​ ​​- ​ -​ ​- ​ ​ - ​ ​​- - - ​ ​ ​ ​ ​ ​ ​ ​ ​- - ​ ​ - ​ ​ ​ - ​@99S ​R ​ - ​ ​ ​ ​ ​ ​ - ​ ​ ​- ​ ​ ​ ​ -​ ​@99S​ ​- - ​ ​ - ​ ​- ​ ​ ​ ​ ​- - ​ ​​- ​ -​ ​ ​ - 7 ​ ​660​ ​- ​ - ​ ​ - ​ ​ ​- ​ ​ ​ ​ ​​-​ - ​ ​ ​@99S ​​ ​- ​- ​ ​​- ​ ​ ​ ​ ​ ​ ​ ​ - ​ ​- ​ - ​ ​- ​ ​ - ​ ​ -​ - ​ ​ ​- ​​- ​F G ​R ​ ​7 ​ ​660​​-​ - ​ ​ ​ ​ - ​ 7 ​ ​ ​-​ ​ -c​ ​ ​4/8: ​ ​ ​7 ​ ​660​ ​ - ​ ​ ​ ​ ​ - ​​- ​ -​ ​ ​ - ​7 ​ ​ ​-​ ​ -​ ​ [[\​Vd​efghdZXf ​​8-​ ​ ​ - ​ ​ - ​7 ​ ​660​ -​ -​ ​ ​ ​ ​ ​​ ​ ​- - ​​ ​​- ​- ​ ​- ​ ​ ​ ​ ​ - ​ -​ - ​ ​​ ​ ​​ ​ - ​F ​ G​ - ​ ​ ​F ​- G ​ ​- ​ - ​ - ​ ​ - ​ ​F - ​ G​ ​ ​ ​ ​ ​ ​ - ​ ​ - ​ ​ ​ ​ ​ ​ -​ ​F ​ G ​ ​ ​ F ​ G ​ ​ B​ ​ ​ -​ - ​ - ​ - ​​-​ B​ ​ ​ -​F]660​ ​9 G ​: ​ - ​ ​- ​ ​ B ​ -​ ​ ​: - ​ -​ - ​ ​​ ​​- ​ - ​ -​ B - ​ - ​ ​- i ​​- ​ ​ ​ ​ ​ ​ - ​ 1 ​ ​ ​ - ​ - ​ ​ - - ​ ​ ​- ​ -​ ​ ​ ​ ​S - ​ ​F - ​ G​ ​ ​ ​ ​ ​ ​ - ​ ​ ​​- ​ ​ ​ ​ ​ - ​ ​ ​ ​- - ​- ​ ​ ​ ​ ​ - ​ ​ B - ​ ​ - ​ 5 ​ - ​ - ​ ​ ​ ​ ​​- ​ ​ ​ ​ ​ ​ ​ - ​ ​ - ​ ​ ​0 ​​ ​ - ​F ​ G​ - ​ ​ ​F ​- G​​- ​​- ​​- ​ ​ ​ ​ ​ ​ - ​ ​ ​ - ​ ​ - ​ ​ ​ - ​ ​ ​ ​ ​- ​ ​ ​ ​ ​- - ​ ​ ​​- ​- ​ ​ ​,6A ​ - ​ - ​ ​ - ​ - ​ ​ ​j - - ​ ​ ​ ​660​ ​9 ​ ​ ​ ​ -​- ​ - ​ - ​ ​ ​660​ - ​ - ​​ ​ 1 - ​ ​ ​ - ​​- ​ - ​ ​​- ​ ​ ​​-​ ​ ​ -​ ​ ​ - ​ ​ ​4/8: ​9 ​ klmnonpnqor s

​-​ ​ ​ ​ ​- ​ ​ ​ ​ ​​ ​ ​ ​ ​ ​ ​-​ ​ ​ ​ ​ ​- ​ ​ ​ ​ ​ - ​ ​ ​ ​ - ​-​ ​ ​ ​- ​ ​ - ​ ​- ​ ​ ​ ​ ​ ​-​ ​ !​ ​ ​"​ ​ #- ​ ​​ ​ "​ ​ ​ $- ​" ​$ ​ ​ ​ ​ ​ ​ ​ ​ "​ % ​​ ​ ​ ​ ​- ​ ​ ​ ​ ​-​ & ​ ​ ​ ​ ​​ ​ ' ( ​ ​ & ​ ​ ​ ​ ​ "​ ​ ​-​ ​ ​ ​ ​ ​ ​ ) & ​​ ​ ​ ​ ​ ​ ​-​ ​ ​ ​ ​ ​ $​ ​ ​"​ ​ ​ ​ ​- ​ ​ #- ​ ​​ ​ "​ ​ ​ ​ ​ ​- ​ ​ ​ ​ ​ ​ !​ ​ ) & ​​ ​ * ' ( ​" ​​ ​ ​ $ ​- ​+ ​ ​​ ​ ​ ​ ​ ​" ​ ​ ​ "​ ​ ​ ​ ​ ​ ' ( ​" ​​ ​-​ ​ ​ ​ ​ ​ ' ( ​​ ​ ​ ​ ​ ​ ​ ​ ​ ​-​ ​ ​ ​ ' "( ​ ​ ​ ​ $ ​- ​ ​ ​ ​​ ​ ​-​ ​ ​ ​ '"( ​" ​​ - $ ​ ​​ ​ "​ ​ ​ ​ $ ​ ​ ​ ​ ​ ​-​ ​ ​ ​ ​​ ​ ​ ​ ​ ​ ​​- ​ ​ & ​​ ​ ​ ) & ​​ ​ ​ ​ ​ ​- ​ ​ ​​ ​-​ ,-./012/-1 3-4 5671869:6 ,-./012/-1 ​ ​ ​ ​ * ' ( ​-​ ​ ​ ​ ​ ​​ ​​ ​ ​ ​​ # ​​ ​ ​ ​ ​ ​ ' ( ​-​ ​ ; < ;​ ​ "​ ​ ​ ​ = ​ "​ ​ ​ ​ ​ ​ - ​ ​-​ ​ ​ ​ ​​ ​​ ​ ​ -​ ​​ >? ​ ​ ​​ ​-​ ​ "​ ​ ​ ​ ​+ ​ ​ ​​ ​ ​ @ ​ - ​ ​-​ ​ ​ ​ ​​ ​​ ​ ​ -​ ​​ >? ​ ​ ​​ ​-​ ​ "​ ​ ​ ​ = ​ "​ ​ ​ ​ ​+ ​ -​ ​"​ ​ ​ A/1 B/C1 ​​ ​ ;​ ​ ​ ​-​ ​ - - ​D " ​ ​ ​ ​ ​​ - ​+ ​ ​​ ​​ ​​ ​-​ ​ ​ ​​​ ​ ​ ​ - ​ ​ ​- - ​D ​ $ ​ ​ ​ ​​ ​​ ​ ​​ ​ ​ ​ - ​ - - ​D " ​ ​ ​ ​ ​​ - ​​ >? E ​​ ;​ ​ ​-​ ​ ​ ​ ​ F))= ​ ​ ​ ​​ ;​ ​ ​​ ;​ ​ ​ ​ ​ ​ ​ ​ $- - ​ ​ ​- ​ ​ ​ "​ ​ ​ ​ ​"​ ​ ​ ​ ​"​ ​ ​ ​- ​ ​-​ ​ A/1 B/C1 16 G4HI01/4 JK,LBG7/ ​​ ;​ ​ " ​ ) & ​​ M ;) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ M​ ​ $​ ​ ​ ​ ​ ​ - ​ ​ ​ ​ ​ % % ​- ​ ​ - "​ ​​ ​ ​ A/1 NO/731:-P ,-Q62/ RSAN,TU 3-4 V30W RG4HI01/4U AN, ) & ​​ ​ %X Y ​ ​ ​ ​​ ​ ​ ' F))= ( ​ ​ ​ ​ ​ ​ ​ ​" ​​ ​-​ ​ ​ ​ ​ ​ ​ ​ ​​ ​ ​ ​ ​ ​ ​​ ​"​ ​ ' "​ ​ ​ ​ ​​ ​"​ ​ ​ ​ ​ ​​ ​ " ​ ​ ​ ​ ​ ​ "​ ​ ​ ​ ​ ​+ "​ ​​ ​ ​ ​( ​ ​ ​ ​"​ ​ ​ ​+ ​ ​ Z ​+ ​ ​-​ ​ ​​ ​ ​ ​ ​ ​​ ​ ' ( ) & ​​ ​​ ​​ ​ ​ ​-​ ​ ​ ​ ​ -​% ​ ​ ​ ; < % - ​​ ​ ​ ​ ​ #​​ ​ ​ ​ ​ ​​ ​ ​​ ​ ​ ​ "​ ​ ​- ​ - "​ ​​ ​ ​ ​ ​ ​​ ​-​ ​ ​ ​ ​ ​ ​​ ​ ​+ ​ ​ ) & ​​ ​ ​​ ) & ​​ ​​ ​ ​ ​ - ​ ) & ​​ ​​ & ​ "​ ​ ​ ' ​​ ​ $ ​ - ​ ​ ​ ​ ​-​ ​ ( ​ ​ ​​ ​ ​ [ - ​ ) & ​​ ​​ & ​ "​ ​ ​ ' ​​ ​ $ ​ - ​ ​ ​ ​ ​-​ ​ ( \ ​ ​ ​ ​ ​ ​ - ​ ) & ​​ ​ ​ ​ ​ $​ - "​ " & ​ "​ ​ ​ ​- ​ ​ ​​ ​ ​ ​ ​ !​ ​ ​ ​​ & ​ "​ ​ ​ - ​ ​ ​​ & ​ "​ ​ ​ ​ ​ ​ ​ ​ ​ ​ - ​​ - ​ ) & ​​ - ​ ​ ​ ​ ​ ​ ​​ - ​ ​ ​ ​ ​​-​ $ ​- ​ ​ ​ ​ ​ ​ ​ ​​ ​ $ ​- F))= ) & ​​ ​​ ​ ​ ​ ​ ​ ​ E - \ ​ ​ ​ ​ ​"​ ) & ​​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​-​ " ​ ​ ​" ​ ​ ​ ​ ​ ​ ​ ​ ​ ​+ ​ ​ ​​ ​- ​ ​ ​ ​ ​-​ ​ ​ ​"​ ​ ​ ​ ​-​ ​"​ ​ !​ ​ ) & ​​ ​ #​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​"​ ​ ​ ​ ​" ​​ Y ​%Y​ ​ ' YY ( ​ ​ ​ ​ ​ $ !​ ​ ​"​ ​- ​ ​​ ​ ' ( ​-​ ​ ​ ​ ​ F))= ​ ​ ​ ) & ​​ ) & ​​ - ​ ​ " ​$​ ​​ ​ "​ ​ ​ ​ ​ ​ ​ ​ ​​ ​ ' ( ​ ​ F))= ​ ​-​ ​ ​ ​ ​ " ​+ ​ ​​ ​-​ ​ ​ ) & ​​ ​ ​ ​ ​ ​-​ ​ ​ ​ ​-​ ​ ​ ​ ​​ ​ ​-​ ​ ​ ​ ​ ​​- ​ ​ ) & ​​ ​ ​ ​+ ​ ​ ​ ​ ​ ​​ ​ ​ ​ ​ ​ ​ ​ ​ $​ EE E ​ ​ !​ ​ ​ ​ "​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​+ ​ ​ ​- - ​​ ​ ​ "​ ​ !​ ​ ​ ​ ​+ ​ ​ ​ ​ ​ ​ ​ ​ "​ ​ ​-​ ​ ​ ​ ​-​ ​+ ​ ​ 5671869:6 G4HI01/4 AN, = ​ ) & ​​ = ​ E - ​ ​ ​​ ​"​ ​ ​ = ​ E - ​ ​ + ​ ​ 5671869:6 NO/731:-P J]O/-0/0 3-4 5671869:6 V30W NO/731:-P J]O/-0/0 = ​ ​ ​ + ​ ​ = ​ E - ​ ​ + ​ ​ ​ %F))= ​ ​ ​ ​ ​ = ​ ​ ​ + ​ ​ ​ ​ ​ ​ ​ ​ ​"​ ​ ​ ​+ ​ ​ '$- - ​+ ​ ​ ​ ​ ( = ​ ​ ​ + ​ ​ ​ ​​ ​ ​ ​+ ​ ​ ​-​ E @ ​ - ​ ​ ​ ​+ ​ ​ ​ ​​ >? ​ ​ ​​ ​ ​ @ ​ - ​ ​ ​ ​+ ​ ​ ​​ >? = ​ E - ​ ​ + ​ ​ ​ ​ ​ ​ = ​ ​ ​ + ​ ​ ​​ ​ ​ ​-​ ​ ​ ​ ​ -​% ​ ​ ​ ​ ​ ​​ ​ ​​ ​ ​ ​ "​ ​ ​- ​ - "​ ​​ ​ ​ ​ ​ ​​ ​-​ ​ ​ ​ ​ ​ ​​ ​+ ​ ​ 5671869:6 ,-Q62/ E - ') & ​​ ( ​​ ​ ​ ​ ​ - ​ E - ') & ​​ ( ​​ >? ​ ​ ​​ ​ ​ @ ​ - ​ E - ') & ​​ ( ​​ >? \ ​ ​ ​ ​ ​"​ ​- ​ = ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ " ​ ​ ​" ​ ​ ​ ​ ​ ​Z ​ ​ ​ ​ ​ ​ ​"​ ​ ​ ​-​ E "​ ​​ ​ ​ ​ \ ​ ​ ​ ​ ​"​ ​- ​ ​​ ​ ' ( ​-​ ​ ​ ​ ​ F))= ​ ​ ​ = ​ ​ = ​ ​ - ​ ​ " ​$​ ​​ ​ "​ ​ ​ ​ ​ ​ ​ ​ ​​ ​ ' ( ​ ​ F))= ​ ​ ​ ​ ​ ​ ​ " ​+ ​ ​​ 5671869:6 /39 J0131/ /./-I/0 3-4 5671869:6 V30W /39 J0131/ /./-I/0 = ​ ​ ​ ​​ ​"​ ​ = ​ E - ​ ​ ​​ ​"​ ​ ​ %F))= ​ ​ ​ ​ ​ = ​ ​ ​ ​​ ​"​ ​ ​ ​ ​ ​ ​​ ​"​ ​ ​ ​ ​ ​​ ​ " ​ ​ ; < "​ ​ ​ ​ ​ $- - ​ ​-​ ​ '​+ ​ ​( ​​ E ​​ Y​ ​​ ​ ​ ​ ​ = ​ ​ ​ ​​ ​"​ ​ ​ ​-​ E @ ​ - ​ ​​ >? ​ ​ ​​ ​-​ ​ ​+ ​ _`abcbdbecf g

​-​​-​ - ​ ​ - - ​-​ - ​ -​ - - - ​ ​​ - - - ​ ​ ​ ​ - ​ ​ ! ​-​ ​ ​ - " -​ - # ​ ​ ​ -​ ​ ​ - ​- ​ $ ​​- %&'()*+), -+./0102), 30)1, -4 ​ 56 4 7 89: ; " -​ $ < ​ - - ​ ​- = ​ ​ ​-​ -4 ​ ; " > ​ - ​ - - ​-​ < - < ​ ​ - ​ -4 ​ ? -​ - ​$@ - ​​ -​​ " ABC%DA E F -​ ​ -​​ ​ - - ​ ​ - 9 <​ ​ ? $ ​- ​ - ​G - ​-​ - ​ ? - ​ ​ ​ ​ - ​ - ​ - ​ < ​​ ​ $ ​ ​ ​ ​ $ ​ - -​ 9 ​ ​​- - ​ - -​ ​ - 9 - - - ​ ​ HIIJ - ​ ​ ​ - ​​-​ - ​ ​ - ​$ - 6 ​ $ -​​ ​​$ ? - $ - ​ - -​ - $ - - ? - ​ ​ ​ ​ -​ $ 9 - - 9 ​-​ - ​ 9 ​ - ​ ​ ​ ​ ​ $ ​ - - ​ - - - ​ ​ ​ - ​ ​ -​​ ​​$ : - ​ ​- -​ ​ ​ $ ​ ​- - ​ #​-?​ - G $ - - - ABC%DA KKAK E F -​ ​ -​​ ​ <​ ​ 8 - - ​ ​ - 9 <​ ​ ? $ ​- ​ - - ​G ​ ​ - ​ - ​ - ​ < ​​ ​ $ ​ ​ ​ ​ $ ​ - -​ 6 ​ $ -​​ ​​$ ? - $ - ​ - -​ - $ - - ? - ​ ​ ​ ​ -​ $ 9 ​ - ​ ​ ​ ​ ​ $ ​ - - ​ - - ​ ​ ​ - ​ ​ -​​ ​​$ : - ​ ​- -​ ​ ​ $ ​ ​- - ​ #​-?​ - G $ - - ALMBN 6 ​ ? $ < :E $ - ​ ​ ​ $ - ​ :E ​ ​ ​ ​ ​ ​-​ ​ - - - ​ $ -.O)P-+'&) QR--ST ; ; - 89: ​ 56 4 7 89: ​ - -​ -? - - ​​ - - - $ - - - ​ ​-​ ​ - -​ $ ​ ​ ​ ​ ​ ​- - -​ - - - - - - - <​ ​ - ? ​ - ​-​ - ​ U ​​ - - - ​-​ - - - - ? - -?​ $ - ​​-​ - 4- ​ ​ ​ ; ; - 89: ​ 6 4 89: 5 89: ​ -​ - - ​ -​ ​ - - - ​ - -​ ​ -​ 7 ; ; - 89: ​ 6 4 89: <​ - ​ ​ ​ ​​- ​ 6 ; 6​ ; ; - 6 4 89: - <​ - " -​ - ​ - ​ ​ ​ - ​ ​ ​ ​ ​-​ - $ ​ ​ - ​ < ​ -​ - ​ - ​ ​ -​ ​-​ - - ​​ ​ ; ; - -​​ $ " - - ​ - ​- -​ - 8 ? $ ​G - ​ ​ $ ​-​ " - 5 $ ​ $ ? ​ ​ ​ 5 7 ​-​ - 5 7 $ ​ - VIJ - ​ ​ ​ $ ​ ​- ​​ 7 - HW -​ - ​G -​ 8 ? $ ​- - ​ ​ - ​ ​-​ " - - WX -​ - - $ ​ ​ ​ - < ​​ ​ ​ ​ - ​ ​ ​-​ " HW -​ ​ - -​ ​ ​-​ ​ - ​ ​ 6 - $ - - ; ; - ? ​ ​ - - ​ ​ - - ​ < ​​ ​ $ ​ ​ ​ ​ $ ​ - -​ ​ ​ ​ - ​ ​ - - - ​ -​ ​ - - ​ ​ ​ ​ ​ -​ - ; ; - - $ - ​-​ ; ; - - $ ​ ​ ​ ​ ​- -​ ​ ​​ ​ ​ U - ​- - ; ; - ​ - - - ​-​ - ​ -)*Y&), M)/+ A.+0' ​ ; ​ $ ​ Z - 6 ; ​ - ​ - - ​ ​​ - -​ ? ​ ​ - ​ ​ ​ ​ - - ​ $" - ​ - ​- - - - - ​- ​ 9 - ​ - -​ ​ ​ $ $ ​ - ​ -?​ ​ ​ - - ​ <​ ​ $ - - 9 - - E- ; ​ - - ​​-​ - ​- ​ ​ - ​ - ​ $ - $ - ​​ - ​ ​$ - ​ - ​ - G -​ - -)[O)\+] E - ​$@ - - - ​- - ​ ​ ​ - -? ​ - ​ ​ 5 7 _ 5 7 - ​ ​ _ ​ 5 7 ​-​ ​ ​ ​ ​ ​- ​ $ 5` a7 -b.&) 'c K'\]'10,.+), d'0\+ C)\+Y&)] QedC]eT 8-​​-​ - ​ ​ - ​ - -​ $ $ ​ ​-​​-​ - ​ ​ ​ -?​ ​ ​ - - ​ ​ ​ - ​ ​-​​-​ - ​ ​ - - -​ ​-​- ​ ​ ​ ​ ​​ - -​ ​ - ​ - - ​ - - - - -b.&) 'c f\*'\]'10,.+), d'0\+ C)\+Y&)] QedC]eT 9 - ​ - -​ $ $ ​ - ​ -?​ ​ ​ - - ​ ​ ​ - ​ - - - -​ ​-​- ​ ​ ​ ​ ​​ - -​ ​ - ​ - - ​ - - - - -+./0102), g -+./0102.+0'\ 8 ? $ ​G - ​ ​ $ ​-​ ; " - 5 $ ​ $ ? ​ ​ ​ 5 7 ​-​ - 5 7 $ ​ - VIJ - ​ ​ ​ $ ​ ​- ​​ 7 - HW -​ - ​G -​ 8 ? $ ​- - ​ ​ - ​ ​-​ ; " - - WX -​ - - $ ​ ​ ​ - < ​​ ​ ​ ​ - ​ ​ ​-​ ; " HW -​ ​ - -​ ​ ​-​ ​ - ​ ​ hijklkmknlo p

​-​ ​ ​ ! ​ "​ # $ % &'( ) "​ # $ % &'( *+*& *+** *+*& *+** , ​$ -. / . $ %. $ ​ 0 1+(121 0 3(&22 0 &+4(*24 0 451(15* 6789 7:;8;7 <798;7= =7><7?@8;@AB 8B= 8CA<;@D8;@AB EFFGHII EJKGEHJ JIKGKLE JELGHMK N789;O>78PQ: :O8<7 AR <789 7:;8;7 <798;7= =7><7?@8;@AB 8B= 8CA<;@D8;@AB R<AC SB?AB:A9@=8;7= TA@B; U7B;S<7: MGJVW FGMIV VIGFLL VJGMKE XAB?AB;<A99@BY @B;7<7:;:Q :O8<7 AR <789 7:;8;7 <798;7= =7><7?@8;@AB 8B= 8CA<;@D8;@AB ZIGMEL[ ZIGJLK[ ZEFGMHI[ ZEKGVLE[ \A:: ZY8@B[ AB :897: AR =7><7?@8]97 <789 7:;8;7G B7; KFM ZFMGIMW[ ZELGIVV[ N789;O>78PQ: :O8<7 AR 9A:: ZY8@B[ AB :897: AR =7><7?@8]97 <789 7:;8;7G B7;G R<AC SB?AB:A9@=8;7= TA@B; U7B;S<7: IH EWI XAB?AB;<A99@BY @B;7<7:;:Q :O8<7 AR Y8@B Z9A::[ AB :897: AR =7><7?@8]97 <789 7:;8;7G B7; EEGHIM EV \A:: ZY8@B[ S>AB ?O8BY7 AR ?AB;<A9G B7;ZE[ ZVWI[ ZWEEGIWF[ _8`7: 8::A?@8;7= a@;O <789 7:;8;7 =@:>A:@;@AB: VK X8<7@; bbc 8>>9@?8]97 ;A ?ACCAB :O8<7: VMEGIII EKLGHLK KFHGEFL FKHGEMM d@:;<@]S;@AB: AB =@9S;@U7 ?ABU7<;@]97 SB@;: 8B= A;O7< VGWMM EGMIK KGWKI KGILJ # .- , ​​ . $ %. $ ​ 0 *3&(2'+ 0 '5*('e2 0 554(e14 0 5+4(e1& f7@YO;7= 8U7<8Y7 :O8<7: AS;:;8B=@BY g =@9S;7= X8<7@; bbc HHIGMWH HIWGFJK HHIGHHK HIMGIMV hC>8?; AR 8=TS:;C7B;: ;A X8<7@; bbci _<8B:8?;@AB 8B= C7<Y7<g<798;7= @;7C:ZV[ j ELGFIV j WGVEH j EWGFWH j IGJFF c;O7< @C>8@<C7B;: Z<7?AU7<@7:[ 8B= A;O7< 9A::7: ZY8@B:[G B7;ZW[ ZIGILJ[ KGJLV ZWGFHL[ WGFVK 67:;<S?;S<@BY 8B= :7U7<8B?7g<798;7= ?O8<Y7:ZI[ WVGJIK EGWMF WVGJIK k8:S89;lg<798;7= ?O8<Y7: Z<7?AU7<@7:[G B7;ZH[ ZWGIVI[ VKF ZIGLWW[ IGILE 67?AYB@;@AB Z<7U7<:89[ AR U89S8;@AB 899Aa8B?7 AB =7R7<<7= ;8` 8::7;:ZM[ ZEIGEKI[ ZEIGEKI[ _A;89 8=TS:;C7B;: ZEEGEFW[ IHGKMI ZMGFJI[ IHGJMJ bbc 8: m=TS:;7= 8>>9@?8]97 ;A ?ACCAB :O8<7: VHLGVME VWMGIJW KJFGWLM KILGKWW d@:;<@]S;@AB: AB =@9S;@U7 ?ABU7<;@]97 SB@;: 8B= A;O7< VGWJF VGVJE KGILV KGWVM # .- ​​ n o- . $ %. $ ​ 0 *e*(3&5 0 *&2(144 0 521(1+2 0 5e+(*e5 f7@YO;7= 8U7<8Y7 :O8<7: AS;:;8B=@BY g =@9S;7= bbc 8: m=TS:;7= HHIGMWH HIHGJLI HHIGHHK HIMGIMV bbc 8: m=TS:;7= 8>>9@?8]97 ;A ?ACCAB :O8<7: j VHLGVME j VWMGIJW j KJFGWLM j KILGKWW p;A?Pg]8:7= ?AC>7B:8;@AB 8CA<;@D8;@AB 7`>7B:7 WGHEW EGKLW EIGIFL EMGHWJ mCA<;@D8;@AB AR =7R7<<7= R@B8B?@BY ?A:;: WGLFF VGFEV EEGKEM ELGFFE p;<8@YO;g9@B7 <7B;:ZJ[ ZEGMJJ[ ZEVGWIM[ ZEIGWFJ[ ZIKGEFW[ mbbc ?8>@;89 7`>7B=@;S<7: ZIJGWWV[ ZWWGILJ[ ZEEWGHKM[ ZELFGHEL[ d7R7<<7= @B?AC7 ;8`7: EEJ ZWHH[ ZFEM[ ZIGLKM[ mCA<;@D8;@AB AR 8]AU7 Z]79Aa[ C8<P7; 978:7 @B;8BY@]97:G B7; ZHGHVH[ ZHGFHE[ ZVHGJKE[ ZVWGWFL[ c;O7< mbbc 8=TS:;C7B;: ZJGIFM[ WGHWM ZKGWWH[ HVL mbbc 8>>9@?8]97 ;A ?ACCAB :O8<7: EKIGKHK EKVGJMH FILGJJJ JFWGJLV d@:;<@]S;@AB: AB =@9S;@U7 ?ABU7<;@]97 SB@;: 8B= A;O7< EGMMW EGMIK MGHFE MGHKI # .- n​​ . $ %. $ ​ 0 '53(3** 0 '54(4'4 0 241(&e2 0 15+(*53 f7@YO;7= 8U7<8Y7 :O8<7: AS;:;8B=@BY g =@9S;7= mbbc HHVGFEL HIWGFJK HHVGJWI HIIGMWJ qrstusvwvxyvtuz M

​-​ ​ ​ ! ​ "​ # $ % &'( ) "​ # $ % &'( *+*& *+** *+*& *+** # ,- ​ ​- $ ​ . +/'& . +/+' . +/01 . +/2* 34564789:8;< 9<= 9>;6:8?9:8;< @ABC @ABD EABF EABB G;HH IJ98<K ;< H9L4H ;M =4564789NL4 649L 4H:9:4O <4: P @A@@ I@AEDK I@A@QK G;HH IJ98<K R5;< 7S9<J4 ;M 7;<:6;LO <4:IEK P P @A@@ I@ACFK T9U4H 9HH;789:4= V8:S 649L 4H:9:4 =8H5;H8:8;<H P P P @A@@ # ,- W ​​ $ ​ . +/XY . +/&0 . '/Z2 . '/11 T69<H97:8;< 9<= >46J46[64L9:4= 8:4>HIQK @A@Q @A@E @A@B @A@E \:S46 8>5986>4<:H I647;]4684HK 9<= ;:S46 L;HH4H IJ98<HKO <4:IBK I@A@EK @A@Q I@A@EK @A@@ 4H:6R7:R68<J 9<= H4]469<74[64L9:4= 7S96J4HIDK P @A@_ @A@E @A@_ `9HR9L:a[64L9:4= 7S96J4H I647;]4684HKO <4:ICK I@A@EK @A@@ I@A@EK @A@E 47;J<8:8;< I64]46H9LK ;M ]9LR9:8;< 9LL;V9<74 ;< =4M4664= :9U 9HH4:HI_K I@A@QK P I@A@BK P # ,- ​​ b c- $ ​ . +/X1 . +/XX . '/ZY . '/ZX d:;7e[N9H4= 7;>54<H9:8;< 9>;6:8?9:8;< 4U54<H4 @A@E @A@@ @A@B @A@B f>;6:8?9:8;< ;M =4M4664= M8<9<78<J 7;H:H @A@E @A@E @A@Q @A@Q d:698JS:[L8<4 64<:HIFK @A@@ I@A@QK I@A@BK I@A@gK fhh\ 7958:9L 4U54<=8:R64H I@AE@K I@A@_K I@AQ@K I@AQ@K 34M4664= 8<7;>4 :9U4H @A@@ @A@@ @A@@ I@A@EK f>;6:8?9:8;< ;M 9N;]4 IN4L;VK >96e4: L49H4 8<:9<J8NL4HO <4: I@A@EK I@A@QK I@A@CK I@A@DK \:S46 fhh\ 9=iRH:>4<:H I@A@EK @A@E I@A@QK @A@@ # ,- b​​ $ ​ . +/&1 . +/&1 . '/0& . '/X0 jjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjj IEK TS4 a496 4<=4= 3474>N46 BEO Q@QQ 8<7LR=4H 9 J98< R5;< 7S9<J4 ;M 7;<:6;L 64L9:4= :; :S4 H9L4 ;M 9 B@k 8<:464H: :; 9 H;]4648J< V49L:S MR<= 9<= =47;<H;L8=9:8;< ;M H4]4< 564]8;RHLa 7;<H;L8=9:4= L9N NR8L=8<JH 8< d;R:S d9< h69<78H7;O `9L8M;6<89A TS4 J98< R5;< 7S9<J4 ;M 7;<:6;L 8H 8<7LR=4= 8< ;:S46 8<7;>4 I4U54<H4KO <4: 8< :S4 `;<H;L8=9:4= d:9:4>4<:H ;M \5469:8;<HA IQK TS4 :S644 >;<:SH 9<= a496 4<=4= 3474>N46 BEO Q@QB 8<7LR=4 7;H:H 64L9:4= :; :S4 56;5;H4= >46J46 V8:S lSaH8789<H 49L:a T6RH:O VS87S 964 568>968La 7;>568H4= ;M L4J9LO 977;R<:8<JO :9UO 9<= ;:S46 7;H:H :S9: V464 8<7R664= 568;6 :; a496[4<=O 596:89LLa ;MMH4: Na :46>8<9:8;< M44 8<7;>4 9HH;789:4= V8:S m695S8:4 n8;O o<7AO M;6 VS87S :S4 L49H4 :46>H S9]4 N44< >;=8M84= :; 9774L469:4 4U5869:8;< ;M :S4 L49H4 :; 3474>N46 Q@QDA T46>8<9:8;< M44 8<7;>4 8H 8<7LR=4= 8< 64<:9L 9<= 64L9:4= 64]4<R4H ;< :S4 `;<H;L8=9:4= d:9:4>4<:H ;M \5469:8;<HA IBK TS4 :S644 >;<:SH 9<= a496 4<=4= 3474>N46 BEO Q@QQ 8<7LR=4 pF >8LL8;< ;M 7S96J4H 8<7R664= 8< 7;<<47:8;< V8:S :S4 =;V<H8?8<J ;M :S4 `;>59<aqH 7;65;69:4 S49=rR96:46H 8< 34<]46O `;L;69=;O VS87S 964 8<7LR=4= 8< J4<469L 9<= 9=>8<8H:69:8]4 4U54<H4H 8< :S4 `;<H;L8=9:4= d:9:4>4<:H ;M \5469:8;<HA TS4 a496 4<=4= 3474>N46 BEO Q@QQ 9LH; 8<7LR=4H :S4 M;LL;V8<JO VS87S 964 8<7LR=4= 8< ;:S46 8<7;>4 I4U54<H4KO <4: 8< :S4 `;<H;L8=9:4= d:9:4>4<:H ;M \5469:8;<Hs I8K pED >8LL8;< ;M 4U54<H4H 8<7R664= M;6 :4<9<: 64L;79:8;< 9<= ;:S46 7;H:H 9HH;789:4= V8:S :S4 =4>;L8:8;< ;M 9< ;R:59:84<: >4=879L NR8L=8<J 9<= I88K 9 pQB >8LL8;< J98< ;< H9L4 ;M 9 S;H58:9L R<=46 9 =8647: M8<9<78<J L49H4A TS4 :S644 >;<:SH 9<= a496H 4<=4= 3474>N46 BEO Q@QB 9<= Q@QQ 8<7LR=4 64H46]4H 9<= I647;]4684HK M;6 4U547:4= L;9< L;HH4H 647;J<8?4= 8< 8>5986>4<:H 9<= L;9< L;HH 64H46]4H I647;]4684HKO <4: 8< :S4 `;<H;L8=9:4= d:9:4>4<:H ;M \5469:8;<HA IDK TS4 :S644 >;<:SH 9<= a496 4<=4= 3474>N46 BEO Q@QQ 8<7LR=4 pBQ >8LL8;< ;M H4]469<74[64L9:4= 7S96J4H 9HH;789:4= V8:S :S4 =4596:R64H ;M ;R6 M;6>46 `S84M tU47R:8]4 \MM8746 9<= M;6>46 `S84M G4J9L \MM8746 9<= m4<469L `;R<H4L 8< :S4 M;R6:S rR96:46 ;M Q@QQA TS4H4 4U54<H4H 964 8<7LR=4= 8< J4<469L 9<= 9=>8<8H:69:8]4 4U54<H4H 8< :S4 `;<H;L8=9:4= d:9:4>4<:H ;M \5469:8;<HA ICK `9HR9L:a[64L9:4= 7S96J4H I647;]4684HKO <4: 964 647;J<8?4= 8< ;:S46 8<7;>4 I4U54<H4KO <4: 9<= 4rR8:a 8<7;>4 IL;HHK M6;> R<7;<H;L8=9:4= i;8<: ]4<:R64H 8< :S4 `;<H;L8=9:4= d:9:4>4<:H ;M \5469:8;<HA I_K o< 7;<iR<7:8;< V8:S 7L9HH8Ma8<J :S4 9HH4:H 64L9:4= :; :S4 `9LL9< 8=J4 uv 9H S4L= M;6 H9L4 9H ;M 3474>N46 BEO Q@QBO V4 7;<7LR=4= 8: V9H >;64 L8e4La :S9< <;: :S9: V4 V;RL= 649L8?4 :S4 MR:R64 ]9LR4 ;M 746:98< =4M4664= :9U 9HH4:H J4<469:4= Na :S4 <4: ;5469:8<J L;HH4H ;M :9U9NL4 toT HRNH8=89684HA f77;6=8<JLaO =R68<J :S4 :S644 >;<:SH 9<= a496 4<=4= 3474>N46 BEO Q@QBO V4 647;J<8?4= :S4 64]46H9L ;M 9 5;6:8;< ;M :S4 9HH;789:4= ]9LR9:8;< 9LL;V9<74 9<= 647;J<8?4= 9 7;664H5;<=8<J 8<7;>4 :9U N4<4M8:A IFK TS4 a496 4<=4= 3474>N46 BEO Q@QB 8<7LR=4H 9< pwAF >8LL8;< V68:4[;MM ;M H:698JS:[L8<4 64<: 64748]9NL4 9HH;789:4= V8:S d;664<:; TS46954R:87HO o<7AO VS87S 7;>>4<74= ];LR<:96a 64;6J9<8?9:8;< 56;744=8<JH R<=46 `S95:46 EE ;M :S4 xAdA n9<e6R5:7a `;=4A TS8H 97:8]8:a 8H 64ML47:4= 9H 9 64=R7:8;< ;M 64<:9L 9<= 64L9:4= 64]4<R4H 8< :S4 `;<H;L8=9:4= d:9:4>4<:H ;M \5469:8;<HA yz{|}{~ ~€~|}‚ F

​ -​- ​ - ​ ​ ​ ​-​- ​ ! "​ # # $​% ​& '' #​$ (​ ​)​*​ (​ ​) +​ ,-./​-01.1-​2-/.1-3​3-42-56.1678​.83​.97216:.1678 ​;<==​ ​ ;<==​ >-./1?4-.@A0​0?.2-​7B​2-./​-01.1-​2-/.1-3​3-42-56.1678​.83​.97216:.1678​B279​C857807/63.1-3​ D7681​E-81C2-0 ​ F<FG​ ​ F<FG​ H78578127//68I​681-2-010A​0?.2-​7B​2-./​-01.1-​2-/.1-3​3-42-56.1678​.83​.97216:.1678 ​JF<FKL​​ JF<FKL​ M700​JI.68L​C478​5?.8I-​7B​578127/N​8-1 ​JF<;KL​​ JF<;KL​ O.P-0​.00756.1-3​Q61?​2-./​-01.1-​360470616780 ​F<FK​ ​ F<FK​ ! "​R ​ ​% ​& '' #​$ (​ )S ​ (​ )T​​ O2.80.51678U2-/.1-3​61-90 V​ F<;W​ V​ F<;W​ ! "​ ​ $​X"Y $ "​% ​& '' #​$ (​ )*+​ (​ )*Z​ [175@U\.0-3​5794-80.1678​.97216:.1678​-P4-80- V​ F<F]​ V​ F<F]​ 97216:.1678​7B​3-B-22-3​B68.8568I​57010 ​F<F=​ ​ F<F=​ [12.6I?1U/68-​2-810 ​ JF<F_L​​ JF<F_L​ ``a​5.461./​-P4-8361C2-0 ​JF<;bL​​ JF<;bL​ 97216:.1678​7B​.\7E-​J\-/7QL​9.2@-1​/-.0-​681.8I6\/-0N​8-1 ​JF<FGL​​ JF<FGL​ a1?-2​``a​.3DC019-810 ​JF<FKL​​ JF<FKL​ ! "​X ​% ​& '' #​$ (​ )S​​ (​ )ST​ cccccccccccccccccccccccccccccccccccccc J;L O?-0-​KFKG​7C1/77@​2.8I-0​427E63-​.​B2.9-Q72@​B72​9-12650​7B​>-./1?4-.@​B7//7Q68I​1?-​9-2I-2​Q61?​d?e0656.80​,-./1e​O2C01<​00C9-0​5/7068I​3.1-​7B​f.25?​;N​ KFKG​.83​Q-6I?1-3​.E-2.I-​0?.2-​57C81​7B​.4427P69.1-/e​gWF​96//678​B72​KFKG< JKL O?-​B72-I768I​427D-516780​2-B/-51​9.8.I-9-81A0​E6-Q​7B​5C22-81​.83​BC1C2-​9.2@-1​5783616780​.0​7B​`-\2C.2e​bN​KFKG​685/C368I​.00C9416780​Q61?​2-04-51​17​2-81./​ 2.1-0N​755C4.85e​/-E-/0N​3-E-/749-81​61-90N​.83​1?-​-.2868I0​694.51​7B​1?-​-E-810​2-B-2-85-3​68​7C2​-.2868I0​42-00​2-/-.0-​1?.1​Q.0​600C-3​78​`-\2C.2e​bN​ KFKG<​>7Q-E-2N​1?-0-​427D-516780​37​871​2-B/-51​1?-​694.51​7B​C8.887C85-3​BC1C2-​12.80.516780N​-P5-41​.0​3-0526\-3​?-2-68<​aC2​.51C./​2-0C/10​9.e​36BB-2​ 9.1-26.//e​B279​1?-​427D-516780​0-1​B721?​.\7E-<​hP5-41​.0​71?-2Q60-​2-iC62-3​\e​/.QN​9.8.I-9-81​.00C9-0​87N​.83​?-2-\e​3605/.690​.8eN​7\/6I.1678​17​C43.1-​ ..8e​7B​1?-​B72-I768I​427D-516780​.0​.​2-0C/1​7B​8-Q​68B729.1678​72​8-Q​72​BC1C2-​3-E-/749-810< jklmnlopoqromns b

​-​ ​ - !"​ ! ​ ​" " ​ # $ % & '() )& *+,-./0-+/. 1+ 2+3 23,2+4-. /5 6+45+.57132/-3 851+/ ,-+/69-. :;<=><?@A B4460672/-3 3-C9-412/15+ 2+3 2059/1D2/15+ 5E 9-27 -./2/- @>?FG>F?G B4460672/-3 2059/1D2/15+ 5E 9-27 -./2/- 1+/2+H1I7-. J=?>K;= B4460672/-3 3-C9-412/15+ 2+3 2059/1D2/15+ 5E 9-27 -./2/- 2..-/. L-73 E59 .27- ?>@M; - !"​ ! ​ % ) ( ) )N O-27/LC-2PQ. .L29- 5E 6+45+.57132/-3 851+/ ,-+/69- H95.. 2..-/. G>K=G>KF; ​-​ ​ % ( (&( R)R SSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSS :GA T5+.57132/-3 /5/27 2..-/. 9-C9-.-+/. /5/27 2..-/. 5+ /L- T5+.57132/-3 U272+4- VL--/ 2. 5E W-4-0I-9 @G> =K=@ C9-.-+/-3 5+ C2H- < X1/L1+ /L- Y29+1+H. Z-7-2.- 2+3 V6CC7-0-+/27 Z-C59/ E59 /L- [629/-9 -+3-3 W-4-0I-9 @G> =K=@\ ] ​ _-` ​ -​ a" bc​ "​ -​ d ! " e b​f g ​" h-/ 9-27 -./2/- i ;>=;J>FJJ i J>K;F><;@ i G>M;@>?JM i j i G@>K=<>@M@ Z-27 -./2/- 2..-/. L-73 E59 .27-> +-/ GKF>;=? <>K<K j j GG;><K? *+/2+H1I7- 2..-/.> +-/ ;@>;@F GG=>@FM G=<>K=G j @GJ>G?M B4460672/-3 3-C9-412/15+ 2+3 2059/1D2/15+ 5E 9-27 -./2/- G>JJJ><;G G>;FK><GM @?M>=MJ j @>?FG>F?G B4460672/-3 2059/1D2/15+ 5E 9-27 -./2/- 1+/2+H1I7-. MM>;G@ GJF>;K= =K<>M?; j J=?>K;= B4460672/-3 3-C9-412/15+ 2+3 2059/1D2/15+ 5E 9-27 -./2/- 2..-/. L-73 E59 .27- j ?>@M; j j ?>@M; O-27/LC-2PQ. .L29- 5E 6+45+.57132/-3 851+/ ,-+/69- H95.. 9-27 -./2/- 2..-/. JMJ>K?G =G>F?K j J;G>JG= F?;>JG@ k677l 3-C9-412/-3 2+3 2059/1D2/15+ 9-27 -./2/- 2+3 1+/2+H1I7-. 2..-/. ??@>K@; ;KK>JMF =K>FJF j G>=;J>J?? m-2.1+H 45001..15+. 2+3 5/L-9 F@>@@@ ;=>@=? j j GM?>M?< W-I/ 1+,-./0-+/. j j j G;<>?J; G;<>?J; m2+3 L-73 E59 3-,-75C0-+/ :;K@>MFGA :J>M;MA j j :;K<>@M;A Z-27 -./2/- 1+/2+H1I7- 712I171/1-.> H95.. :GFK>F==A :G@M><?@A j j :@=;>;;?A h5+45+/95771+H 1+/-9-./.Q .L29- 5E 45+.57132/-3 851+/ ,-+/69- 9-27 -./2/- 2+3 9-72/-3 1+/2+H1I7-. :?>KFJA :@<@>FK?A j j :@<<>FFFA ] ​ _-` ​ -​ % ( ) N ' % ' R & &RR % )N R N % 'R( (&( % ) ' 'R' nopqrpstsuvsqrw F

​-​- - -- - - - - ! " ! # - ! ! $-% - - ! ! - - - ! &'( ) *+,-./* ) *+/-010 ) **2-2+1 ) **1-+/. ) **2-0., 3456'57895 :8;7<'= >?0-*.2 >?1-.1, >?1-11> >.>-+>1 >??-?2/ @@A@ >*/-?,2 >*,-+?0 >2+->?0 >22-?+? >21-20> 35B8C 1-2/+ 1->12 /-*,. /-21+ 0-.,. @DC6DC'58 ED9FG8HI895 J J J J J "K -​- - L M N NOP L M M OQP L MNM N ! L MMO N L MM OM &'( J J J J J 3456'57895 :8;7<'= J J J J J @@A@ J >2, 0, J J 35B8C J J J J J @DC6DC'58 ED9FG8HI895 J J J J J R ​- - S " T - L U L Q L NQ L U L U &'( J J J J J 3456'57895 :8;7<'= J J J J J @@A@ J J J J J 35B8C V1-2/+W V1->12W V/-*,.W V/-21+W V0-.,.W @DC6DC'58 ED9FG8HI895 J J J J J X- Y Z - - T - L [O M!\ L [O O \ L [M Q]\ L [M O!\ L [N ]Q]\ &'( 0-*?/ *->1/ >-.*? *-0*/ 2-0+1 3456'57895 :8;7<'= ,/+ ,0/ ,/0 ,01 ,?? @@A@ J J J J J 35B8C >?-.1. *+-201 *+-*1> *+-/,* *>-*0, @DC6DC'58 ED9FG8HI895 J J J J J -"K %-"_` " - a KT " - b T ​- - -"K - " - -​- - L N !!N L MO L ]N L QN L M NN &'( J J J J J 3456'57895 :8;7<'= J J J J J @@A@ 0, J J J J 35B8C J **? J J > @DC6DC'58 ED9FG8HI895 J J J J J -"K %-"_` " - a KT " - b T ​- - S ​- - S " T - L NQ L P L U L U L &'( V.0W V>02W V>/>W V>/0W V>,>W 3456'57895 :8;7<'= V?-.?1W V?-.12W V?-11/W V?-,2/W V?-,>+W @@A@ J J J J J 35B8C J J J J J @DC6DC'58 ED9FG8HI895 J J J J J c KKT S T - - ` " - a KT " - b T ​- - -"K - " - -​- - L [] !P!\ L [] !O\ L [P P O\ L [P PP]\ L [P PP \ &'( *>*->02 *+,-0?1 **/-+?2 **?-22+ **1-,2* 3456'57895 :8;7<'= >,1-+/, >,?-,0. >,?-,0. >?2-+*, >?+-.>2 @@A@ >*/-.*+ >*,-**> >2+-*2> >22-?+? >21-20> 35B8C >?-.1. *+-/,0 *+-*1> *+-/,* *>-*0? @DC6DC'58 ED9FG8HI895 J J J J J d a KT ​-"K " - ​-​- - L M !P] L M N ! ! L MMN N L MOM Q Q L MOM N e T - fghijhklkmnkijo >+

​-​- - -- - - - - ! " ! # - ! ! $-% - - ! ! - - - ! &'( )**+,-./ )-01/ )*0+234/ )2+0,,/ )*4+12./ 5678'79:;7 <:=9>'? )3+.@*/ )0+0,4/ )0+.-3/ )0+11@/ )@+.*1/ AABA C C C C )*/ 57D:E 33 )-/ *, )3/ )-*/ AFE8FE'7: GF;HI:JK:;7 C C C C C L M " " N - O P QR ​-"Q " - ​-​- - S T U V W S TX !W S T Y V ZW S T U!XW S T YY!W &'( 144+@3, 14.+.00 1*4+*@@ 1*-+-30 1*.+0@. 5678'79:;7 <:=9>'? *,4+01. *,0+1,2 *,0+4.0 *,-+-40 *,,+@4* AABA *13+214 *1,+11* *@4+1@* *@@+-4- *@.+@04 57D:E *2+410 14+3.. 14+1,- 14+3., 1*+*., AFE8FE'7: GF;HI:JK:;7 C C C C C O P QR [" ​-"Q " - ​-​- - S X X U U S X Z U ! S X \ U!V S XX ! S XX \\ &'( **+,-. -01 *0+234 2+0,, *4+12. 5678'79:;7 <:=9>'? 3+.@* 0+0,4 0+.-3 0+11@ @+.*1 AABA C C C C * 57D:E )33/ - )*,/ 3 -* AFE8FE'7: GF;HI:JK:;7 C C C C C L M " " N - O P QR ​-"Q " - ​-​- - S U V S X ! S Y V Z S U!X S YY! &'( )@0+140/ )@4+114/ )00+4-1/ )34+@,,/ )30+*@-/ 5678'79:;7 <:=9>'? )*@+,**/ )*0+2*1/ )*0+1@@/ )*0+133/ )*0+@.1/ AABA )0,/ )*@-/ )1@1/ )143/ )13-/ 57D:E )*-+2.2/ )14+3,0/ )14+1.*/ )14+3,1/ )1*+10-/ AFE8FE'7: GF;HI:JK:;7 C C C C C L M$$ O P QR ​-"Q " - ​-​- - S TVV Y W S TVX Z\\W S TUZ Z!ZW S TZX \!YW S TY! !!VW &'( *,,+2@2 *,,+1.. *-*+44* *,,+230 *,1+320 5678'79:;7 <:=9>'? *.1+@0. *.@+-@, *.0+3*. *.-+,,1 *..+33* AABA *13+-,@ *1,+4-@ *12+222 *@@+.4@ *@.+4-@ 57D:E C C C C C AFE8FE'7: GF;HI:JK:;7 C C C C C O P QR ​-"Q " - ​-​- - M $$T W S \VV XZ S \VZ ZV S \UX X V S \Z! Y S \UX Z &'( )**+021/ )3+.2./ )*1+14./ )3+302/ )@+@12/ 5678'79:;7 <:=9>'? )3+@0./ )0+1.-/ )0+@3./ )@+23@/ )@+@2,/ AABA C * C C C 57D:E C C C C C AFE8FE'7: GF;HI:JK:;7 C C C C C L M " " N - $$ O P QR ​-"Q " - ​-​- - S T V Z ZW S TY YV W S T V XV W S TY X! W S TV U VW &'( *..+00, *,*+3,4 *.-+,23 *,1+043 *.2+1.3 5678'79:;7 <:=9>'? *3,+444 *32+3.2 *.4+*.4 *.0+-*2 *.@+*30 AABA *13+-,@ *1,+4-0 *12+222 *@@+.4@ *@.+4-@ 57D:E C C C C C AFE8FE'7: GF;HI:JK:;7 C C C C C O P QR [" ​-"Q " - ​-​- - M $$T W S \\Y ! S \XZ S \XZ YX\ S \U! Z U S \VZ X! ]_`a_bcbdeb`af **

​-​ -​ ​ ​​ ​ ​ ​ ​ !" #$## !" #$# %& ​ $" #$# '​- ​ ​ $" #$# ​ ​ ​ !" #$# ()* + ,-./0- + ,1.,-- + ,0.2/3 + -4.3-2 + ,-.5-0 6789)8:;<8 =;>:?)@ -0.4/- -0./52 -,./,4 -1.-5/ -,.-5A BBCB A44.AA4 A4A.A30 A4A.-,, A40.11/ A4,.534 68D;E F F F F F BGE9GE)8; HG<IJ;KL;<8 F F F F M0.A10N ​-​ ​ -​ ​ O ##$"PQ# O ## "$RR O ##!"R S O # #"S P O ##P"P$! ()* A.A04 A.A23 202 5,2 A.A40 6789)8:;<8 =;>:?)@ 3-, /4, 322 /4A 35, BBCB F F F F F 68D;E A0.232 A,.44- A0.-A2 A,.0/5 A,.102 BGE9GE)8; HG<IJ;KL;<8 F F F F F T​ U -​ VW ​ X & U ​ Y Z​ & ​ -​ ​ -​ ​ O !["# O !["PQ O !\"S\P O !["[QR O !S"!PS ()* M32N M04N M/,N M//N M02N 6789)8:;<8 =;>:?)@ M3.0/AN M3.,5,N M3.045N M3.010N M3.00/N BBCB F F F F F 68D;E F F F F F BGE9GE)8; HG<IJ;KL;<8 F F F F F ] UU ​ ​ W ​ X U ​ Y Z​ & ​ -​ ​ -​ ​ O #"P\Q_ O #"[ \_ O #"PPP_ O #"\$S_ O #"PQ!_ ()* F F F F F 6789)8:;<8 =;>:?)@ F F F F F BBCB F F F F F 68D;E F F F F F BGE9GE)8; HG<IJ;KL;<8 F F F F M0.A10N ] `- -​ a U​Z​U -​ ​ -​ ​ O b O b O b O b O P"!SP_ ()* ,1.0,2 ,2.142 ,,.-0, -A.A5/ ,2.434 6789)8:;<8 =;>:?)@ -A.214 -3.A42 -/.335 -,.,34 -/.,0/ BBCB A44.AA4 A4A.A30 A4A.-,, A40.11/ A4,.534 68D;E A0.232 A,.44- A0.-A2 A,.0/5 A,.102 BGE9GE)8; HG<IJ;KL;<8 F F F F F c X U ​-​ -​ ​ O # P"#[[ O # ["QP[ O # \"!PS O #P["Q#\ O #P "# ! ()* M2N MA4N M1N /-, -A3 6789)8:;<8 =;>:?)@ M-53N M-05N M-11N M-1-N M-1,N BBCB M3.355N M,4N 132 F 504 68D;E 2 A/ 31 33 M,4,N BGE9GE)8; HG<IJ;KL;<8 F F F F F ] ` Y& ​ c X U ​-​ -​ ​ O #"QQ!_ O [Q[_ O S! O #RQ_ O S# ()* ,1.0,4 ,2.-52 ,,.-/2 -A.,,2 ,2.-/3 6789)8:;<8 =;>:?)@ -A.A12 -A.0,5 -3.,,3 -0.200 -3.2-2 BBCB 51.2AA A4A.410 A43./2/ A40.11/ A4-.2-4 68D;E A0.2/- A,.4A5 A0.-0, A,.0-A A,.30/ BGE9GE)8; HG<IJ;KL;<8 F F F F F c X U d ​-​ -​ ​ O # !"#S\ O # ["#\$ O # \"#!R O #P["[ [ O #P "[$ d &​ efghigjkjlmjhin A3

​-​ -​ ​ ​​ ​ ​ ​ ​ !" #$## !" #$# %& ​ $" #$# '​- ​ ​ $" #$# ​ ​ ​ !" #$# ()* + ,- . /0123 /1,43 5678)79:;7 <:=9>)? 1@4 1A@ 1.. 1.1 1.2 BBCB 4D4@@ 2- /.4+3 E /@A-3 57F:G /+3 /,03 /4.3 /443 2-2 BHG8HG)7: IH;JK:LM:;7 E E E E E N O P& ​ Q R S ​-​ -​ ​ T #"UU! T VUV T WX!Y T #ZU T W X#Y ()* /@D.0,3 /@D,,,3 /+D@@-3 /,-D@4,3 /,-D1AA3 5678)79:;7 <:=9>)? /1D@4A3 /1D4203 /1D@003 /.D-@@3 /1D+2+3 BBCB /0A,3 /AA.3 /AA23 /20.3 /2-A3 57F:G /,AD+4+3 /,2D--13 /,AD1,+3 /,2DA0@3 /,2D.A+3 BHG8HG)7: IH;JK:LM:;7 E E E E E N O'' Q R S ​-​ -​ ​ T W !"Z#[Y T W $"Z!XY T W $"UZVY T W "UUVY T W "X\[Y ()* A.D.4. A@D2@. A1D122 2-D4.4 A.D0.1 5678)79:;7 <:=9>)? 2AD@A1 22D+22 21D4@1 2+DA4, 21D1+2 BBCB @@D.1@ ,--D1.. ,-,D4,- ,-AD401 ,-2DA,1 57F:G E E E E E BHG8HG)7: IH;JK:LM:;7 E E E E E Q R S ​-​ -​ ​ O ''W!Y T #$#"[[# T #$V"!#U T #$["!V! T #!#"U#U T #$U"[XX ()* /,,3 /@3 /13 /03 /43 5678)79:;7 <:=9>)? /1223 /1,23 /1A23 /1A03 /10+3 BBCB /4D0--3 /A@3 .4+ E @A- 57F:G E E E E E BHG8HG)7: IH;JK:LM:;7 E E E E E N O P& ​ '' Q R S ​-​ -​ ​ T W#"UVVY T WVX Y T XX T WV[VY T $$ ()* A.D.,1 A@D2++ A1D1A@ 2-D41@ A.D0.A 5678)79:;7 <:=9>)? 2AD4@, 22D4A- 22D12, 2.D..+ 21D-A. BBCB @.DA1@ ,--D14+ ,-,D@0+ ,-AD401 ,-1D021 57F:G E E E E E BHG8HG)7: IH;JK:LM:;7 E E E E E Q R S ] ​-​ -​ ​ O ''W!Y T !UU"[XV T #$\"[\V T #$["# Z T #!#"#Z T #$U"XXX _`ab`cdcefcabg ,0

​-​- - - - - - - - - - !" #$# - - - - - !" #$# %&' ( )*)+,-. %&' ( --/+.,0 1234&35673 8695:&; *<,+=*/ 1234&35673 8695:&; -.,+>,- ??@? <-*+=>* ??@? =>,+=*- 13A6B ->+*)> 13A6B C ?DB4DB&36 ED7FG6HI673 C ?DB4DB&36 ED7FG6HI673 J=+>*=K LM N -​- - O #"!P!"$$ - - - - O Q$#"$R$ %&' C %&' =+0/- 1234&35673 8695:&; C 1234&35673 8695:&; >+>)/ ??@? >)= ??@? C 13A6B C 13A6B .0+)>> ?DB4DB&36 ED7FG6HI673 C ?DB4DB&36 ED7FG6HI673 C SM​- - M - O !PT U- N V - WX V - MY M MN - ZM ​- - M - - - - O RR"$Q# %&' C %&' J><.K 1234&35673 8695:&; C 1234&35673 8695:&; J/+/->K ??@? C ??@? C 13A6B J->+*)>K 13A6B C ?DB4DB&36 ED7FG6HI673 C ?DB4DB&36 ED7FG6HI673 C [- \ ] - - M - O #!"_P!` aM M MNN - - X V - MY M MN - ZM ​- - M - - - - O !$"$__` %&' /+/-= %&' C 1234&35673 8695:&; ,+0,, 1234&35673 8695:&; C ??@? C ??@? C 13A6B )-+=-. 13A6B C ?DB4DB&36 ED7FG6HI673 C ?DB4DB&36 ED7FG6HI673 J=+>*=K U- N V - WX V - MY M MN - ZM ​- - - N - - -​- - O Qb" P aM c M - d N-​-N M - - - - O T"!_T` %&' C %&' -,,+<.. 1234&35673 8695:&; C 1234&35673 8695:&; -<=+=00 ??@? C ??@? =>,+=*- 13A6B --/ 13A6B .0+)>> ?DB4DB&36 ED7FG6HI673 C ?DB4DB&36 ED7FG6HI673 C U- N V - WX V - MY M MN - ZM ​- - M​- - M - O ##Q eM YMN M - - - O QR#"#TQ %&' J.>/K %&' /.> 1234&35673 8695:&; J,<+0*,K 1234&35673 8695:&; J-+.*.K ??@? C ??@? >+.>) 13A6B C 13A6B J==,K ?DB4DB&36 ED7FG6HI673 C ?DB4DB&36 ED7FG6HI673 C aM M MNN - - X V - MY M MN - ZM ​- - - N - - -​- - O b"RQ#` aM c V Z - M eM YMN M - - - O bT$` %&' ))*+.,> %&' -,=+<-* 1234&35673 8695:&; *->+=,/ 1234&35673 8695:&; -<>+*-= ??@? <-*+.0> ??@? =><+0/0 13A6B )-+.<< 13A6B .0+,.) ?DB4DB&36 ED7FG6HI673 C ?DB4DB&36 ED7FG6HI673 C eM YMN M ​- N - ​-​- - O #"#!Q" #R eM YMN M f V - - - O QR!"_$Q fM - ghijkilmlnoljkp >=

​-​- - - - - - - - - - !" #$# - - - - - !" #$# %&' ()*+*,)- %&' (.,/- 0123&24562 75849&: (/,+../- 0123&24562 75849&: ;+,<, ==>= ? ==>= (/+,/@- 02A5B (<<- 02A5B CC) =DB3DB&25 ED6FG5HI562 ? =DB3DB&25 ED6FG5HI562 ? JK L M N - K OK PKQ K ​- Q - ​-​- - R ST#"U !V JK L M OK PKQ K W M - - - R TX$ %&' @*;+Y,@ %&' (C@+)*.- 0123&24562 75849&: <YC+CC@ 0123&24562 75849&: ())+,C*- ==>= *;<+,Y/ ==>= (/+.))- 02A5B @;+*<@ 02A5B (,Y+@//- =DB3DB&25 ED6FG5HI562 ? =DB3DB&25 ED6FG5HI562 ? OK PKQ K W M ​- Q - ​-​- - R #"!UU"UZT JK L[[ OK PKQ K - - - R S!XX"\X]V %&' )*+*,) %&' /@*+;Y< 0123&24562 75849&: /,+../ 0123&24562 75849&: ;;Y+<** ==>= ? ==>= C//+*). 02A5B << 02A5B ? =DB3DB&25 ED6FG5HI562 ? =DB3DB&25 ED6FG5HI562 ? JK L M N - K OK PKQ K ​- Q - ​-​- - R T#"U ! OK PKQ K - - - L [[S!V R ]!\"T$! %&' (;/<+)/,- %&' (/.- 0123&24562 75849&: (<)+,);- 0123&24562 75849&: (;+*Y.- ==>= (@);- ==>= /+,/@ 02A5B (@;+,**- 02A5B ? =DB3DB&25 ED6FG5HI562 ? =DB3DB&25 ED6FG5HI562 ? JK L[[ OK PKQ K ​- Q - ​-​- - R S \X"X TV JK L M N - K [[ OK PKQ K - - - R SZ!$V %&' ,<Y+)/* %&' /@*+/@@ 0123&24562 75849&: ,C<+@Y< 0123&24562 75849&: ;/@+;C, ==>= *;,+<,. ==>= C/)+/*< 02A5B ? 02A5B ? =DB3DB&25 ED6FG5HI562 ? =DB3DB&25 ED6FG5HI562 ? OK PKQ K ​- Q - ​-​- - L [[S!V R !"]XX"]Z! OK PKQ K W M - - - L [[S!V R ]!U"TZ! %&' (;)+..@- 0123&24562 75849&: (/C+/.)- ==>= ? 02A5B =DB3DB&25 ED6FG5HI562 ? JK L M N - K [[ OK PKQ K ​- Q - ​-​- - R S ]"!Z!V %&' ,C,+)/< 0123&24562 75849&: ,))+,/C ==>= *;,+<,. 02A5B ? =DB3DB&25 ED6FG5HI562 ? OK PKQ K W M ​- Q - ​-​- - L [[S!V R !"]$U"\$$ (/- _A5 3BD35B2` 9D162 1G58 aDB bDB2aD:4D >5&: cG2&25 >5d5615G F ee+ bDB2aD:4D =&GA >5&: cG2&25 >5d5615G F ee+ bDB2aD:4D 035B&246H cf356G5G F ee+ &68 bDB2aD:4D =&GA 035B&246H cf356G5G F ee 84aa5B58 aDB 2A5 2AB55 &68 2g5:d5 ID62AG 56858 h595I'5B )/+ ;Y;)i jklmnlopoqromns /*

​-​ - ​ ​- - -- ​ - - - - !" #$# %-&'- ​ - - - - !" #$# ​-​ ( - )& * + ,-" .- + /",-, 01234352 3673153 89:;<= 9>>:??@ 01ABC3 2D6 3673153 EF313GH2I E@@:<=9I EJ:K@;I L3743AHD2HB1 D1M DCB42HND2HB1 @<<:8== ;=J:J>@ O2P34 M3743AHD2HB1 D1M DCB42HND2HB1 @:@K< K:9KJ QB55 ERDH1I B1 5DS35 BG 43DS 352D23 T E<K:=K?I QB55 ERDH1I U7B1 APD1R3 BG AB124BS T E9?=I VPD43 BG U1AB15BSHMD23M WXY 01234352 3673153 <?= @:J<; 01ABC3 2D6 3673153 EF313GH2I @8> K=< L3743AHD2HB1 D1M DCB42HND2HB1 K:;9? 9=:<>> - + ! ",-Z + !"###" ,. [4D15DA2HB1 D1M C34R34\43SD23M H23C5E@I @@:9>9 @=:?>> O2P34 HC7DH4C3125 E43AB]34H35I D1M B2P34 SB5535 ERDH15IE@I E8:==8I E=:8?JI 3524UA2U4H1R D1M 53]34D1A3\43SD23M APD4R35 T @:?K< _D5UDS2`\43SD23M APD4R35 E43AB]34H35IE@I E?:=K9I E=:9@=I V2BAa\FD53M ABC7315D2HB1 DCB42HND2HB1 3673153 ?:8@? @=:=<> 0C7DA2 BG 24D15DA2HB15 ASB53M MU4H1R 2P3 734HBME9I 89 E?:J9;I ​- - + !."Z!Z + !"# ."b/, ​- c(d- e f g- e '- fg- -- ​ - - - - !" #$# %-&'- ​ - - - - !" #$# 01234352 3673153: H1ASUMH1R U1AB15BSHMD23M WX H1234352 3673153 D2 5PD43 8?:K@< 9>9:?@< _D7H2DSHN3M H1234352: H1ASUMH1R U1AB15BSHMD23M WX AD7H2DSHN3M H1234352 D2 5PD43 @=:=?K 8<:=J= c(d- e f g- + Zb"$-/ + #Z$"b!# ​- c(d- e f g- e '- fg- /h,d /hbd iiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiii E@I [PH5 DCBU12 H1ASUM35 2P3 AB44357B1MH1R SH13 B1 2P3 jU1M5 j4BC O734D2HB15 43AB1AHSHD2HB1 B1 7DR3 K BG 2PH5 MBAUC312 36ASUMH1R 2P3 43SD23M 2D6 HC7DA2 H1ASUM3M H1 2P3 DMkU52C312 GB4 H1ABC3 2D6 3673153 EF313GH2I DFB]3l E9I mMkU52C312 43GS3A25 2P3 HC7DA2 BG 24D15DA2HB15 2PD2 ASB53M MU4H1R 2P3 734HBM D5 HG 2P3 24D15DA2HB15 n343 ABC7S323M D2 2P3 F3RH11H1R BG 2P3 734HBMl opqrsqtutvwtrsx @K

​-​ ​ - ​ ​ !" #$!% &' ()%*$+ !* (&,,%)($ # - -%) . /012111 3%), #& !4 5672805 9%!$&) :!4%(:)%* !&+%4 ;251<2</8 =&)+> >% *%?+ 0;7216/ @A- AB ​ ​ C D EFD GG 9H )% &' :!(&!4&#$* +%* IJ ,&)+> >% *%?+ <62617 ​-​ ​ C D G D K L 4H !* ( 4H %M:$N #%!+4 OPP/27<;Q 9H )% &' :!(&!4&#$* +%* IJ ( 4H !* ( 4H %M:$N #%!+4 O06205<Q R%4+)$(+%* ( 4H O;P2<88Q 9H )% &' :!(&!4&#$* +%* IJ )%4+)$(+%* ( 4H O82100Q ​ ​ C D F G G F S - - B T U V W!+%)-)$4% X%?+ . 726P7201; W!+%)-)$4% Y)&44 Z44%+4 P626;62585 [$! !($ # \%N%) >% <5]/ _ ` ​ a ​ A =&)+> >% *%?+ . 0;7216/ 9H )% &' :!(&!4&#$* +%* IJ ,&)+> >% *%?+ <62617 ​-​ _ ` ​ C GD W!+%)-)$4% Y)&44 Z44%+4 P626;62585 9%(:)%* X%?+ R +$& P]; ​ ​ ​A b c` ​ ​def b fg hA-​g ​- fi BU hA-​g ​- j%+ X%?+ . 72/1626P/ . 72/1626P/ Z!!: #$k%* Z*l:4+%* W m3XZ)%OPQ P20/82575 P20<6285/ j%+ X%?+ +& Z*l:4+%* W m3XZ)% ;]0n ;]5n oooooooooooooooooooooooooooooooooooooo OPQ [&) +H% +H)%% ,&!+H4 %!*%*2 )%-)%4%!+4 +H% (:))%!+ M: )+%) Z*l:4+%* W m3XZ)% ,:#+$-#$%* ?p ' (+&) &' '&:)] [&) +H% +q%#N% ,&!+H4 %!*%*2 )%-)%4%!+4 +) $#$!> +q%#N% ,&!+H4 Z*l:4+%* W m3XZ)%] rstuvtwxwyzwuv{ P/

​-​ - - - ​​ !"#$ %# &'()* +',(-'*.' / -- 0 1 - 2- - 3- 45 6766 0 45 6764 8 - 47 6764 ​-9 - 3- 47 6764 2- - 3- 45 6764 - - : 57 ;76 : 54< =7> : =? 5@@ : ?; ?=? : >= 4@= ABCDEFGH IEJJ KLEF MNJDECONCPGM EQGLRONECJ ASTUH V V V V - ​ 9- : @ @6@ : 54< =7> : =? 5@@ : ?; ?=? : >= 4@= BCOGLGJO NCDEFG AWXUYZH AWX[WUH AYX\T]H AYXUWZH AX]T]H BCOGLGJO G_QGCJG ]X[U TX]WU ]XZT YZXY[Z Y\XTS `GQLGDNRONEC RCM RFELONaRONEC [T]X[YT [T]X\\Y []TXYTU [SXYY] [SSXY bGCGLRI RCM RMFNCNJOLRONcG YTXST\ \XYT \YX]UW \UXZ]U \[XYYW dLRCJRDONEC RCM FGLeGLfLGIROGM DEJOJ UX\[T \X\Y WUT UW [X[T BFQRNLFGCOJ RCM IERC IEJJ LGJGLcGJX CGO UXU\W A\X\[UH \XWZT AYYZH AYXYH AbRNCH IEJJ EC JRIGJ EK LGRI GJOROGX CGO ]W] AS[XYTSH AXSSYH V V gOhGL ANCDEFGH G_QGCJGX CGO YST ATT\H A[X]YYH A[XS[H A\XWZZH bEcGLCFGCO eLRCO NCDEFG V [UT T V V BCDEFG OR_ AiGCGKNOH G_QGCJG AWYZH UZ\ [X[UW TST A[[XS\H jkPNOl ANCDEFGH IEJJ KLEF PCDECJEINMROGM mENCO cGCOPLGJ [YW A[XS[WH A\XT\]H A\X[Z[H AUXYYSH nGRIOhQGRopJ JhRLG EK PCDECJEINMROGM mENCO cGCOPLG qgB TXS[S WX]][ TX[S] TXZY SX\]Y qECDECOLEIINCe NCOGLGJOJp JhRLG EK DECJEINMROGM mENCO cGCOPLG qgB AWXW\[H AWXT[H AWXUT\H AWXUS\H AWXU]ZH qECfQLEQGLOl IGcGI qgB V V V V AX[TH : 6@; ;64 : 6@> 7;< : 45@ 5>; : 45; ;56 : 466 774 rMmPJOFGCOJ OE sELOKEINE qgB A[XUT[H AXW\H A[]XWSSH A[UX[WH A[XUW[H - : 6;< <=6 : 6@6 <?7 : 6@@ <@7 : 47= 4@? : 47> ?<6 BCOGLGJO NCDEFG WXUYZ WX[WU YX\T] YXUWZ X]T] - : 6@7 ;76 : 6@; ?64 : 47< >?@ : 457 >=? : 456 ?65 BCOGLGJO NCDEFG AWXUYZH AWX[WUH AYX\T]H AYXUWZH AX]T]H rMmPJOFGCOJ OE sELOKEINE qgB [XUT[ XW\ []XWSS [UX[W [XUW[ qECftt sELOKEINE qgB AUYX[ZTH AUYXZ\TH ATXS\UH AY[X[\H AYWX\Y\H ​​ : 6?4 >5? : 6?6 7=> : 6>5 4== : 6?> <77 : 6?= >=5 qECfDRJh RMmPJOFGCO OE tt sELOKEINE qgB A[UXST\H A]X\]ZH A[WXWU]H ASXSYYH ATXZ\WH ​​ - : 6<@ ;<< : 6=6 >?> : 6=< >5? : 6=; =<= : 6=; >6= - uvw'xw.*.)(.'xy [S

​-​ - - - ​​ !"#$ %# &'( ) -- * + - ,- - -- ./ 0100 * ./ 010. 2 - .1 010. ​-3 - -- .1 010. ,- - -- ./ 010. - - 4 56 656 4 /.. 067 4 58 66/ 4 77 ..5 4 78 9/. :;<=>?@A B>CC DE>? FGC=><HG<I@F >J@EKHG><C L L L L L - ​ 3- 4 56 656 4 /.. 067 4 58 66/ 4 77 ..5 4 78 9/. M@JE@=GKHG>< K<F K?>EHGNKHG>< OPQRSO OTQTUV SWQVWT OUQRPR UXQUUR YEK<CK=HG>< K<F ?@EZ@E[E@BKH@F =>CHC VX \TU L T\ \VP :]KG<A B>CC >< CKB@C >D E@KB @CHKH@Q <@H \\V :RXQPSUA L L L H_@E :G<=>?@A @`J@<C@Q <@H :OA :PA V \ :RA abIGHc :G<=>?@A B>CC DE>? I<=><C>BGFKH@F d>G<H e@<HIE@C \QVXS :TSUA :\QW\PA :\QVPPA :\QWUPA f@KBH_J@KghC C_KE@ >D I<=><C>BGFKH@F d>G<H e@<HIE@ i; WQ\PT SUW \QXUX \QPRO VQWXV i><=><HE>BBG<Z G<H@E@CHCh C_KE@ >D =><C>BGFKH@F d>G<H e@<HIE@ i; :RRA :\XWA :\\RA :\V\A :\VWA 4 /6j 876 4 /j7 557 4 /89 j.7 4 /85 /.5 4 /87 5/0 kFdICH?@<HC H> l>EHD>BG> i; :\\QOOUA :UWVA :\PQSPWA :SQUPVA :\XQSXOA - / 4 /j0 915 4 /j5 9j8 4 /6j j96 4 /65 096 4 /65 716 kFdICH?@<HC H> l>EHD>BG> i; \\QOOU UWV \PQSPW SQUPV \XQSXO i><[mm l>EHD>BG> i; :VPQPOWA :V\Q\XSA :WTQXSVA :WSQPTTA :PWQPSPA ​​ 4 /.1 0/0 4 /05 889 4 /.j .j8 4 /05 870 4 /06 0/7 i><[=KC_ KFdICH?@<H H> mm l>EHD>BG> i; :\\QPU\A :TQRUOA :\VQVXXA :TQTPRA :WQWVOA ​​ - 4 //7 5./ 4 /0/ 970 4 /00 /j8 4 /00 /.8 4 /0/ 79/ nopq'prstp usvrw'x ) -- * + - ,- - -- ./ 0100 * ./ 010. 2 - .1 010. ​-3 - -- .1 010. ,- - -- ./ 010. - - 4 j6 65/ 4 5/ 18j 4 j7 187 4 j7 918 4 j7 671 :;<=>?@A B>CC DE>? FGC=><HG<I@F >J@EKHG><C L L L L L - ​ 3- 4 j6 65/ 4 5/ 18j 4 j7 187 4 j7 918 4 j7 671 ;<H@E@CH @`J@<C@ \QSOX \QSVX \QSVP \QSPO \QSOS M@JE@=GKHG>< K<F K?>EHGNKHG>< O\QSUW O\Q\TU O\QOVV OVQOWR OPQXRO YEK<CK=HG>< K<F ?@EZ@E[E@BKH@F =>CHC \QXUO \WV \R VW SPS :]KG<A B>CC >< CKB@C >D E@KB @CHKH@Q <@H VWT :V\QW\VA L L L H_@E :G<=>?@A @`J@<C@Q <@H :WTPA :VXPA :VWTA :OUA :VQ\UXA abIGHc :G<=>?@A B>CC DE>? I<=><C>BGFKH@F d>G<H e@<HIE@C :VWTA :\USA :\UPA :V\\A :VT\A f@KBH_J@KghC C_KE@ >D I<=><C>BGFKH@F d>G<H e@<HIE@ i; PUT PPX PRR PPT PSW i><=><HE>BBG<Z G<H@E@CHCh C_KE@ >D =><C>BGFKH@F d>G<H e@<HIE@ i; :RQTTTA :RQWRUA :RQVTRA :RQVR\A :RQVROA 4 //j /75 4 //8 8j/ 4 //6 60/ 4 //5 615 4 //5 .51 kFdICH?@<H H> l>EHD>BG> i; :PQSWSA :WQUV\A :PQXXUA :WQTPOA :VQSWUA - / 4 /19 0j7 4 //0 701 4 /// 6/. 4 //. 981 4 //j j.0 kFdICH?@<H H> l>EHD>BG> i; PQSWS WQUV\ PQXXU WQTPO VQSWU i><[mm l>EHD>BG> i; :RQOUOA :UQRTSA :OQWX\A :OQ\TRA :OQTXPA ​​ 4 /15 j11 4 /15 970 4 /17 001 4 //1 .6/ 4 /19 788 i><[=KC_ KFdICH?@<H H> mm l>EHD>BG> i; :PQRS\A :WQRTWA :WQO\\A :WQWXSA :VQOTSA ​​ - 4 /10 519 4 /1j .09 4 /1j 619 4 /15 1j0 4 /15 /15 - yswztwrxr'przt{ \S

​-​ - - - ​​ !"#$ %# &&'& ( -- ) * - +- - ,- -. /0// ) -. /0/- 1 - -0 /0/- ​-2 - ,- -0 /0/- +- - ,- -. /0/- - - 3 .0 045 3 4 //5 3 6 6.7 3 6 8-- 3 8 /.- 9:;<=>?@ A=BB CD=> EFB<=;GF;H?E =I?DJGF=;B K K K K K - ​ 2- 3 .0 045 3 4 //5 3 6 6.7 3 6 8-- 3 8 /.- :;G?D?BG ?LI?;B? MNOOM MNOMP MNOQR MNORS MNTUM V?ID?<FJGF=; J;E J>=DGFWJGF=; RQNUXX RQNUOT RQNPMP RRNMXX RRNTYM ZDJ;BJ<GF=; J;E >?D[?D\D?AJG?E <=BGB PX QMY QXO 9OT@ MNUPY ]G?D 9F;<=>?@ ?LI?;B?N ;?G MNURT PPX 9PXU@ 9QTU@ RR _=`?D;>?;G [DJ;G F;<=>? K MRX UX K K a?JAGI?JbcB BJD? =C H;<=;B=AFEJG?E d=F;G `?;GHD? e]: UX K K K K 3 /6 f.0 3 /8 045 3 /f 658 3 /4 0-6 3 -0 7/. gEdHBG>?;GB G= h=DGC=AF= e]: QNQYY TS 9XQO@ K 9YUS@ - . 3 /f .04 3 /8 .75 3 /5 f7f 3 /4 0-6 3 /4 7f. gEdHBG>?;GB G= h=DGC=AF= e]: 9QNQYY@ 9TS@ XQO K YUS e=;\ii h=DGC=AF= e]: QYU RSY QMR RRQ QUP ​​ 3 /8 .07 3 /8 708 3 /f 5f4 3 /4 -85 3 -0 885 e=;\<JB JEdHBG>?;G G= ii h=DGC=AF= e]: QNRSS TS 9XQO@ K 9YUS@ ​​ - 3 /f 707 3 /8 768 3 /f 08. 3 /4 -85 3 /4 5/5 jklmn ( -- ) * - +- - ,- -. /0// ) -. /0/- 1 - -0 /0/- ​-2 - ,- -0 /0/- +- - ,- -. /0/- - - 3 - //. 3 4 .5- 3 f 584 3 8 60- 3 ./ --f 9:;<=>?@ A=BB CD=> EFB<=;GF;H?E =I?DJGF=;B K K K K K - ​ 2- 3 - //. 3 4 .5- 3 f 584 3 8 60- 3 ./ --f :;G?D?BG F;<=>? 9PNRTS@ 9PNMPR@ 9TNQXY@ 9TNRPS@ 9UNYXY@ :>IJFD>?;GB J;E A=J; A=BB D?B?D`?BN ;?G RNRQP 9QNQMR@ QNPSX 9TTS@ 9TNUUT@ 9_JF;@ A=BB =; BJA?B =C D?JA ?BGJG?N ;?G PQQ QRQ 9UNOOT@ K K ]G?D 9F;<=>?@ ?LI?;B?N ;?G 9M@ K MY TR Y opHFGq 9F;<=>?@ A=BB CD=> H;<=;B=AFEJG?E d=F;G `?;GHD?B 9OMO@ 9MNSQY@ 9MNQRM@ 9PUP@ 9MNYQR@ a?JAGI?JbcB BJD? =C H;<=;B=AFEJG?E d=F;G `?;GHD? e]: UNMUM TNTPO TNPUR TNMRR TNTSS 3 7 .7. 3 6 68f 3 6 87- 3 6 .-- 3 6 600 gEdHBG>?;G G= h=DGC=AF= e]: UX 9QM@ 9Y@ 9QX@ UQU - 3 7 .ff 3 6 675 3 6 8-7 3 6 .08 3 6 4/7 :;G?D?BG F;<=>? PNRTS PNMPR TNQXY TNRPS UNYXY - 3 .0 6-f 3 .. 5.0 3 .0 4.- 3 .0 788 3 .0 40- :;G?D?BG F;<=>? 9PNRTS@ 9PNMPR@ 9TNQXY@ 9TNRPS@ 9UNYXY@ gEdHBG>?;G G= h=DGC=AF= e]: 9UX@ QM Y QX 9UQU@ e=;\ii h=DGC=AF= e]: 9UNMUM@ 9TNTPO@ 9TNPUR@ 9TNMRR@ 9TNTSS@ ​​ 3 r 3 r 3 r 3 r 3 r ​​ - 3 r 3 r 3 r 3 r 3 r - 'mstusvwvxkvtuy QS

​-​ - - - ​​ !"#$ %# &'()'(*+, -'./0,12,.+ 3 -- 4 5 - 6- - 7- 89 :;:: 4 89 :;:8 < - 8; :;:8 ​-= - 7- 8; :;:8 6- - 7- 89 :;:8 - - > 9;8 ?@A > @B C@9 > C9 @CD > @B ?DC > @@ ::8 EFGHIJKL MINN OPIJ QRNHIGSRGTKQ IUKPVSRIGN EWXYL Z Z Z Z - ​ =- > 9;? 8?9 > @B C@9 > C9 @CD > @B ?DC > @@ ::8 FGSKPKNS K[UKGNK \]]_` \\``X \]Y`X \_XYY \a`_\ bKGKPVM VGQ VQJRGRNSPVSRcK ]XWX` `\]\X `]aY_ `YdaY `e]]_ fPVGNVHSRIG VGQ JKPgKPhPKMVSKQ HINSN `d\Y eae_ Y\Y \X eeWX] iSjKP ERGHIJKL K[UKGNK GKS E\W_L Ee`YeL Eed_XL Ee`dYL E\]_L FGHIJK SV[ EkKGKORSL K[UKGNK E_]dL Yd` eeY_ XWX EeeW\`L lIGhUPIUKPSm MKcKM liF n Z n Z n Z n Z n E\eX\L > o > o > o > o > o ​​ > o > o > o > o > o ​​ - > o > o > o > o > o pppppppppppppppppppppppppppppppppppppp EeL qIPSOIMRI FGHIJK VGQ qIPSOIMRI rVNj EsQtTNSKQL liF VPK SjK NVJK OIP uVk iTSUVSRKGS vKQRHVM VGQ rrwr OIP VMM UKPRIQN UPKNKGSKQ VN SjKPK RN GI RGSKPKNS RGHIJK PKMVSKQ SI NTHj NKgJKGSNx y,z'.z{|{*+{'.} `e

​-​ - - - ​​ !"#$ %# & - '- - - (- - )- *+ ,-,* .. ) / - 0- 1 - 2 -/ ) - / - 2 -​ - 3 - - 4 *56 -67 4 ,+8 8+5 4 ,8 659 4 *8 95* 4 ,99 ++8 4 **: 969 ;<=>?@AB C?DD EF?@ GHD>?=IH=JAG ?KAFLIH?=D M M M M M M - ​ /- 4 *56 -67 4 ,+8 8+5 4 ,8 659 4 *8 95* 4 ,99 ++8 4 **: 969 <=IAFADI H=>?@A M M M ;NOPQROB M ;NOPQROB <=IAFADI ASKA=DA M QPQQT QPTOT M ORUPUUO NTTPVVO WAKFA>HLIH?= L=G L@?FIHXLIH?= VNRPVYZ NRZP[RV OVOPR[Z M M QYZPZTO \A=AFLC L=G LG@H=HDIFLIH]A M M M M ZUPOVN ZUPOVN FL=DL>IH?= L=G @AF_AF`FACLIAG >?DID VVV OPONT OPRRO M OYPORO OQPUOU <@KLHF@A=ID L=G C?L= C?DD FADAF]ADP =AI M M M ;UP[TOB M ;UP[TOB ;\LH=B C?DD ?= DLCAD ?E FALC ADILIAP =AI ;[TPYZRB ;NOPVONB M ;YP[UVB M ;R[PY[VB aIbAF ;H=>?@AB ASKA=DAP =AI ;QB ;NP[ZQB ;NNRB RO ;VPZUQB ;[PRTRB \?]AF=@A=I _FL=I H=>?@A M M ORY M M ORY <=>?@A ILS ;cA=AEHIB ASKA=DA M M M M ;ZP[OQB ;ZP[OQB deJHIf ;H=>?@AB C?DD EF?@ J=>?=D?CHGLIAG g?H=I ]A=IJFAD ;YPUYTB ;RVUB M ;YPRNZB M ;OTPNTYB hALCIbKALijD DbLFA ?E J=>?=D?CHGLIAG g?H=I ]A=IJFA ka< UPRVN OPRYY M NOPRYY M NZPUNT k?=>?=IF?CCH=_ H=IAFADIDj DbLFA ?E >?=D?CHGLIAG g?H=I ]A=IJFA ka< ;Y[VB ;NUPOUNB M M M ;NUP[OUB k?=`KF?KAFIf CA]AC ka< M M M M ;YPOQYB ;YPOQYB 4 86: -86 4 :89 -*7 4 ++: +,7 4 ,+ 5:: 4 l 4 + ,69 -99 mGgJDI@A=ID I? ka< ;V[PUNYB ;OYPVOYB ;OP[ORB V[[ M ;UNPTZTB - 4 8+9 6:+ 4 :6, 9,6 4 ++, 6++ 4 ,, ,+- 4 l 4 + ,-: 759 <=IAFADI <=>?@A M M M NOPQRO M NOPQRO - 4 8+9 6:+ 4 :6, 9,6 4 ++, 6++ 4 :* 77+ 4 l 4 + ,,8 985 <=IAFADI H=>?@A M M M ;NOPQROB M ;NOPQROB mGgJDI@A=ID I? ka< V[PUNY OYPVOY OP[OR ;V[[B M UNPTZT k?=`nn o?FIE?CH? ka< ;O[RPZUQB ;VZPZRQB OPOTO ;NOPRYYB M ;NNZP[RQB ​​ + 4 :56 +-5 4 :,9 -6, 4 ++6 ,*- 4 l 4 l 4 + -,9 *7- k?=`>LDb LGgJDI@A=I I? nn o?FIE?CH? ka< ;NVPZQZB ;OOP[RUB ;OP[ORB M M ;VQPNRNB ​​ - + 4 :8+ +,7 4 :+6 *89 4 ++* 8+, 4 l 4 l 4 77- +-5 pppppppppppppppppppppppppppppppppppppp ;OB bA KF?KAFIf >?J=I JDAG E?F nn o?FIE?CH? ka< L=G nn o?FIE?CH? qLDb ;mGgJDIAGB ka< GHEEAFAG E?F IbA IbFAA L=G IrAC]A @?=IbD A=GAG WA>A@cAF VOP NTNV L=G NTNNs tuvwxvyzy{|ywx} NN

​-​ - - - ​​ !"#$ %# & - '- - - (- - )- *+ ,-,, .. ) / - 0- 1 - 2 -/ ) - / - 2 -​ - 3 - - 4 5,- +-6 4 ,-7 67- 4 8* -6* 4 +, 6,8 4 ,7+ 9*, 4 6+5 8,8 :;<=>?@A B>CC DE>? FGC=><HG<I@F >J@EKHG><C L L L L :MNOOPA :MNOOPA - ​ /- 4 5,- +-6 4 ,-7 67- 4 8* -6* 4 +, 6,8 4 ,78 5+5 4 6+* 68- ;<H@E@CH G<=>?@ L L L :MQNQRRA L :MQNQRRA ;<H@E@CH @SJ@<C@ L TNURR VNWRU L XWONWQW XVMNUPP Y@JE@=GKHG>< K<F K?>EHGZKHG>< QRMNTPU MVUNWPT XMONQVP L L VXRNWTU [@<@EKB K<F KF?G<GCHEKHG\@ L L L L XQXNRQQ XQXNRQQ ]EK<CK=HG>< K<F ?@E@E_E@BKH@F =>CHC QOV XNMWW VMW L MNPOT PNOWQ ;?JKGE?@<HC K<F B>K< B>CC E@C@E\@CN <@H L L L VNRRP L VNRRP :[KG<A B>CC >< CKB@C >D E@KB @CHKH@N <@H :QNVPPA :XRNTWUA L WNQMW L :UNRVOA `Ha@E :G<=>?@A @SJ@<C@N <@H :QXXNUQUA :XMNVRUA XNQOR XQ :QNRXQA :QMTNMTOA [>\@E<?@<H EK<H G<=>?@ L L TNVTW L L TNVTW ;<=>?@ HKS :b@<@DGHA @SJ@<C@ L L L L :PNPMWA :PNPMWA cdIGHe :G<=>?@A B>CC DE>? I<=><C>BGFKH@F f>G<H \@<HIE@C UVM :OWMA :WQUA :XNWTTA L :XNUOWA g@KBHaJ@KhiC CaKE@ >D I<=><C>BGFKH@F f>G<H \@<HIE@ j`; VNRQO XNOMX QOR XTNVWX L MWNUUR j><=><HE>BBG< G<H@E@CHCi CaKE@ >D =><C>BGFKH@F f>G<H \@<HIE@ j`; :XOXA :MWNPRRA L L L :MWNWOXA 4 5+6 ,79 4 887 87, 4 +-+ 68+ 4 +5 96+ 4 k 4 + +7, -5+ lFfICH?@<HC H> j`; :TMNVWPA :XWNWXQA MNQRR XTU L :VWNVUOA - 4 66, 6** 4 8*, m5m 4 +-* 78+ 4 +5 m,- 4 k 4 + +-5 ,5* ;<H@E@CH ;<=>?@ L L L MQNQRR L MQNQRR - 4 66, 6** 4 8*, m5m 4 +-* 78+ 4 8- ,,- 4 k 4 + +,m 65* ;<H@E@CH G<=>?@ L L L :MQNQRRA L :MQNQRRA lFfICH?@<HC H> j`; TMNVWP XWNWXQ :MNQRRA :XTUA L VWNVUO j><_nn o>EHD>BG> j`; :XMWNMTRA :QMNOUUA :WNWMXA :XTNVWXA L :XORNPQXA ​​ + 4 8m- -,9 4 8+6 67* 4 m5 -,- 4 k 4 k 4 + --+ 5*- j><_=KCa KFfICH?@<H H> nn o>EHD>BG> j`; :PWNPUTA :XQNVTQA MNQRR L L :WTNUWUA ​​ - + 4 888 6*+ 4 8-+ 7,- 4 m7 *,- 4 k 4 k 4 m88 59+ pppppppppppppppppppppppppppppppppppppp :XA ]a@ JE>J@EHe =>I<H IC@F D>E nn o>EHD>BG> j`; K<F nn o>EHD>BG> qKCa :lFfICH@FA j`; FGDD@E@F D>E Ha@ HaE@@ K<F Hr@B\@ ?><HaC @<F@F Y@=@?b@E QXN MRMQ K<F MRMMs tuvwxvyzy{|ywx} MQ

​-​ -​ ​ - ​ - - - !" #! $%&'( )%*&+%(,% - -- . / - 0- -12- 345 6766 ..​ 345 6763 - 375 6763 - -12- 375 6763 0- -12- 345 6763 /8 9 1- : ; 1 ​ - < =- - > :4?@; > 45A4@ > 65B6C > 65474 > 35??A DEFGEHIJKILM JMN JOLGKIPJKILM QRSTU VRWWX VRQWX SRYWZ SR[UT \EMEGJ] JMN JNOIMIKGJKI_E YS[ TTT UTW US[ YWW `\JIMa ]L LM J]E Lb GEJ] EKJKER MEK TV c c c c dKeEG `IMHLOEa EfFEMER MEK `QSYa `YRT[Qa `YRWY[a `YRVVQa `URXQWa gMHLOE KJf `hEMEbIKa EfFEME `YWa UYS UXV TV UZX ​-​ -​ ​ - ​ - < =- - > B5A4A > @5CC4 > B54AC > B57i? > A56C? j'k - -- . / - 0- -12- 345 6766 .​ 345 6763 - 375 6763 - -12- 375 6763 0- -12- 345 6763 /8 9 1- : ; 1 ​ - < =- - > :4567C; > ?CA > 4534i > 456ii > 453Ai DEFGEHIJKILM JMN JOLGKIPJKILM VRZX[ YRVUY YRTYV YRVSQ YRWWU \EMEGJ] JMN JNOIMIKGJKI_E YSZ XTV UZW UUZ YXT gMHLOE KJf `hEMEbIKa EfFEME `QTXa `YRTQYa `YRQVQa `YRVSVa `YRUZQa ​-​ -​ ​ - ​ - < =- - > 354i? > CA3 > 457A7 > 45i@B > 65376 lm&n'&,op& qor,s'( - -- . / - 0- -12- 345 6766 .​ 345 6763 - 375 6763 - -12- 375 6763 0- -12- 345 6763 /8 9 1- : ; 1 ​ - < =- - > 63? > 4AC > 4Ai > 644 > 6?4 DEFGEHIJKILM JMN JOLGKIPJKILM UTZ UXQ UVS UYQ UTY \EMEGJ] JMN JNOIMIKGJKI_E X [ UY YV `Xa gMHLOE KJf EfFEME `hEMEbIKa [ S V Y T ​-​ -​ ​ - ​ - < =- - > iA? > ii7 > i@@ > ii? > iC3 ttut - -- . / - 0- -12- 345 6766 ..​ 345 6763 - 375 6763 - -12- 375 6763 0- -12- 345 6763 /8 9 1- : ; 1 ​ - < =- - > v > v > v > v > v `\JIMa ]L LM J]E Lb GEJ] EKJKER MEK TV c c c c dKeEG `IMHLOEa EfFEMER MEK U c c c c ​-​ -​ ​ - ​ - < =- - > iB > v > v > v > v l&wo* - -- . / - 0- -12- 345 6766 .​ 345 6763 - 375 6763 - -12- 375 6763 0- -12- 345 6763 /8 9 1- : ; 1 ​ - < =- - > A4A > 4576C > 45634 > @i@ > 45C63 DEFGEHIJKILM JMN JOLGKIPJKILM XRXSV TRUXT TRUUU TRTZT TRTWY \EMEGJ] JMN JNOIMIKGJKI_E T WU YW XU SQ dKeEG `IMHLOEa EfFEMER MEK `UZa X `VWa [ `YRYQYa gMHLOE KJf `hEMEbIKa EfFEME `USa UYZ UXZ TT YWW ​-​ -​ ​ - ​ - < =- - > i54i4 > ?5?@A > ?5@i3 > ?5433 > ?5?77 uos%ps,(,'&,%px UT

​-​ -​ ​ - ​ - - - !" #! $ - %-​ - - &- -'(- )*+ ,-,) ..​( ​ - /- ​ 0010 - 2 ​ 34 % '- 5 6 ' ​ - 7 8- - 9 :+;:- 9 <); 9 = 9 :+<,> 9 *-+,-: ?@AB@CDEFDGH EHI EJGBFDKEFDGH LMNOL OPQ R STMQPS UNMVWW X@H@BEY EHI EIJDHDZFBEFD[@ OWV NW R USS SMSPO \F]@B DHCGJ@_ @`A@HZ@M H@F LMSSU_ R R SMUQW_ TMQNU_ aHCGJ@ FE` b@H@cDF_ @`A@HZ@ R SL R LVQ LOO ​-​ -​ ​ - ​ - 7 8- - 9 ;+<), 9 *+<:: 9 = 9 ,*+<:: 9 ,>+;,- $ - %-​ - - &- -'(- )*+ ,-,, ..​( ​ - /- ​ 0010 - 2 ​ 34 % '- 5 6 ' ​ - 7 8- - 9 5>d,6 9 <;, 9 ;)> 9 *+;ee 9 *+><; ?@AB@CDEFDGH EHI EJGBFDKEFDGH SWMUVU OSS R SLMNOV UTMLOS X@H@BEY EHI EIJDHDZFBEFD[@ UVU QQ R SUO NNN XEDH_ YGZZ GH ZEY@Z Gc B@EY @ZFEF@M H@F R U_ UUL R UUN \F]@B DHCGJ@_ @`A@HZ@M H@F UMPPN_ R QVP_ SMLNO_ NMPVV_ aHCGJ@ FE` b@H@cDF_ @`A@HZ@ R UT R UWT UQN ​-​ -​ ​ - ​ - 7 8- - 9 d+-)< 9 *+<,* 9 )<- 9 *e+d;* 9 ,;+>>- fghijhklkmnkijo UP

​-​ -​ - ​ ​ - -​ - - ​ ​ ​ ! "#$%& '#($)#&*# + ,-​ -​ .. /0 123 4544 , 123 4541 ​ 153 4541 6 /0 153 4541 .. /0 123 4541 ​ -/ 7 - 8 -/ -​ ​ ​ -6 -​ 0 0 - ​-​ -​ - ​ ​ 9 :34;: 9 2<3<<< 9 :3155 9 :3::4 9 :3:<2 =>?@AB CDEE DA E?CFE DG HF?C FEI?IFJ AFI K =LLJMNOB K K K PFQHFR@?I@DA ?AS ?TDHI@U?I@DA NJOMV NJOWL NJMWX NJNVN NJMYZ [I\FH =@ARDTFB F]QFAEFJ AFI OW LLX NY O ZX P@@SFASE ?IIH@_`I?_CF ID ADARDAIHDCC@Aa @AIFHFEI =ZJXVWB =ZJXNZB =ZJMOLB =ZJMNYB =ZJMbOB ​-​ -​ - ​ ​ - -​ - c- ​ d ​ ​ 9 e3e42 9 e3:;2 9 e31;4 9 e31f4 9 e31g5 h%i + ,-​ -​ .. /0 123 4544 , 123 4541 ​ 153 4541 6 /0 153 4541 . /0 123 4541 ​ -/ 7 - 8 -/ -​ ​ ​ -6 -​ 0 0 - ​-​ -​ - ​ ​ 9 23555 9 23:f1 9 235;f 9 235e2 9 235g1 =>?@AB CDEE DA E?CFE DG HF?C FEI?IFJ AFI K =NLXB K K K PFQHFR@?I@DA ?AS ?TDHI@U?I@DA XL XV MZ MZ MY [I\FH =@ARDTFB F]QFAEFJ AFI =XMB =LYXB =bNB =WLB =WNB P@@SFASE ?IIH@_`I?_CF ID ADARDAIHDCC@Aa @AIFHFEI =WXYB =WYLB =WXYB =WYLB =WZOB ​-​ -​ - ​ ​ - -​ - c- ​ d ​ ​ 9 ee 9 251 9 22e 9 242 9 241 jk$l%$*mn$ omp*q%& + ,-​ -​ .. /0 123 4544 , 123 4541 ​ 153 4541 6 /0 153 4541 . /0 123 4541 ​ -/ 7 - 8 -/ -​ ​ ​ -6 -​ 0 0 - ​-​ -​ - ​ ​ 9 134;: 9 2:35;4 9 13514 9 132f2 9 132e4 =>?@AB CDEE DA E?CFE DG HF?C FEI?IFJ AFI K =LLJLXXB K K K PFQHFR@?I@DA ?AS ?TDHI@U?I@DA NJOZO NJOMN NJMNL NJNZZ NJNMZ [I\FH =@ARDTFB F]QFAEFJ AFI LYN ZLO LZN WV LLV P@@SFASE ?IIH@_`I?_CF ID ADARDAIHDCC@Aa @AIFHFEI =LJNNWB =LJNNLB =LJNNLB =LJNXWB =LJNONB ​-​ -​ - ​ ​ - -​ - c- ​ d ​ ​ 9 e3<<< 9 e31ef 9 e34<e 9 e34e2 9 e34e; r#(l#(%$m s#ntumvwmn$ + ,-​ -​ .. /0 123 4544 , 123 4541 ​ 153 4541 6 /0 153 4541 .. /0 123 4541 ​ -/ 7 - 8 -/ -​ ​ ​ -6 -​ 0 0 - ​-​ -​ - ​ ​ 9 x 9 x 9 2g5 9 455 9 2ge P@@SFASE ?IIH@_`I?_CF ID ADARDAIHDCC@Aa @AIFHFEI K K =LWYB =ZYYB =LWOB ​-​ -​ - ​ ​ - -​ - c- ​ d ​ ​ 9 x 9 x 9 x 9 x 9 x ymq#nq*&*%$*#nu ZO

​-​ -​ - ​ ​ - -​ - - ​ ​ ​ ! "- # ​ $ %& '() *+*' , & - ​ .. - -- ​-​/ % ​ 0- ​ -% 1 - 2 -% -​ ​ ​ -- -​ & & - ​-​ -​ - ​ ​ 3 4)5(6 3 *')445 3 678 3 *7)547 9:;<=> ?@AA @= A;?BA @C DB;? BAE;EBF =BE 9GHI> 9HHFHII> J 9HHFKGL> MBNDBO<;E<@= ;=P ;Q@DE<R;E<@= HST HUFVLS J HUFTLH WEXBD 9<=O@QB> BYNB=ABF =BE 9IZT> KKG J HUT M<[<PB=PA ;EED<\]E;\?B E@ =@=O@=ED@??<= <=EBDBAE 9IFLKS> 9KFZUK> 9KUL> 9HVFVIV> ​-​ -​ - ​ ​ - -​ - _- ​ ` ​ ​ 3 48' 3 *6)(6* 3 a 3 *6)8(6 "- # ​ $ %& '() *+** , & - ​ .. - -- ​-​/ % ​ 0- ​ -% 1 - 2 -% -​ ​ ​ -- -​ & & - ​-​ -​ - ​ ​ 3 ')574 3 (*)(b( 3 a 3 (6)b56 9:;<=> ?@AA @= A;?BA @C DB;? BAE;EBF =BE J 9HT> J 9HT> MBNDBO<;E<@= ;=P ;Q@DE<R;E<@= US HUFLLZ J HUFZKL WEXBD 9<=O@QB> BYNB=ABF =BE 9TU> IKV J ITT M<[<PB=PA ;EED<\]E;\?B E@ =@=O@=ED@??<= <=EBDBAE 9IFLLG> 9KFZSL> J 9SFGLV> ​-​ -​ - ​ ​ - -​ - _- ​ ` ​ ​ 3 (7( 3 *6)4++ 3 a 3 *6)67( cdefgehihjkhfgl TZ

​-​ ​ ​ !" # -!$ $ %&'()% **%* + , -. / 0 1211 3 , / 0 121/ 45! /20 121/ 6 7" -. /20 121/ + , -. / 0 121/ 89:;<9=>9 ?@AB CD@= EA;@;D CDFDGHDAIJK L MJNOPJQ L MJROJJM L MSQOJSM L MSSOTQT L MSUOSVQ W;BD: @XYHA;ZDG;A ;9 CE[8WC ??C?ISK IVRK \ IMTVK IJQUK \ CE[8WC ??C? :DFDGHDA ] 10_`/ ] 1`011 ] /202ab ] //0b2/ ] /b0/a2 cFD:@dD 9eeHf>DX HG>;AgZ9G;B NOPMT NOPQT NOPJN NOPNU UOQSM CE[8WC ??C? fD: Z9G;BIVK L ROQPQ L ROMRP L ROSMR L ROVRR L RONSU !" # -!$ $ %&'()% **%* hijklmnop q%&r stuvwnxywnuo + , -. / 0 1211 3 , / 0 121/ 45! /20 121/ 6 7" -. /20 121/ + , -. / 0 121/ CE[8WC ??C? :DFDGHDA L MJNOTRS L MJROJJM L MSQOQVU L MSSOUQS L MSUOSVQ zCE{ cZ9:;>|@;>9GINK IJMOJUQK IMPOTTRK IJQOJTRK IJQORUJK IJJOMQNK CE[8WC ??C? :DFDGHDA D}e=HX>Gd zCE{ cZ9:;>|@;>9G ] 2a0b 1 ] 2`0//a ] 2~0`~ ] 10_a ] a01/ cFD:@dD 9eeHf>DX HG>;AgZ9G;B NOPMT NOPQT NOPJN NOPNU UOQSM CE[8WC ??C? D}e=HX>Gd zCE{ cZ9:;>|@;>9G fD: Z9G;BIVK L NOTPJ L UOQNU L UOMRN L UOSMN L UOSMV !" # -!$ $ %&'()% **%* + , -. / 0 1211 3 , / 0 121/ 45! /20 121/ 6 7" -. /20 121/ + , -. / 0 121/ €€ CE[8WC ??C? :DFDGHDAIUK L MJNOTRS L MJROQTV L MJPOPPP L MSSOUQS L MSUOQTS €€ @FD:@dD 9eeHf>DX HG>;AgZ9G;B NOPMT NOPQT NOPJN NOPNU UOQJQ €€ CE[8WC ??C? fD: Z9G;BIVK L ROQPQ L ROMRM L ROSMV L ROVRR L RONSN !" # -!$ $ %&'()% **%* hijklmnop q%&r stuvwnxywnuo + , -. / 0 1211 3 , / 0 121/ 45! /20 121/ 6 7" -. /20 121/ + , -. / 0 121/ €€ CE[8WC ??C? :DFDGHDAIUK L MJNOTRS L MJROQTV L MJPOPPP L MSSOUQS L MSUOQTS zCE{ cZ9:;>|@;>9GINK IJMOJUQK IMPOTTRK IJQOJTRK IJQORUJK IJJOQJVK €€ CE[8WC ??C? :DFDGHDA D}e=HX>Gd zCE{ cZ9:;>|@;>9G ] 2a0b 1 ] 2`0 ~` ] 2~0` 1 ] 10_a ] a02~ €€ cFD:@dD 9eeHf>DX HG>;AgZ9G;B NOPMT NOPQT NOPJN NOPNU UOQJQ €€ CE[8WC ??C? D}e=HX>Gd zCE{ cZ9:;>|@;>9G fD: Z9G;BIVK L NOTPJ L UOQVP L UOMRS L UOSMN L UOSMN  IMK ‚@ƒ G9; <99; XHD ;9 :9HGX>Gd„ IJK €DD f@dDA MQ @GX MM 9< ;B>A X9eHZDG; <9: @ :De9Ge>=>@;>9G 9< 89:;<9=>9 ?@AB CD@= EA;@;D CDFDGHDA„ ISK …Ge=HXDA :DFDGHD <:9Z <@e>=>;>DA ;B@; @:D BD=X <9: A@=D 9: A9=XO <@e>=>;>DA >G :DXDFD=9fZDG; 9: :DeDG;=ƒ e9Zf=D;DX :DXDFD=9fZDG;A ;B@; @:D G9; ƒD; A;@†>=>|DX„ IVK CDf:DADG;A ;BD ‡H@:;D: CE[8WC ??C? X>F>XDX †ƒ @ <@e;9: 9< ;B:DD„ INK zCE{ @Z9:;>|@;>9G D}e=HXDA @ :DeDG;=ƒ e9Zf=D;DX :DXDFD=9fZDG; ;B@; >A G9; ƒD; A;@†>=>|DX @A >; >A @=:D@Xƒ D}e=HXDX <:9Z CE[8WC ??C? :DFDGHDA„ IUK €DD f@dDA MQ @GX MM 9< ;B>A X9eHZDG; <9: @ :De9Ge>=>@;>9G 9< 89:;<9=>9 ?@AB CD@= EA;@;D CDFDGHDA ˆ €€„ %hjuojnknywnuo‰ JT

​-​ ​ ! " - # # $%&'($ ()*+, - . /0 1 2 3433 5 . 1 2 3431 67 142 3431 8 9! /0 142 3431 - . /0 1 2 3431 :;<=>;?@; ABCD EFB? GC=B=F EFHFIJFCKLM N OPQRLS N LRQTUU N LRQLVW N LRQTUV N LOQOUV X=DF< BYZJC=[FI=C =; EG\:XEK]M KLQSL]M KLQT]LM KLQ]UTM KLQSTUM EG\:XE <FHFIJFC _ `2`4 _ a241b _ c2d b _ a2 _ 3 2 `c eHF<BfF ;ggJh@FY JI@=Ci[;I=D OQ]RL OQLPV OQ]R] OQ]LR OQSOR EG\:XE hF< [;I=DKSM N SQLTR N SQU]] N SQTWS N SQTV] N TQRRT jjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjjj KOM kBl I;= >;;= YJF =; <;JIY@Ifm KLM nFF hBfFC OR BIY OO ;> =D@C Y;gJ[FI= >;< B <Fg;Ig@?@B=@;I ;> :;<=>;?@; ABCD EFB? GC=B=F EFHFIJFCm K]M oIg?JYFC <FHFIJF >;< BCCF=C @I <FYFHF?;h[FI= ;< <FgFI=?l g;[h?F=FY <FYFHF?;h[FI=C =DB= B<F I;= lF= C=Bp@?@qFYm KSM EFh<FCFI=C =DF rJB<=F< EG\:XE Y@H@YFY pl B >Bg=;< ;> =D<FFm $+stusvwvx)vtuy LP

​-​ - - ​ - - - ! " ! # $ % & %' ()* +,+( ! +,++ ! ' # ! ! # - % . / % ! 0 ! 1 ! % 2 ! ! % ! 3 " 4! " 5 ! ! 1 % ! 5 6 - ! ! ! !% " & ! 5 ! 7 89::; < ! ! = ! ! ! % ! 3 " 4! " 5 ! ! 1 % ! 5 * ! ! ! %! ! ! # $ % & %' ()* +,+( ! +,++ ' # . ! /> ?@ A @​ B ​ CD EFG H B ​ CD EFG IJIE IJII IJIE IJII K ​L 5 ! $ M N M O+P M N M O*QRS ! $ N O+P N O*QRS T ​ ​ U ​ ​L 2 ! " N N N V*QP+ ! ! W N N N V*QP+ @ - C X U ​ YL 9! . / ! ! ! * N .)O/ N )*(QQ 2 % . W /* N )PQ N )VS ! % . W /* N )(O N )*P)( Z C X ​​Y D [ - C U ​ \ - ] - C X ​​Y [ C ​ - - K ​ N RV+ N +*PP, - % !W ' . W / N )) N +O, 4_ 3 % . / % ! ` $ N N N VQ Z C X ​​Y [ C -​ - - ​ a b a cdE a b a IGcce fghijhklkmnkijo (,

​-​ ​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

​-​ ​-- ​ ​ ​ ​ ​ - ​ ​ ​ ​ ! " #$ %&'#' " ( - - ​ ) * +, -.-/ 0 - ​ 1 2 3 ​ ​ 456 7 4 8 9 - :- - ​ ​ ​ ​ ​ - - ​ 3 9 - :- - ​ - * ​ - - ​ ​ ​ 3 7 4 8 ​ ​ ​ 0 - ​ 1 2 3 ​ ​ 9 - :- - ​ ​​ ​ - 7 4 8 ; ​ ++ -.-8 43<6=0<>)524 ?25 @2A5) ?B) ?)C(45) 3< 25?) 305 ;<(B3 12<DE 43?35F5B3:12<41563@4 G(B6>@)(BA ?>> ?F5B)F5B34 ?B) 4@11>5F5B34 305253<H ?B) <3052 25>5C?B3 )<6@F5B34 7(>5) I(30 305 456 6?257@>>E J56?@45 305E 6<B3?(B (F1<23?B3 (B7<2F?3(<B ?J<@3 05?>3015?= 10E4(6(?B4 25?>3E 32@43 ?B) 305 12<1<45) 32?B4?63(<B ( ​ ​ ​ 0 - ​ 1 2 3 ​ * * - 9 - :- - ​ ​ ​ ​ ​ * 0 - ​ 1 2 3 ​ 456 ​ * ​ * 456 6 - ​ ​ ​ * 0 - 456 * 0 - K * - ​ - ​ ​ ​ * 1 2 3 ​ 456 * 1 2 3 ​ K * ​ L # M L N &' N ! M 0 - 1 2 3 ​ ​ - ​ ​ ​ ​ * ​ ​ * - - - 0 - K ​ ​ 1 2 3 ​ K ​ - - - ​ ( ​ 0 - K ​ ​ ​ * ​ ​ 0 - K ​ - ​ 456 F +O -.-/ ( ​ 1 2 3 ​ K ​ ​ ​ * ​ ​ 1 2 3 ​ K ​ - ​ 456 F -/ -.-/ ?​​ ​ ​ - - - ​​ ​ 9 - :- - ​ ​ ​ ​ ​ 456 - - ​ 3 ​ ​ * 456K * ​ 0 - ​ 1 2 3 ​ -- * ​ ​ ​ ​ * ""'# # N ! M 3 ​ -​ - ​ -​ ​ 9​ ​ -​ ​ - - ​ * ​ ​ 9​ ​ -- * B ​ * ​ - * - - ​ P​ 4 +. 4 ​ ? +Q// ​ ​ RS

EX-99.2

Exhibit 99.2

Earnings Release and Supplemental Report ___________________________________________________________________ Fourth Quarter 2023 Nexus on Grand South San Francisco, CA

Return to TOC 2 Earnings Release 3 Consolidated Financial Statements 9 Overview 13 Portfolio Summary 14 Property Count Reconciliations 17 Capitalization 18 Indebtedness 19 Investment Summary 21 Developments and Redevelopments 22 Capital Expenditures 24 Portfolio Diversification 25 Portfolio Lab 26 Outpatient Medical 31 CCRC 37 Other 39 Outlook 40 Glossary and Debt Ratios 41 Company Information 46 Forward-Looking Statements & Risk Factors 47 Discussion and Reconciliation of Non-GAAP Financial Measures TABLE OF Contents The Boardwalk San Diego, CA

Return to TOC 3 Healthpeak Properties Reports Fourth Quarter and Year Ended 2023 Results DENVER, February 8, 2024 - Healthpeak Properties, Inc. (NYSE: PEAK), a leading owner, operator, and developer of real estate for healthcare discovery and delivery, today announced results for the fourth quarter and full-year ended December 31, 2023. FOURTH QUARTER 2023 FINANCIAL PERFORMANCE AND RECENT HIGHLIGHTS – Net income of $0.13 per share, Nareit FFO of $0.48 per share, FFO as Adjusted of $0.46 per share, AFFO of $0.36 per share, and Total Same-Store Portfolio Cash (Adjusted) NOI growth of 3.6% – Fourth quarter new and renewal lease executions totaled 1.1 million square feet: • Outpatient Medical new and renewal lease executions totaled 743,000 square feet • Lab new and renewal lease executions totaled 312,000 square feet ▪ Year-to-date 2024 Lab lease executions of 58,000 square feet with an additional 115,000 square feet under signed LOI – Received entitlements for an additional 1.3 million square feet of lab development at the Vantage campus in South San Francisco – Commenced two on-campus outpatient developments in our HCA Healthcare ("HCA") development program – Entered into a new $236 million joint venture through the sale of a 65% interest in the Callan Ridge lab campus in the Torrey Pines submarket of San Diego in January 2024 – Net Debt to Adjusted EBITDAre was 5.2x for the quarter ended December 31, 2023 FULL-YEAR 2023 HIGHLIGHTS – Net income of $0.56 per share, Nareit FFO of $1.79 per share, FFO as Adjusted of $1.78 per share, AFFO of $1.53 per share, and Total Same-Store Portfolio Cash (Adjusted) NOI growth of 4.8% – Portfolio leasing summary: • Full-year outpatient lease executions totaled 4.1 million square feet, with +4% cash releasing spreads on renewals • Full-year lab lease executions totaled 985,000 square feet, with +23% cash releasing spreads on renewals – Development highlights: • 2023 completions and new starts: ▪ Nexus on Grand: Delivered the fully leased, 148,000 square foot, $161 million lab building in South San Francisco ▪ Vantage: Delivered the fully leased, 154,000 square foot, $201 million first building of Phase I in South San Francisco ▪ Callan Ridge: Completed core and shell work and delivered the space to the tenant for T.I. build out; the fully leased development in Torrey Pines totals 185,000 square feet with an expected total development cost of $146 million ▪ HCA Development Program: Commenced construction on two new outpatient developments totaling 192,000 square feet with total expected development costs of $90 million • Land bank and future developments: ▪ In September 2023, the Cambridge City Council unanimously approved a comprehensive rezoning to allow for greater density and developable heights in the West Cambridge neighborhood of Alewife where Healthpeak owns a total of 39 acres ▪ In December 2023, Healthpeak received entitlements for an additional 1.3 million square feet of lab development at the Vantage campus – Issued $750 million of senior unsecured notes at blended yield of approximately 5.35% and weighted average initial maturity of approximately 10 years – Sold $130 million of non-core properties at an average trailing cash yield of 5.4% and received $205 million of seller financing and other loan repayments – 2023 sustainability and responsible business recognitions include: • Received a Green Star rating from the Global Real Estate Sustainability Benchmark (GRESB) and named a constituent in the FTSE4Good Index for the twelfth consecutive year • Named to CDP's Leadership band for the eleventh consecutive year, named a constituent in the S&P Global Dow Jones Sustainability N. America Index for the eleventh consecutive year and World Index for the fourth time; and named to the S&P Global Sustainability Yearbook for the ninth consecutive year • Named an ENERGY STAR Partner of the Year for the third time • Named to Newsweek’s America’s Most Responsible Companies list for the fifth consecutive year • Named Winner for Best Proxy Statement (Mid Cap), and Finalist for Best ESG Reporting (Small to Mid Cap) by IR Magazine and Governance Intelligence • Certified a Great Place to Work for the fourth consecutive year; included in The Tennessean Top Workplaces for the second consecutive year; and a Middle Tennessee Top Workplace for the first time • Included in Fortune's Best Workplaces in Real Estate list for the second consecutive year To learn more about Healthpeak's commitment to responsible business and view our 2022 ESG Report, please visit www.healthpeak.com/ESG.

Return to TOC 4 SAME-STORE ("SS") OPERATING SUMMARY The table below outlines the year-over-year three-month and full-year SS Cash (Adjusted) NOI growth. Year-Over-Year Total SS Portfolio Cash (Adjusted) NOI Growth Three Month Full Year SS Growth % % of SS SS Growth % % of SS Lab 2.7% 47.1% 3.7% 46.6% Outpatient Medical 4.3% 41.4% 3.4% 42.0% CCRC 4.7% 11.5% 15.6% 11.5% Total Portfolio 3.6% 100.0% 4.8% 100.0% Nareit FFO, FFO as Adjusted, AFFO, Same-Store Cash (Adjusted) NOI, and Net Debt to Adjusted EBITDAre are supplemental non-GAAP financial measures that we believe are useful in evaluating the operating performance and financial position of real estate investment trusts (see the "Funds From Operations" and "Adjusted Funds From Operations" sections of this release for additional information). See "December 31, 2023 Discussion and Reconciliation of Non-GAAP Financial Measures" for definitions, discussions of their uses and inherent limitations, and reconciliations to the most directly comparable financial measures calculated and presented in accordance with GAAP in the Investor Relations section of our website at http://ir.healthpeak.com/quarterly-results. FOURTH QUARTER COMPARISON Three Months Ended December 31, 2023 Three Months Ended December 31, 2022 (in thousands, except per share amounts) Amount Per Share Amount Per Share Net income, diluted $ 70,787 $ 0.13 $ 6,388 $ 0.01 Nareit FFO, diluted 263,810 0.48 192,158 0.35 FFO as Adjusted, diluted 252,639 0.46 238,744 0.44 AFFO, diluted 196,622 0.36 194,414 0.36 Year Ended December 31, 2023 Year Ended December 31, 2022 (in thousands, except per share amounts) Amount Per Share Amount Per Share Net income, diluted $ 304,284 $ 0.56 $ 497,792 $ 0.92 Nareit FFO, diluted 994,574 1.79 904,573 1.66 FFO as Adjusted, diluted 987,708 1.78 950,259 1.74 AFFO, diluted 847,358 1.53 790,296 1.45 FULL YEAR COMPARISON

Return to TOC 5 CALLAN RIDGE LAB CAMPUS JOINT VENTURE SALE As previously announced, in January 2024, Healthpeak formed a new strategic joint venture with Breakthrough Properties (“Breakthrough”) through a sale of a 65% interest in Healthpeak’s fully leased Callan Ridge lab campus in the Torrey Pines submarket of San Diego. The formation of the 65% Breakthrough / 35% Healthpeak joint venture values Callan Ridge at $236 million, or $1,275 per square foot, and represents a stabilized cash capitalization rate of 5.3% based on the initial annual rental rate of approximately $67 per square foot. At closing, net proceeds to Healthpeak were approximately $130 million. Additionally, the formation of the joint venture reduces Healthpeak's future tenant improvement funding by approximately $20 million. Healthpeak began construction on the 185,000 square foot Callan Ridge campus in 2021. The two-building campus is fully leased to Turning Point Therapeutics, Inc., a subsidiary of Bristol-Myers Squibb Company (NYSE: BMY), through April 2035. DEVELOPMENT UPDATES VANTAGE ENTITLEMENTS As previously announced, in December 2023, Healthpeak received entitlements for an additional 1.3 million square feet of lab space at the Vantage campus, bringing the combined campus to approximately 1.7 million square feet upon full build out. The additional entitlements represent double the allowable density compared to when Healthpeak originally acquired the land. The long-term nature of the entitlements offers flexibility to deliver the balance of the development in phases to align with market demand. Strategically located in the heart of South San Francisco and at the doorstep of Genentech’s headquarters, the 20-acre purpose-built lab campus offers tenants a highly amenitized, world-class campus setting with access to multiple modes of transportation including direct access to the Rails-to-Trails pathway, which provides a pedestrian connection to downtown South San Francisco's restaurant and retail corridor, as well as the Caltrain station, which recently completed a multi-year renovation. Healthpeak is South San Francisco's largest investor-owned landlord with a portfolio that encompasses 4.9 million square feet, including some the submarket's most desirable campuses including The Cove, Portside at Oyster Point, The Shore, Vantage, and Pointe Grand, among others. OUTPATIENT DEVELOPMENT PROGRAM WITH HCA During the fourth quarter, Healthpeak added two on-campus outpatient developments with total expected development costs of $90 million to its program with HCA. • Galen Aurora: 72,000 square foot Class A medical training facility located on HCA’s Medical Center of Aurora hospital campus, a 325-bed acute care hospital in Denver, CO where Healthpeak currently owns three on-campus buildings totaling approximately 165,000 square feet. HCA nursing and professional education affiliates have pre-leased 100% of the development. • McKinney Medical Center: 120,000 square foot Class A outpatient building on the campus of HCA's Medical City McKinney campus, a 281-bed acute care hospital in McKinney, TX where Healthpeak currently owns two on-campus buildings totaling approximately 120,000 square feet. HCA affiliates have pre-leased approximately 62% of the development for future outpatient services, including oncology, orthopedic, cardiology, wound care, imaging, and other services. Since 2019, Healthpeak’s development program with HCA has delivered 9 outpatient buildings totaling 785,000 square feet with total development costs of approximately $235 million and is under construction on an additional three buildings totaling 262,000 square feet with total expected development costs of $121 million. MERGER WITH PHYSICIANS REALTY TRUST AND TERM LOAN UPDATE As previously announced on October 30, 2023, Healthpeak and Physicians Realty Trust entered into a definitive agreement to combine in an all-stock merger of equals. Each company will hold its respective special meeting of stockholders on February 21, 2024. Subject to Physicians Realty Trust's stockholders approving the proposed merger and Healthpeak's stockholders approving the issuance of Healthpeak common stock in connection with the proposed merger, among other matters, as well as the satisfaction or waiver of customary closing conditions, the transaction is expected to close on March 1, 2024. Additionally, Healthpeak expects to enter into a new $750 million 5-year unsecured term loan. Proceeds from the term loan are expected to fund the repayment of $210 million of Physicians Realty Trust private placement notes and to be used for general corporate purposes, including transaction costs and repayment of borrowings under Healthpeak's credit facility and commercial paper program. Healthpeak has entered into forward-starting swap agreements to fix the interest rate of the new term loan at approximately 4.5% for the full 5-year term of the loan. DIVIDEND On January 31, 2024, Healthpeak's Board declared a quarterly common stock cash dividend of $0.30 per share to be paid on February 26, 2024, to stockholders of record as of the close of business on February 14, 2024.

Return to TOC 6 2024 OUTLOOK For full year 2024, we have established the following outlook ranges, which are inclusive of the impact from the Physicians Realty Trust merger: • Diluted earnings per common share of $0.07 – $0.13 • Diluted Nareit FFO per share of $1.54 – $1.60 • Diluted FFO as Adjusted per share of $1.73 – $1.79 • Diluted AFFO per share of $1.50 – $1.56 • Total Portfolio Same-Store Cash (Adjusted) NOI growth of 2.25% – 3.75% This outlook assumes the merger with Physicians Realty Trust closes on March 1, 2024. These estimates are based on our view of existing market conditions, transaction timing, and other assumptions for the year ending December 31, 2024. Additionally, the outlook includes estimates for certain merger-related accounting adjustments, which will not be finalized until after the merger closes. For additional details and assumptions underlying this outlook, please see page 40 in our corresponding Supplemental Report and the Discussion and Reconciliation of Non-GAAP Financial Measures, both of which are available in the Investor Relations section of our website at http://ir.healthpeak.com. CONFERENCE CALL INFORMATION Healthpeak has scheduled a conference call and webcast for Friday, February 9, 2024, at 8:00 a.m. Mountain Time. The conference call can be accessed in the following ways: • Healthpeak’s website: https://ir.healthpeak.com/news-events • Webcast: https://events.q4inc.com/attendee/292488797. Joining via webcast is recommended for those who will not be asking questions. • Telephone: The participant dial-in number is (800) 715-9871. An archive of the webcast will be available on Healthpeak's website through February 7, 2025, and a telephonic replay can be accessed through February 15, 2024, by dialing (800) 770-2030 and entering conference ID number 58822. ABOUT HEALTHPEAK Healthpeak Properties, Inc. is a fully integrated real estate investment trust (REIT) and S&P 500 company. Healthpeak owns, operates and develops high-quality real estate for healthcare discovery and delivery.

Return to TOC 7 FORWARD-LOOKING STATEMENTS Statements contained in this release that are not historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, among other things, statements regarding our and our officers' intent, belief or expectation as identified by the use of words such as "may," "will," "project," "expect," "believe," "intend," "anticipate," "seek," "target," "forecast," "plan," "potential," "estimate," "could," "would," "should" and other comparable and derivative terms or the negatives thereof. Examples of forward-looking statements include, among other things: (i) statements regarding timing, outcomes and other details relating to current, pending or contemplated acquisitions, dispositions, transitions, developments, redevelopments, densifications, joint venture transactions, leasing activity and commitments, financing activities, or other transactions discussed in this release, including statements regarding our proposed merger with Physicians Realty Trust; (ii) the payment of a quarterly cash dividend; and (iii) the information presented under the heading "2024 Outlook." Pending acquisitions, dispositions, joint venture transactions, leasing activity, and financing activity, including those subject to binding agreements, remain subject to closing conditions and may not be completed within the anticipated timeframes or at all. Forward-looking statements reflect our current expectations and views about future events and are subject to risks and uncertainties that could significantly affect our future financial condition and results of operations. While forward-looking statements reflect our good faith belief and assumptions we believe to be reasonable based upon current information, we can give no assurance that our expectations or forecasts will be attained. Further, we cannot guarantee the accuracy of any such forward-looking statement contained in this release, and such forward-looking statements are subject to known and unknown risks and uncertainties that are difficult to predict. These risks and uncertainties include, but are not limited to: macroeconomic trends, including inflation, interest rates, labor costs, and unemployment; risks associated with the proposed merger transactions with Physicians Realty Trust (the “Mergers”), including, but not limited to, our ability to consummate the Mergers on the proposed terms or on the anticipated timeline, or at all, potential loss or disruption of current and prospective commercial relationships due to the uncertainties about the Mergers, and the outcome of legal proceedings instituted against us, our Board of Directors, and others related to the Mergers; our ability to integrate the operations of the Company and Physicians Realty Trust successfully and realize the anticipated synergies and other benefits of the Mergers or do so within the anticipated time frame; changes within the industries in which we operate; significant regulation, funding requirements, and uncertainty faced by our lab tenants; factors adversely affecting our tenants’, operators’, or borrowers’ ability to meet their financial and other contractual obligations to us; the insolvency or bankruptcy of one or more of our major tenants, operators, or borrowers; our concentration of real estate investments in the healthcare property sector, which makes us more vulnerable to a downturn in a specific sector than if we invested across multiple sectors; the illiquidity of real estate investments; our ability to identify and secure new or replacement tenants and operators; our property development, redevelopment, and tenant improvement risks, including project abandonments, project delays, and lower profits than expected; the ability of the hospitals on whose campuses our outpatient medical buildings are located and their affiliated healthcare systems to remain competitive or financially viable; our ability to develop, maintain, or expand hospital and health system client relationships; operational risks associated with third party management contracts, including the additional regulation and liabilities of our properties operated through RIDEA structures; economic conditions, natural disasters, weather, and other conditions that negatively affect geographic areas where we have concentrated investments; uninsured or underinsured losses, which could result in significant losses and/or performance declines by us or our tenants and operators; our investments in joint ventures and unconsolidated entities, including our lack of sole decision making authority and our reliance on our partners’ financial condition and continued cooperation; our use of fixed rent escalators, contingent rent provisions, and/or rent escalators based on the Consumer Price Index; competition for suitable healthcare properties to grow our investment portfolio; our ability to foreclose or exercise rights on collateral securing our real estate-related loans; any requirement that we recognize reserves, allowances, credit losses, or impairment charges; investment of substantial resources and time in transactions that are not consummated; our ability to successfully integrate or operate acquisitions; the potential impact on us and our tenants, operators, and borrowers from litigation matters, including rising liability and insurance costs; environmental compliance costs and liabilities associated with our real estate investments; ESG and sustainability commitments and requirements, as well as stakeholder expectations; epidemics, pandemics, or other infectious diseases, including Covid, and health and safety measures intended to reduce their spread; human capital risks, including the loss or limited availability of our key personnel; our reliance on information technology systems and the possibility of a cybersecurity incident or cybersecurity threat affect our information systems or the information systems of our tenants, operators or borrowers; volatility, disruption, or uncertainty in the financial markets; increased borrowing costs, including due to rising interest rates; cash available for distribution to stockholders and our ability to make dividend distributions at expected levels; the availability of external capital on acceptable terms or at all, including due to rising interest rates, changes in our credit ratings and the value of our common stock, bank failures or other events affecting financial institutions; our ability to manage our indebtedness level and covenants in and changes to the terms of such indebtedness; the failure of our tenants, operators, and borrowers to comply with federal, state, and local laws and regulations, including resident health and safety requirements, as well as licensure, certification, and inspection requirements; required regulatory approvals to transfer our senior housing properties; compliance with the Americans with Disabilities Act and fire, safety, and other regulations; laws or regulations prohibiting eviction of our tenants; the requirements of, or changes to, governmental reimbursement programs such as Medicare or Medicaid; legislation to address federal government operations and administrative decisions affecting the Centers for Medicare and Medicaid Services; our participation in the CARES Act Provider Relief Fund and other Covid-related stimulus and relief programs; our ability to maintain our qualification as a REIT; our taxable REIT subsidiaries being subject to corporate level tax; tax imposed on any net income from “prohibited transactions”; changes to U.S. federal income tax laws, and potential deferred and contingent tax liabilities from corporate acquisitions; calculating non-REIT tax earnings and profits distributions; ownership limits in our charter that restrict ownership in our stock; provisions of Maryland law and our charter that could prevent a transaction that may otherwise be in the interest of our stockholders; conflicts of interest between the interests of our stockholders and the interests of holders of Healthpeak OP common units; provisions in the operating agreement of Healthpeak OP and other agreements that may delay or prevent unsolicited acquisitions and other transactions; our status as a holding company of Healthpeak OP; and other risks and uncertainties described from time to time in our Securities and Exchange Commission filings. Except as required by law, we do not undertake, and hereby disclaim, any obligation to update any forward-looking statements, which speak only as of the date on which they are made.

Return to TOC 8 ADDITIONAL INFORMATION AND WHERE TO FIND IT In connection with the proposed transaction, on December 15, 2023, Healthpeak and Physicians Realty Trust filed with the SEC a registration statement on Form S-4 containing a joint proxy statement/prospectus and other documents regarding the proposed transaction. The joint proxy statement/prospectus contains important information about the proposed transaction and related matters. The Form S-4 was declared effective, and each of Healthpeak and Physicians Realty Trust commenced mailing of the joint proxy statement/prospectus included as part of the Form S-4, on January 11, 2024. STOCKHOLDERS ARE URGED AND ADVISED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS (INCLUDING ALL AMENDMENTS AND SUPPLEMENTS THERETO) AND OTHER RELEVANT DOCUMENTS FILED WITH THE SEC CAREFULLY BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT HEALTHPEAK, PHYSICIANS REALTY TRUST AND THE PROPOSED TRANSACTION. Investors and security holders of Healthpeak and Physicians Realty Trust are able to obtain free copies of the registration statement, the joint proxy statement/prospectus and other relevant documents filed by Healthpeak and Physicians Realty Trust with the SEC through the website maintained by the SEC at www.sec.gov. Copies of the documents filed by Healthpeak with the SEC are also available on Healthpeak’s website at www.healthpeak.com, and copies of the documents filed by Physicians Realty Trust with the SEC are available on Physicians Realty Trust’s website at www.docreit.com. PARTICIPANTS IN THE SOLICITATION Healthpeak, Physicians Realty Trust and their respective directors, trustees and executive officers may be deemed to be participants in the solicitation of proxies from Healthpeak’s stockholders and Physicians Realty Trust’s shareholders in respect of the proposed transaction. Information regarding Healthpeak’s directors and executive officers can be found in Healthpeak’s definitive proxy statement filed with the SEC on March 17, 2023. Information regarding Physicians Realty Trust’s trustees and executive officers can be found in Physicians Realty Trust’s definitive proxy statement filed with the SEC on March 23, 2023. Additional information regarding the interests of such potential participants is included in the joint proxy statement/prospectus and other relevant documents filed with the SEC in connection with the proposed transaction. These documents are available on the SEC’s website and from Healthpeak and Physicians Realty Trust, as applicable, using the sources indicated above. NO OFFER OR SOLICITATION This communication is for informational purposes only and is neither an offer to purchase, nor a solicitation of an offer to sell, any securities or the solicitation of any vote in any jurisdiction pursuant to the proposed transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended. CONTACT Andrew Johns, CFA Senior Vice President – Investor Relations 720-428-5400

Return to TOC 9 December 31, 2023 December 31, 2022 Assets Real estate: Buildings and improvements $ 13,329,464 $ 12,784,078 Development costs and construction in progress 643,217 760,355 Land and improvements 2,647,633 2,667,188 Accumulated depreciation and amortization (3,591,951) (3,188,138) Net real estate 13,028,363 13,023,483 Loans receivable, net of reserves of $2,830 and $8,280 218,450 374,832 Investments in and advances to unconsolidated joint ventures 782,853 706,677 Accounts receivable, net of allowance of $2,282 and $2,399 55,820 53,436 Cash and cash equivalents 117,635 72,032 Restricted cash 51,388 54,802 Intangible assets, net 314,156 418,061 Assets held for sale, net 117,986 49,866 Right-of-use asset, net 240,155 237,318 Other assets, net 772,044 780,722 Total assets $ 15,698,850 $ 15,771,229 Liabilities and Equity Bank line of credit and commercial paper $ 720,000 $ 995,606 Term loans 496,824 495,957 Senior unsecured notes 5,403,378 4,659,451 Mortgage debt 256,097 346,599 Intangible liabilities, net 127,380 156,193 Liabilities related to assets held for sale, net 729 4,070 Lease liability 206,743 208,515 Accounts payable, accrued liabilities, and other liabilities 657,196 772,485 Deferred revenue 905,633 844,076 Total liabilities 8,773,980 8,482,952 Commitments and contingencies Redeemable noncontrolling interests 48,828 105,679 Common stock, $1.00 par value: 750,000,000 shares authorized; 547,156,311 and 546,641,973 shares issued and outstanding 547,156 546,642 Additional paid-in capital 10,405,780 10,349,614 Cumulative dividends in excess of earnings (4,621,861) (4,269,689) Accumulated other comprehensive income (loss) 19,371 28,134 Total stockholders’ equity 6,350,446 6,654,701 Joint venture partners 310,998 327,721 Non-managing member unitholders 214,598 200,176 Total noncontrolling interests 525,596 527,897 Total equity 6,876,042 7,182,598 Total liabilities and equity $ 15,698,850 $ 15,771,229 Healthpeak Properties, Inc. Consolidated Balance Sheets In thousands, except share and per share data

Return to TOC 10 Healthpeak Properties, Inc. Consolidated Statements of Operations In thousands, except per share data Three Months Ended December 31, Year Ended December 31, 2023 2022 2023 2022 Revenues: Rental and related revenues $ 412,332 $ 392,245 $ 1,631,805 $ 1,541,775 Resident fees and services 136,341 125,873 527,417 494,935 Interest income 4,979 6,350 21,781 23,300 Income from direct financing leases — — — 1,168 Total revenues 553,652 524,468 2,181,003 2,061,178 Costs and expenses: Interest expense 52,784 49,413 200,331 172,944 Depreciation and amortization 188,544 179,157 749,901 710,569 Operating 224,401 220,492 902,060 862,991 General and administrative 21,556 57,872 95,132 131,033 Transaction and merger-related costs 14,417 3,217 17,515 4,853 Impairments and loan loss reserves (recoveries), net (5,445) 3,326 (5,601) 7,004 Total costs and expenses 496,257 513,477 1,959,338 1,889,394 Other income (expense): Gain (loss) on sales of real estate, net — (969) 86,463 9,078 Other income (expense), net 2,600 (587) 6,808 326,268 Total other income (expense), net 2,600 (1,556) 93,271 335,346 Income (loss) before income taxes and equity income (loss) from unconsolidated joint ventures 59,995 9,435 314,936 507,130 Income tax benefit (expense) 11,842 650 9,617 4,425 Equity income (loss) from unconsolidated joint ventures 3,558 (156) 10,204 1,985 Income (loss) from continuing operations 75,395 9,929 334,757 513,540 Income (loss) from discontinued operations — 873 — 2,884 Net income (loss) 75,395 10,802 334,757 516,424 Noncontrolling interests’ share in continuing operations (4,451) (4,274) (28,748) (15,975) Net income (loss) attributable to Healthpeak Properties, Inc. 70,944 6,528 306,009 500,449 Participating securities’ share in earnings (157) (140) (1,725) (2,657) Net income (loss) applicable to common shares $ 70,787 $ 6,388 $ 304,284 $ 497,792 Basic earnings (loss) per common share: Continuing operations $ 0.13 $ 0.01 $ 0.56 $ 0.92 Discontinued operations — 0.00 — 0.00 Net income (loss) applicable to common shares $ 0.13 $ 0.01 $ 0.56 $ 0.92 Diluted earnings (loss) per common share: Continuing operations $ 0.13 $ 0.01 $ 0.56 $ 0.92 Discontinued operations — 0.00 — 0.00 Net income (loss) applicable to common shares $ 0.13 $ 0.01 $ 0.56 $ 0.92 Weighted average shares outstanding: Basic 547,091 537,992 547,006 538,809 Diluted 547,361 538,396 547,275 539,147

Return to TOC 11 Healthpeak Properties, Inc. Funds From Operations In thousands, except per share data Three Months Ended December 31, Year Ended December 31, 2023 2022 2023 2022 Net income (loss) applicable to common shares $ 70,787 $ 6,388 $ 304,284 $ 497,792 Real estate related depreciation and amortization 188,544 179,157 749,901 710,569 Healthpeak’s share of real estate related depreciation and amortization from unconsolidated joint ventures 6,723 8,642 24,800 27,691 Noncontrolling interests’ share of real estate related depreciation and amortization (4,610) (4,709) (18,654) (19,201) Loss (gain) on sales of depreciable real estate, net — 986 (86,463) (10,422) Healthpeak’s share of loss (gain) on sales of depreciable real estate, net, from unconsolidated joint ventures — 45 — 134 Noncontrolling interests’ share of gain (loss) on sales of depreciable real estate, net — — 11,546 12 Loss (gain) upon change of control, net(1) — — (234) (311,438) Taxes associated with real estate dispositions — — — 29 Nareit FFO applicable to common shares 261,444 190,509 985,180 895,166 Distributions on dilutive convertible units and other 2,366 1,649 9,394 9,407 Diluted Nareit FFO applicable to common shares $ 263,810 $ 192,158 $ 994,574 $ 904,573 Diluted Nareit FFO per common share $ 0.48 $ 0.35 $ 1.79 $ 1.66 Weighted average shares outstanding - diluted Nareit FFO 554,635 543,879 554,559 546,462 Impact of adjustments to Nareit FFO: Transaction and merger-related items(2) $ 10,842 $ 3,215 $ 13,835 $ 4,788 Other impairments (recoveries) and other losses (gains), net(3) (4,407) 9,702 (3,850) 3,829 Restructuring and severance-related charges(4) — 32,749 1,368 32,749 Casualty-related charges (recoveries), net(5) (3,424) 298 (4,033) 4,401 Recognition (reversal) of valuation allowance on deferred tax assets(6) (14,194) — (14,194) — Total adjustments (11,183) 45,964 (6,874) 45,767 FFO as Adjusted applicable to common shares 250,261 236,473 978,306 940,933 Distributions on dilutive convertible units and other 2,378 2,271 9,402 9,326 Diluted FFO as Adjusted applicable to common shares $ 252,639 $ 238,744 $ 987,708 $ 950,259 Diluted FFO as Adjusted per common share $ 0.46 $ 0.44 $ 1.78 $ 1.74 Weighted average shares outstanding - diluted FFO as Adjusted 554,635 545,704 554,559 546,462 (1) The year ended December 31, 2022 includes a gain upon change of control related to the sale of a 30% interest to a sovereign wealth fund and deconsolidation of seven previously consolidated lab buildings in South San Francisco, California. The gain upon change of control is included in other income (expense), net in the Consolidated Statements of Operations. (2) The three months and year ended December 31, 2023 include costs related to the proposed merger with Physicians Realty Trust, which are primarily comprised of legal, accounting, tax, and other costs that were incurred prior to year-end, partially offset by termination fee income associated with Graphite Bio, Inc., for which the lease terms have been modified to accelerate expiration of the lease to December 2024. Termination fee income is included in rental and related revenues on the Consolidated Statements of Operations. (3) The three months and year ended December 31, 2022 include $7 million of charges incurred in connection with the downsizing of the Company’s corporate headquarters in Denver, Colorado, which are included in general and administrative expenses in the Consolidated Statements of Operations. The year ended December 31, 2022 also includes the following, which are included in other income (expense), net in the Consolidated Statements of Operations: (i) $14 million of expenses incurred for tenant relocation and other costs associated with the demolition of an outpatient medical building and (ii) a $23 million gain on sale of a hospital under a direct financing lease. The three months and years ended December 31, 2023 and 2022 include reserves and (recoveries) for expected loan losses recognized in impairments and loan loss reserves (recoveries), net in the Consolidated Statements of Operations. (4) The three months and year ended December 31, 2022 include $32 million of severance-related charges associated with the departures of our former Chief Executive Officer and former Chief Legal Officer and General Counsel in the fourth quarter of 2022. These expenses are included in general and administrative expenses in the Consolidated Statements of Operations. (5) Casualty-related charges (recoveries), net are recognized in other income (expense), net and equity income (loss) from unconsolidated joint ventures in the Consolidated Statements of Operations. (6) In conjunction with classifying the assets related to the Callan Ridge JV as held for sale as of December 31, 2023, we concluded it was more likely than not that we would realize the future value of certain deferred tax assets generated by the net operating losses of taxable REIT subsidiaries. Accordingly, during the three months and year ended December 31, 2023, we recognized the reversal of a portion of the associated valuation allowance and recognized a corresponding income tax benefit.

Return to TOC 12 Healthpeak Properties, Inc. Adjusted Funds From Operations In thousands Three Months Ended December 31, Year Ended December 31, 2023 2022 2023 2022 FFO as Adjusted applicable to common shares $ 250,261 $ 236,473 $ 978,306 $ 940,933 Stock-based compensation amortization expense 3,513 1,903 14,480 16,537 Amortization of deferred financing costs 3,088 2,812 11,916 10,881 Straight-line rents(1) (1,677) (12,346) (14,387) (49,183) AFFO capital expenditures (47,332) (33,407) (113,596) (108,510) Deferred income taxes 117 (355) (816) (4,096) Amortization of above (below) market lease intangibles, net (5,525) (5,851) (25,791) (23,380) Other AFFO adjustments (7,486) 3,536 (9,335) 520 AFFO applicable to common shares 194,959 192,765 840,777 783,702 Distributions on dilutive convertible units and other 1,663 1,649 6,581 6,594 Diluted AFFO applicable to common shares $ 196,622 $ 194,414 $ 847,358 $ 790,296 Diluted AFFO per common share $ 0.36 $ 0.36 $ 1.53 $ 1.45 Weighted average shares outstanding - diluted AFFO 552,810 543,879 552,734 544,637 (1) The year ended December 31, 2023 includes an $8.7 million write-off of straight-line rent receivable associated with Sorrento Therapeutics, Inc., which commenced voluntary reorganization proceedings under Chapter 11 of the U.S. Bankruptcy Code. This activity is reflected as a reduction of rental and related revenues in the Consolidated Statements of Operations.

Return to TOC 13 Overview(1) As of and for the quarter and year ended December 31, 2023, dollars, square feet, and shares in thousands, except per share data 4Q23 Full Year 2023 Financial Metrics Diluted earnings per common share $0.13 $0.56 Diluted Nareit FFO per common share $0.48 $1.79 Diluted FFO as Adjusted per common share $0.46 $1.78 Dividends per common share $0.30 $1.20 Portfolio Real Estate Revenues $565,234 $2,219,325 Portfolio NOI $322,005 $1,257,076 Portfolio Cash (Adjusted) NOI $307,641 $1,204,987 Portfolio Income $312,621 $1,226,768 4Q23 % of Total SS Full Year 2023 % of Total Full Year SS Same-Store Cash (Adjusted) NOI Growth Lab 2.7% 47.1% 3.7% 46.6% Outpatient Medical 4.3% 41.4% 3.4% 42.0% CCRC 4.7% 11.5% 15.6% 11.5% Total 3.6% 100.0% 4.8% 100.0% 4Q23 4Q23 Full Year 2023 Capitalization Debt Ratios Common stock outstanding and DownREIT units 554,374 Financial Leverage 34.7% 34.7% Total Market Equity $10,976,605 Secured Debt Ratio 1.5% 1.5% Enterprise Debt $6,916,205 Net Debt to Adjusted EBITDAre 5.2x 5.4x Adjusted Fixed Charge Coverage 4.7x 4.8x Total Portfolio Operating Portfolio Property Count Capacity(2) Capacity Occupancy(3) Portfolio Statistics Lab 146 12,021 Sq. Ft. 10,959 Sq. Ft. 96.9% Outpatient Medical 297 24,136 Sq. Ft. 23,875 Sq. Ft. 90.7% CCRC 15 7,097 Units 7,097 Units 84.9% Other(4) 19 3,354 Units 3,354 Units 78.6% Total 477 The Numbers (1) Reconciliations, definitions, and important discussions regarding the usefulness and limitations of the non-GAAP financial measures used in this Supplemental Report can be found in the Glossary herein and the Discussion and Reconciliation of Non-GAAP Financial Measures at https:// ir.healthpeak.com/quarterly-results. The contents of this Earnings Release and Supplemental Report are unaudited and totals may not add due to rounding. Throughout this Supplemental Report, segments, NOI, and other key performance metrics are inclusive of our share in unconsolidated JVs and exclusive of noncontrolling interest share in consolidated JVs. See the Glossary herein and the Discussion and Reconciliation of Non-GAAP Financial Measures for further information, including how pro rata information is derived and the limits of such data. (2) Total Portfolio Capacity includes estimated capacity upon the completion of Development and Redevelopment projects. (3) Occupancy for Lab and Outpatient Medical is calculated as of the end of the period presented and is based on square feet. Occupancy for CCRC and Other is calculated based on the most recent three-month average available and is based on units. Occupancy excludes assets held for sale and assets in development or redevelopment. (4) Our Other non-reportable segment includes nineteen assets in our unconsolidated SWF SH JV.

14 Return to TOC Lab 50.5% Outpatient Medical 36.6% CCRC 9.4% Other 3.5% Portfolio Summary As of and for the quarter ended December 31, 2023, dollars in thousands Property Count Weighted Average Age(1) Portfolio Investment Portfolio Income Property Portfolio Lab 131 14 $ 8,359,085 $ 157,805 Outpatient Medical 294 24 6,401,183 114,432 CCRC(2) 15 32 2,387,437 29,481 Other 19 26 471,413 5,924 459 20 $ 17,619,118 $ 307,641 Developments Lab 4 $ 402,482 $ — Outpatient Medical 3 14,361 — 7 $ 416,842 $ — Redevelopments(3) Lab 11 $ 419,139 $ — 11 $ 419,139 $ — Debt Investments Seller financing loans — $ 178,547 $ 4,979 Total Lab 146 $ 9,180,706 $ 157,805 Outpatient Medical 297 6,415,544 114,432 CCRC(2) 15 2,387,437 29,481 Other 19 649,959 10,903 477 $ 18,633,646 $ 312,621 (1) Age is weighted based on current quarter Portfolio Income excluding assets sold or held for sale. (2) The amount in the table above represents Gross Portfolio Investment. Net of the related $814 million of liabilities for Non-Refundable Entrance Fees ("NREFs") and refundable Entrance Fees, Net Portfolio Investment would be $1.6 billion. (3) Includes Construction in Process ("CIP") and buildings or portions of buildings placed in Redevelopment. Portfolio Income for Redevelopments is reflected in the Property Portfolio section above. PORTFOLIO INCOME $312.6M

15 Return to TOC Quarter NOI Summary For the quarter ended December 31, 2023, dollars in thousands PORTFOLIO NOI SUMMARY Portfolio NOI SS Portfolio NOI Portfolio Real Estate Revenues Portfolio Operating Expenses Portfolio NOI SS Portfolio Real Estate Revenues SS Portfolio Operating Expenses SS Portfolio NOI Lab $ 226,732 $ (58,019) $ 168,712 $ 172,594 $ (47,376) $ 125,218 Outpatient Medical 180,915 (63,541) 117,374 166,551 (56,685) 109,866 CCRC 136,340 (105,920) 30,420 136,083 (105,416) 30,667 Other 21,247 (15,749) 5,498 — — — $ 565,234 $ (243,229) $ 322,005 $ 475,228 $ (209,476) $ 265,751 PORTFOLIO CASH (ADJUSTED) NOI SUMMARY Portfolio Cash (Adjusted) NOI SS Portfolio Cash (Adjusted) NOI Portfolio Cash Real Estate Revenues Portfolio Cash Operating Expenses Portfolio Cash (Adjusted) NOI SS Portfolio Cash Real Estate Revenues SS Portfolio Cash Operating Expenses SS Portfolio Cash (Adjusted) NOI Lab $ 216,436 $ (58,632) $ 157,805 $ 169,265 $ (47,374) $ 121,891 Outpatient Medical 177,301 (62,868) 114,432 163,154 (56,047) 107,107 CCRC 136,340 (106,860) 29,481 136,083 (106,356) 29,727 Other 21,167 (15,243) 5,924 — — — $ 551,245 $ (243,603) $ 307,641 $ 468,502 $ (209,777) $ 258,725 THREE-MONTH SS Property Count % of Total SS based on SS Cash (Adjusted) NOI SS % of Segment based on Cash (Adjusted) NOI Year-Over-Year Sequential Occupancy Growth Occupancy Growth 4Q23 4Q22 SS NOI SS Cash (Adjusted) NOI 4Q23 3Q23 SS NOI SS Cash (Adjusted) NOI Lab 120 47% 77% 96.6% 98.7% (3.8%) (1) 2.7% 96.6% 97.2% (1.9%) (0.2%) Outpatient Medical 280 41% 94% 91.6% 91.4% 2.3% 4.3% 91.6% 91.2% (0.4%) 0.1% CCRC 15 12% 100% 84.9% 82.4% 17.5% 4.7% 84.9% 83.9% 4.4% 1.2% Total 415 100% 86% (2) 0.8% 3.6% (0.6%) 0.1% (1) Primarily related to acceleration on certain lease related items associated with early terminations. (2) Segment portfolio Cash (Adjusted) NOI percentage excludes our Other segment, which is not included in same-store.

16 Return to TOC Full Year NOI Summary For the twelve months ended December 31, 2023, dollars in thousands PORTFOLIO NOI SUMMARY Portfolio NOI SS Portfolio NOI Portfolio Real Estate Revenues Portfolio Operating Expenses Portfolio NOI SS Portfolio Real Estate Revenues SS Portfolio Operating Expenses SS Portfolio NOI Lab $ 887,630 $ (233,565) $ 654,065 $ 670,315 $ (185,208) $ 485,107 Outpatient Medical 721,439 (254,400) 467,039 647,808 (220,754) 427,053 CCRC 527,601 (413,472) 114,129 526,769 (411,539) 115,230 Other 82,655 (60,811) 21,843 — — — $ 2,219,325 $ (962,249) $ 1,257,076 $ 1,844,892 $ (817,501) $ 1,027,390 PORTFOLIO CASH (ADJUSTED) NOI SUMMARY Portfolio Cash (Adjusted) NOI SS Portfolio Cash (Adjusted) NOI Portfolio Cash Real Estate Revenues Portfolio Cash Operating Expenses Portfolio Cash (Adjusted) NOI SS Portfolio Cash Real Estate Revenues SS Portfolio Cash Operating Expenses SS Portfolio Cash (Adjusted) NOI Lab $ 852,068 $ (234,527) $ 617,541 $ 646,317 $ (185,188) $ 461,129 Outpatient Medical 704,448 (251,724) 452,725 633,614 (218,246) 415,367 CCRC 527,601 (415,090) 112,511 526,769 (413,157) 113,612 Other 82,578 (60,368) 22,210 — — — $ 2,166,695 $ (961,708) $ 1,204,987 $ 1,806,700 $ (816,591) $ 990,108 TWELVE-MONTH SS % of Total SS based on Cash (Adjusted) NOI SS % of Segment based on Cash (Adjusted) NOI Year-Over-Year Property Count Occupancy Growth 2023 2022 SS NOI SS Cash (Adjusted) NOI Lab 116 47% 75% 96.5% 98.7% (1.0%) (1) 3.7% Outpatient Medical 272 42% 92% 91.9% 91.7% 2.8% 3.4% CCRC 15 11% 100% 83.8% 81.6% 20.0% 15.6% Total 403 100% 84% (2) 2.6% 4.8% (1) The twelve months ended December 31, 2023 includes an $8.7 million write-off of straight-line rent receivable associated with Sorrento Therapeutics, Inc., which commenced voluntary reorganization proceedings under Chapter 11 of the U.S. Bankruptcy Code. (2) Segment portfolio Cash (Adjusted) NOI percentage excludes our Other segment, which is not included in same-store.

17 Return to TOC Property Count Reconciliations SEQUENTIAL SS Lab Outpatient Medical CCRC Other Total Prior Quarter Three-Month SS Property Count 122 279 15 — 416 Assets in Redevelopment (3) — — — (3) Prior Development/Redevelopment 2 1 — — 3 Significant tenant relocation (1) — — — (1) Current Quarter Three-Month SS Property Count 120 280 15 — 415 As of December 31, 2023 PROPERTY COUNT RECONCILIATION Lab Outpatient Medical CCRC Other Total Prior Quarter Total Property Count 146 295 15 19 475 New Developments — 2 — — 2 Current Quarter Total Property Count 146 297 15 19 477 Assets in Development (4) (3) — — (7) Recently completed Developments (5) (5) — — (10) Assets in Redevelopment (11) — — — (11) Recently completed Redevelopments (3) (8) — — (11) Assets held for sale(1) — (1) — — (1) Segment exclusions — — — (19) (19) Significant tenant relocation (3) — — — (3) Three-Month SS Property Count 120 280 15 — 415 Recent acquisitions — (4) — — (4) Recently completed Developments (3) (3) — — (6) Recently completed Redevelopments (1) (1) — — (2) Twelve-Month SS Property Count 116 272 15 — 403 (1) Two Callan Ridge lab properties, which are held for sale in connection with the announced joint venture, are reflected in Assets in Development above.

18 Return to TOC Capitalization Dollars and shares in thousands, except price per share data TOTAL CAPITALIZATION December 31, 2023 Shares Price Total Value Common stock (NYSE: PEAK) 547,156 $ 19.80 $ 10,833,689 Convertible partnership (DownREIT) units 7,218 19.80 142,916 Total Market Equity 554,374 $ 10,976,605 Consolidated Debt 6,876,299 Total Market Equity and Consolidated Debt 554,374 $ 17,852,904 Share of unconsolidated JV debt 39,906 Total Market Equity and Enterprise Debt 554,374 $ 17,892,810 COMMON STOCK AND EQUIVALENTS Weighted Average Shares Weighted Average Shares Three Months Ended December 31, 2023 Twelve Months Ended December 31, 2023 Shares Outstanding December 31, 2023 Diluted EPS Diluted Nareit FFO Diluted FFO as Adjusted Diluted AFFO Diluted EPS Diluted Nareit FFO Diluted FFO as Adjusted Diluted AFFO Common stock 547,156 547,091 547,091 547,091 547,091 547,006 547,006 547,006 547,006 Common stock equivalent securities(1): Restricted stock units 879 270 270 270 270 269 269 269 269 Convertible partnership (DownREIT) units 7,218 — 7,274 7,274 5,449 — 7,284 7,284 5,459 Total common stock and equivalents 555,253 547,361 554,635 554,635 552,810 547,275 554,559 554,559 552,734 (1) The weighted average shares for the three and twelve months ended December 31, 2023 represent the current dilutive impact, using the treasury stock method, of approximately 900 thousand restricted stock units and 7.2 million DownREIT units.

19 Return to TOC Indebtedness As of December 31, 2023, dollars in thousands DEBT MATURITIES AND SCHEDULED PRINCIPAL REPAYMENTS (AMORTIZATION) Senior Unsecured Notes Mortgage Debt Share of Unconsolidated JV Debt Enterprise Debt Bank LOC, Commercial Paper(1) Term Loan(2) Amounts Rates % Amounts Rates % Consolidated Debt Amounts(3) Rates % Amounts Rates % 2024 $ — $ — $ — — $ 7,024 6.90 $ 7,024 $ 11,299 8.02 $ 18,323 7.59 2025 — — 800,000 3.92 3,209 3.82 803,209 28,567 (4) 4.79 831,776 3.95 2026 720,000 — 650,000 3.40 244,523 4.44 1,614,523 — — 1,614,523 4.58 2027 — 500,000 450,000 1.54 366 5.91 950,366 — — 950,366 2.71 2028 — — 500,000 2.35 — — 500,000 — — 500,000 2.35 2029 — — 650,000 3.65 — — 650,000 — — 650,000 3.65 2030 — — 750,000 3.14 — — 750,000 — — 750,000 3.14 2031 — — 600,000 3.07 — — 600,000 — — 600,000 3.07 2032 — — 750,000 5.49 — — 750,000 — — 750,000 5.49 2033 — — — — — — — — — — — Thereafter — — 300,000 6.87 — — 300,000 — — 300,000 6.87 $ 720,000 $ 500,000 $ 5,450,000 $ 255,122 $ 6,925,122 $ 39,866 $ 6,964,988 Premium, (discounts), and debt Issuance costs, net — (3,176) (46,622) 975 (48,823) 40 (48,783) $ 720,000 $ 496,824 $ 5,403,378 $ 256,097 $ 6,876,299 $ 39,906 $ 6,916,205 Weighted average interest rate % 5.70 3.76 3.66 4.50 3.91 5.70 3.92 Weighted average maturity in years 2.1 3.4 5.6 2.6 5.0 1.3 5.0 (1) The Company has a $3.0 billion unsecured revolving line of credit facility (the "Revolving Facility") that matures on January 20, 2026 and contains two six-month extension options. It accrues interest at SOFR plus 85 basis points and incurs an annual facility fee of 15 basis points, based on our current unsecured credit rating. Commercial paper borrowings are backstopped by the Revolving Facility. As such, we calculate the weighted average remaining term of our commercial paper borrowings using the maturity date of the Revolving Facility. (2) The Company has two senior unsecured term loans (the “Term Loan Facilities”) in an aggregate principal amount of $500 million, which mature on February 22, 2027 (plus a 1-year extension option at the Company’s discretion) and August 22, 2027. The Term Loan Facilities accrue interest at Term SOFR plus 94 basis points based on the Company’s current unsecured credit ratings. The Company maintains swaps on the entire $500 million that effectively fix the interest rate at a blended contractual rate of 3.5%. (3) Reflects pro rata share of mortgage debt in our unconsolidated JVs. (4) In November 2023, a loan provided to one of the Company’s unconsolidated JVs was amended to extend the maturity from May 2024 to May 2025, and contains a 1-year extension option. The loan accrues interest at SOFR plus 325 basis points. The JV has a swap that effectively fixes the interest rate at 4.8% through May 2024. The JV also executed a forward-starting swap that will effectively fix the interest rate at 8.4% from May 2024 through May 2025.

20 Return to TOC Indebtedness As of December 31, 2023, dollars in thousands DEBT STRUCTURE Weighted Average Balance % of Total Rates % Years to Maturity Secured Fixed rate $ 280,233 4 4.45 2.5 Floating rate 14,755 — 8.44 1.0 Combined $ 294,988 4 4.65 2.4 Unsecured Fixed rate(1) 5,950,000 85 3.67 5.5 Floating rate(2) 720,000 10 5.70 2.1 Combined $ 6,670,000 96 3.89 5.1 Total Fixed rate(1) 6,230,233 89 3.71 5.3 Floating rate(2) 734,755 11 5.76 2.0 Combined $ 6,964,988 100 3.92 5.0 Premiums, (discounts), and debt issuance costs, net (48,783) Enterprise Debt $ 6,916,205 FINANCIAL COVENANTS(3) Bank Line of Credit Requirement Actual Compliance Leverage Ratio No greater than 60% 35% Secured Debt Ratio No greater than 40% 2% Unsecured Leverage Ratio No greater than 60% 39% Fixed Charge Coverage Ratio (12 months) No less than 1.50x 4.8x Tangible Net Worth ($ billions) No less than $7.7B $10.8B CREDIT RATINGS (SENIOR UNSECURED DEBT) Moody's Baa1 (Stable) S&P Global BBB+ (Stable) (1) The Company has Term Loan Facilities in an aggregate principal amount of $500 million. The Company maintains swaps on the entire $500 million that effectively fix the interest rate at a blended contractual rate of 3.5%. (2) Includes short term commercial paper borrowings that are backstopped by the Revolving Facility. (3) Calculated based on the definitions contained in the credit agreement, which may differ from similar terms used within the Debt Ratios section of this document.

21 Return to TOC Investment Summary As of and for the year ended December 31, 2023, dollars and square feet in thousands INVESTMENT SUMMARY MSA Date Capacity (Sq. Ft.) Property Count Property Type Three Months Ended December 31, 2023 Twelve Months Ended December 31, 2023 ACQUISITIONS 60 Loomis land parcel Boston, MA January — — Lab $ — $ 9,456 Wylie Medical Plaza(1) Dallas, TX April 20 1 Outpatient Medical — 4,000 OTHER INVESTMENTS Development fundings 47,465 271,744 Redevelopment fundings 33,195 139,387 Total $ 80,660 $ 424,587 DISPOSITIONS(3) Date Capacity (Sq. Ft.) Property Count Property Type Sales Price Trailing Cash Yield(2) Various Durham January 166 2 Lab $ 113,000 Tampa Medical Tower March 116 1 Outpatient Medical 16,065 Women's Center March 34 1 Outpatient Medical 850 Total 4 $ 129,915 5.4% (1) On April 3, 2023, we acquired HCP Ventures IV, LLC's remaining 80% interest in Wylie Medical Plaza for $4 million (based on a gross valuation of $5 million), bringing our equity ownership to 100%. Property count and capacity were already included in prior quarters. (2) Represents the weighted average yield calculated using Cash (Adjusted) NOI for the twelve month period prior to sale for dispositions. (3) Subsequent to December 31, 2023, Healthpeak entered into a new $236 million joint venture through a sale of a 65% interest in the Callan Ridge lab campus.

22 Return to TOC Developments As of December 31, 2023, dollars and square feet in thousands DEVELOPMENT PROJECTS IN PROCESS Project MSA Property Count CIP(1) Cost to Complete(1) Estimated Total at Completion Total Project Capacity (Sq. Ft.) % of Total Project Leased Initial Occupancy(2) Projected Stabilized Yield(3) Lab Vantage - Phase I(4)(5) San Francisco, CA 1 $ 165,185 $ 71,815 $ 237,000 189 12 2Q24 6.25% - 6.75% The Gateway at Directors Place San Diego, CA 1 118,561 4,439 123,000 163 — 2Q25 8.25% - 8.75% Callan Ridge(6)(7) San Diego, CA 2 112,199 33,801 146,000 185 100 1Q25 8.75% - 9.25% 4 $ 395,945 $ 110,055 $ 506,000 537 39 Outpatient Medical Savannah Savannah, GA 1 $ 10,178 $ 20,822 $ 31,000 70 58 3Q24 5.50% - 6.00% Galen Aurora Denver, CO 1 2,768 37,232 40,000 72 100 2Q25 5.50% - 6.00% McKinney Medical Center Dallas, TX 1 1,415 48,585 50,000 120 62 2Q25 7.25% - 7.75% 3 $ 14,361 $ 106,639 $ 121,000 262 71 Total 7 $ 410,305 $ 216,695 $ 627,000 799 49 (1) Includes lease commissions and tenant improvements incurred to date, and projected lease commissions through Occupancy. (2) Initial Occupancy is generally reflective of revenue recognition commencement, which may not coincide with the start of cash rental payments. Cash rental payments generally occur three to six months following Initial Occupancy. (3) Yields shown in table are rounded to the nearest 0.25% and include cash rents at the time of projected stabilization. (4) Total project capacity and Development costs for Vantage - Phase I are 343,000 square feet and $438 million, respectively, including 154,000 square feet / $201 million placed in service in 4Q23. During the quarter, Vantage - Phase I generated non-stabilized Portfolio NOI and Portfolio Cash (Adjusted) NOI of $1.9 and $0.5 million, respectively. (5) Amounts in the table above exclude 40,000 square feet related to the amenity building and include $84 million of construction cost related to the amenity building. We expect tenants to pay rent on their pro-rata share of the amenity building based on the total campus' capacity. (6) For multiple building projects, Initial Occupancy is reflective of the first tenant's occupancy date. (7) As of January 10, 2024, Healthpeak formed a 65% Breakthrough / 35% Healthpeak joint venture for the two Callan Ridge properties. Cash rental payments for the first building commenced July 2023 and cash rental payments for the second building are scheduled to begin in July 2024. Initial occupancy of 1Q25 is delayed due to tenant-driven delays with tenant improvements within both buildings. In Process Return to TOC

23 Return to TOC Redevelopments and Land Held for Development LAND HELD FOR DEVELOPMENT Project MSA Property Type Gross Site Acreage Currently Entitled Rentable Sq. Ft.(4) Original Investment Incremental Investment(5) Investment to Date Vantage - Remaining Phases San Francisco, CA Lab 12 1,300 $ 129,154 $ 29,813 $ 158,967 West Cambridge Alewife(6) Boston, MA Lab 24 N/A 317,212 29,607 346,819 Vista Sorrento San Diego, CA Lab 10 N/A 43,850 8,228 52,078 Remaining(7) Various Various 33 N/A 115,835 23,926 139,760 79 $ 606,051 $ 91,574 $ 697,624 (1) During the quarter, the Arlington outpatient medical redevelopment and a portion of one Pointe Grand building including 86,000 square feet / $32 million were completed and placed in service. (2) Includes lease commissions and tenant improvements incurred to date, and projected lease commissions through Occupancy. (3) Includes five of seven buildings that are part of our JV in our Pointe Grand campus. The redevelopment of one building was completed during the third quarter and the remaining building is expected to enter redevelopment in the first half of 2024. (4) Excludes square feet of adjacent land development opportunities at our lab and outpatient medical buildings, along with significant developable land at our existing CCRC campuses. (5) Includes capitalized interest, entitlement and pre-construction costs. (6) Excludes 15 acres and $336 million, which are currently included in our operating portfolio and may be densified in the future. (7) Includes 9 acres as part of the Needham Land Parcel JV at our 37.5% share, 9 acres as part of our Towers at Sierra Point land parcel, and 6 acres as part of our Torreyana land parcel. As of December 31, 2023, dollars and square feet in thousands; includes JV projects at share REDEVELOPMENT PROJECTS IN PROCESS Incremental Costs Project(1) MSA Property Type Property Count CIP Cost to Complete(2) Estimated Total Estimated Completion Date Pointe Grand(3) San Francisco, CA Lab 5 $ 28,316 $ 74,684 $ 103,000 3Q24 - 3Q25 Portside at Oyster Point San Francisco, CA Lab 2 12,920 29,080 42,000 2Q24 - 4Q25 Sierra Point Towers San Francisco, CA Lab 1 14,834 11,166 26,000 1Q25 Directors Place San Diego, CA Lab 3 388 25,612 26,000 4Q24 - 3Q25 11 $ 56,458 $ 140,542 $ 197,000 Projected stabilized cash-on-cash return on incremental capital invested typically ranges from 9.0% to 12.0%

24 Return to TOC Capital Expenditures(1) (1) Excludes corporate capitalized costs such as IT systems, furniture, fixtures and equipment at corporate or satellite offices, etc. (2) Includes AFFO capital expenditures on unconsolidated JVs for the quarter of $0.8 million and $3.8 million full year. Excludes noncontrolling interest share of AFFO capital expenditures on consolidated joint ventures for the quarter of $0.8 million and $2.1 million full year, which are included in the Other AFFO adjustments line item of the Adjusted Funds From Operations reconciliation. (3) Development and Redevelopment include related tenant improvements and lease commissions. For the three and twelve months ended December 31, 2023, dollars in thousands, except per unit/square foot FOURTH QUARTER Lab Outpatient Medical CCRC Other Total Portfolio at share Recurring capital expenditures $ 6,678 $ 16,015 $ 12,333 $ 617 $ 35,643 Tenant improvements - 2nd generation 515 5,091 — — 5,606 Lease commissions - 2nd generation 939 4,583 — — 5,522 AFFO capital expenditures(2) $ 8,132 $ 25,689 $ 12,333 $ 617 $ 46,771 Revenue enhancing capital expenditures 6,651 26,165 22,593 1,267 56,677 Casualty related capital expenditures — 91 4,014 393 4,498 Development(3) 39,669 7,796 — — 47,465 Redevelopment(3) 32,554 642 — — 33,195 Capitalized interest 14,232 204 — — 14,436 Total capital expenditures $ 101,238 $ 60,587 $ 38,939 $ 2,278 $ 203,043 Recurring capital expenditures per unit/sq. ft. $0.62 per Sq. Ft. $0.72 per Sq. Ft. $1,737 per Unit $344 per Unit FULL YEAR Portfolio at share Recurring capital expenditures $ 8,899 $ 29,585 $ 22,690 $ 3,136 $ 64,311 Tenant improvements - 2nd generation 1,372 24,626 — — 25,998 Lease commissions - 2nd generation 7,110 14,826 — — 21,936 AFFO capital expenditures(2) $ 17,381 $ 69,037 $ 22,690 $ 3,136 $ 112,245 Revenue enhancing capital expenditures 51,672 76,192 56,805 4,305 188,974 Casualty related capital expenditures — 4,812 24,551 1,470 30,833 Initial Capital Expenditures ("ICE") — 4,391 — — 4,391 Development(3) 257,441 14,303 — — 271,744 Redevelopment(3) 112,924 23,684 2,779 — 139,387 Capitalized interest 57,284 1,157 53 — 58,494 Total capital expenditures $ 496,702 $ 193,575 $ 106,879 $ 8,911 $ 806,067 Recurring capital expenditures per unit/sq. ft. $0.83 per Sq. Ft. $1.34 per Sq. Ft. $3,192 per Unit $1,748 per Unit

25 Return to TOC Portfolio Diversification As of and for the quarter ended December 31, 2023, dollars in thousands PORTFOLIO INCOME BY MSA MSA Property Count(1) Lab Outpatient Medical CCRC Other Total % of Total San Francisco, CA 84 $ 93,349 $ 993 $ — $ — $ 94,342 30 Boston, MA 21 37,114 740 — — 37,853 12 San Diego, CA 37 25,693 728 — — 26,420 9 Dallas, TX 35 — 19,900 — 224 20,123 7 Houston, TX 40 — 9,595 1,374 2,676 13,646 4 Tampa, FL 6 — 450 10,164 — 10,615 3 Philadelphia, PA 6 — 4,782 4,464 — 9,245 3 Denver, CO 20 — 6,176 — 1,325 7,501 2 Nashville, TN 17 — 7,340 — — 7,340 2 Seattle, WA 7 — 6,494 — — 6,494 2 Louisville, KY 11 — 5,327 — — 5,327 2 Remaining 186 1,650 51,908 13,478 1,698 68,735 22 Portfolio Cash (Adjusted) NOI 470 $ 157,805 $ 114,432 $ 29,481 $ 5,924 $ 307,641 98 Interest income — — — — 4,979 4,979 2 Portfolio Income 470 $ 157,805 $ 114,432 $ 29,481 $ 10,903 $ 312,621 100 (1) Excludes seven properties in Development.

26 Return to TOC Lab As of and for the quarter ended December 31, 2023, dollars and square feet in thousands INVESTMENTS(1) MSA Property Count Portfolio Investment Portfolio Cash (Adjusted) NOI Total Square Feet Occupancy % Annualized Base Rent % San Francisco, CA 83 $ 4,557,969 $ 93,349 5,610 96.4 59.9 Boston, MA 20 2,517,665 37,114 2,738 97.0 23.8 San Diego, CA 35 1,221,748 25,693 2,371 97.8 15.2 Remaining 4 61,703 1,650 240 100.0 1.1 142 $ 8,359,085 $ 157,805 10,959 96.9 100.0 SAME-STORE 4Q22 1Q23 2Q23 3Q23 4Q23 Year-Over-Year Growth Property Count 120 120 120 120 120 — Portfolio Investment $ 6,842,997 $ 6,852,726 $ 6,862,730 $ 6,881,108 $ 6,892,743 Square Feet 9,427 9,427 9,427 9,427 9,427 Occupancy % 98.7 98.2 97.4 97.2 96.6 -210 bps Portfolio Real Estate Revenues $ 177,940 $ 177,266 $ 181,000 $ 177,954 $ 172,594 (3.0%) Portfolio Operating Expenses (47,726) (49,598) (46,655) (50,272) (47,376) (0.7%) Portfolio NOI $ 130,214 $ 127,668 $ 134,346 $ 127,682 $ 125,218 (3.8%) Portfolio Cash Real Estate Revenues $ 166,447 $ 171,570 $ 168,795 $ 172,405 $ 169,265 1.7% Portfolio Cash Operating Expenses (47,717) (49,589) (46,648) (50,270) (47,374) (0.7%) Portfolio Cash (Adjusted) NOI $ 118,730 $ 121,981 $ 122,146 $ 122,136 $ 121,891 2.7% Portfolio Cash (Adjusted) NOI Margin % 71.3 71.1 72.4 70.8 72.0 70 bps Pro Forma Portfolio Cash (Adjusted) NOI Margin %(2) 95.7 96.8 96.3 95.7 95.6 -10 bps (1) Excludes four properties that are in Development, two of which are held for sale as of December 31, 2023. (2) Approximately 85% of operating expenses reported above are recoverable from tenants and are reported gross in both Portfolio Cash Real Estate Revenues and Portfolio Cash Operating Expenses. Pro Forma Portfolio Cash (Adjusted) NOI Margin % has been adjusted to remove recoverable expenses from both revenue and expenses.

27 Return to TOC Lab As of December 31, 2023 TENANT CONCENTRATION(1) Weighted Average Remaining Lease Term in Years Leased Square Feet Annualized Base Rent(3) Parent Name Market Cap (in millions) Cash and Liquid Investments (in millions)(2) Amount (in thousands) % of Total Lab Amount (in thousands) % of Total Lab Amgen $ 154,142 $ 34,741 1.4 564 5 $ 47,058 8 Astellas Pharma 21,444 2,435 6.5 290 3 21,254 3 Bristol-Myers Squibb 104,403 7,685 5.7 242 2 16,588 3 Arcus Biosciences 1,430 799 8.0 260 2 16,094 3 Johnson & Johnson 377,317 23,511 7.3 246 2 15,836 3 Myriad Genetics 1,697 86 5.5 352 3 15,057 2 Novo Nordisk 461,550 6,751 11.0 199 2 14,349 2 Pfizer 162,560 44,182 5.9 180 2 13,670 2 Nkarta 324 276 9.4 130 1 12,683 2 Alphabet(4) 1,755,459 119,935 8.5 168 2 11,985 2 AstraZeneca 209,268 5,115 3.0 180 2 11,744 2 General Atomics Private Private 5.7 702 7 11,310 2 Denali Therapeutics 2,966 1,109 5.3 148 1 11,172 2 Allogene Therapeutics 540 466 8.2 131 1 9,650 2 Globus Medical 7,343 469 11.2 252 2 9,234 1 Pacira 1,567 235 6.5 174 2 8,756 1 Fog Pharmaceuticals Private Private 7.2 122 1 8,716 1 Seres Therapeutics 181 170 9.2 83 1 8,454 1 ElevateBio Private Private 6.2 142 1 7,873 1 Takeda 45,121 2,129 4.8 184 2 7,605 1 Remaining 5.6 5,846 55 342,324 55 6.0 10,595 100 $ 621,412 100 ANNUALIZED BASE RENT(2) (1) Commencing January 2024, Revolution Medicines will lease an additional 40,000 square feet with Annualized Base Rent of $3.0 million, bringing their Annualized Base Rent to $10.0 million. (2) Cash and Liquid Investments balance of public tenants based on the prior quarter's financials. (3) Annualized Base Rent does not include expense recoveries, additional rent in excess of floors, and non-cash revenue adjustments. (4) Represents lab space leased by Calico, a life science subsidiary of Alphabet. Small Cap Biotech 16% Mid Cap Biotech 19% Private Biotech 19% Medical Device 7% R&D / University 6% Office 4% Large Cap Biopharma 29% $621M PEAK publicly-traded biotech classification criteria: Large Cap: market cap > $10B Mid Cap: market cap between $10B and $500M Small Cap: market cap < $500M

28 Return to TOC Lab As of December 31, 2023, dollars and square feet in thousands LEASE EXPIRATION DATA Total San Francisco Boston San Diego Remaining(1) Year Leased Square Feet % Annualized Base Rent(2) % Leased Square Feet Annualized Base Rent(2) Leased Square Feet Annualized Base Rent(2) Leased Square Feet Annualized Base Rent(2) Leased Square Feet Annualized Base Rent(2) 2024(2)(3) 597 6 $ 39,248 6 559 $ 37,485 — $ — 38 $ 1,763 — $ — 2025 1,064 10 50,557 8 447 26,424 105 5,161 512 18,972 — — 2026 618 6 30,694 5 309 18,329 47 3,209 262 9,155 — — 2027 1,466 14 68,274 11 579 38,535 509 16,066 224 10,050 154 3,623 2028 690 7 37,206 6 158 10,229 516 25,744 16 1,234 — — 2029 806 8 50,104 8 567 36,808 238 13,296 — — — — 2030 1,334 13 94,051 15 815 61,423 345 23,872 174 8,756 — — 2031 1,422 13 86,521 14 740 51,995 328 24,640 354 9,886 — — 2032 889 8 56,909 9 506 34,606 244 12,591 140 9,713 — — 2033 643 6 41,713 7 380 27,009 83 8,454 180 6,250 — — Thereafter 1,065 10 66,136 11 348 29,200 214 14,981 418 18,798 85 3,157 10,595 100 $ 621,412 100 5,409 $ 372,041 2,628 $ 148,014 2,318 $ 94,578 240 $ 6,780 (1) In December 2023, we entered into an 85,000 square foot lease of one building, which expires in 2034. In connection with the lease, we granted a purchase option on that building and the three remaining buildings in Utah. If the purchase option is not exercised, a new lease of the entire 154,000 square feet at those three buildings is automatically commenced to lease those buildings through 2036. Healthpeak is the ground lessee across all four buildings through 2062. (2) Annualized Base Rent does not include expense recoveries, additional rent in excess of floors, and non-cash revenue adjustments. Month-to-month and holdover leases are included in 2024 expirations. (3) Includes 250,000 square feet related to the Oyster Point and Pointe Grand campuses, which are planned to undergo Redevelopment and 76,000 square feet of contingent lease expirations tied to the timing of the tenant's relocation to our Vantage Phase I development. (4) Reflects the earliest point at which the purchase option can be exercised. 28 Return to TOC MATERIAL NEAR-TERM PURCHASE OPTIONS(1) Maturity Year Option Date(4) Name Property Count MSA Property Type Cash (Adjusted) NOI Annualized Option Price 2027, 2034 01/2026 Myriad Campus 4 Salt Lake City, UT Lab $ 6,863 $ 68,484

29 Return to TOC (1) Change in cash rents is based on renewals executed during the quarter and represents expiring rate compared to renewal rate. (2) Change in cash rents for the quarter is primarily related to a renewal on 10-year old space with no additional tenant improvement allowance from Healthpeak. (3) Average cost per lease year. (4) New lease commencements excludes tenant improvements and leasing costs on 5,000 square feet of retail amenity space. (5) Current quarter terminations include 40,000 square feet with Adverum, which has been re-leased to Revolution Medicines commencing January 2024, and a proactive early termination of 12,000 square feet with Alumis as part of their relocation to 55,000 square feet in our Pointe Grand redevelopment, which commenced last quarter. (6) The change in cash rents excludes a 103,000 square feet expansion based lease renewal that will affect rents beginning in December 2033. FULL YEAR LEASING ACTIVITY Leased Square Feet Annualized Base Rent Per Sq. Ft. % Change in Cash Rents(1)(6) Tenant Improvements per Sq. Ft.(3)(4) Leasing Costs per Sq. Ft.(3)(4) Average Lease Term (Months) Trailing Twelve Month Retention Rate Leased Square Feet as of December 31, 2022 10,658 $ 55.10 Developments placed in service 318 85.35 Redevelopments placed in service 286 84.11 Properties placed into (re)development (413) 62.07 Expirations (400) 66.02 Renewals, amendments and extensions 197 80.34 22.8 $ 3.73 $ 3.23 51 49.4% New lease commencements 220 71.62 3.77 2.30 81 Terminations (271) 68.39 Leased Square Feet as of December 31, 2023 10,595 $ 58.65 Lab As of December 31, 2023, square feet in thousands, presented at 100% 4Q23 LEASING ACTIVITY Leased Square Feet Annualized Base Rent Per Sq. Ft. % Change in Cash Rents(1)(2) Tenant Improvements per Sq. Ft.(3)(4) Leasing Costs per Sq. Ft.(3)(4) Average Lease Term (Months) Trailing Twelve Month Retention Rate Leased Square Feet as of September 30, 2023 10,587 $ 57.60 Developments placed in service 154 85.80 Redevelopments placed in service 86 89.97 Properties placed in (re)development (168) 47.68 Expirations (66) 62.05 Renewals, amendments and extensions 35 57.35 (7.6) $ — $ 3.52 60 49.4% New lease commencements 19 80.85 7.96 2.49 77 Terminations(5) (52) 67.26 Leased Square Feet as of December 31, 2023 10,595 $ 58.65

30 Return to TOC As of and for the quarter ended December 31, 2023, dollars and square feet in thousands LEASE TYPE Annualized Base Rent San Francisco Boston San Diego Remaining Total % of Total Triple-Net(1) $ 350,106 $ 130,693 $ 91,943 $ 6,780 $ 579,521 93.3 Base Year(2) 21,051 17,181 2,459 — 40,690 6.5 Gross(3) 884 141 176 — 1,201 0.2 Total $ 372,041 $ 148,014 $ 94,578 $ 6,780 $ 621,412 100.0 OWNERSHIP TYPE Total Square Feet San Francisco Boston San Diego Remaining Total % of Total Weighted Average Remaining Lease Term Ground Lease — 20 — 240 260 2.4 39 (4) Fee Simple 5,610 2,719 2,371 — 10,699 97.6 Total 5,610 2,738 2,371 240 10,959 100.0 CONTRACTUAL LEASE ESCALATORS Annualized Base Rent % of Annualized Base Rent Escalator % Fixed $ 614,633 98.9 3.2 CPI 6,780 1.1 4.1 (5) Total $ 621,412 100.0 3.2 Lab (1) Includes net lease structures, where the tenant is responsible for 100% of their pro rata share of operating expenses. (2) A lease structure in which the rental rate includes the tenant's pro rata share of operating expenses. The pro rata share of expenses in the first year of the lease is considered the “base year” and any increase in expenses beyond the “base year” is recoverable from the tenant. (3) A lease structure in which the tenant’s pro rata share of operating expenses is presumed to be included in the rental rate, with no variability for fluctuations in operating expenses. (4) Includes renewal options. (5) Includes both pure CPI leases and leases with a CPI floor averaging 2%. The CPI escalator presented above is based on the average year-to-date year-over-year change in CPI, which will vary over time and is based on specific lease terms.

31 Return to TOC Outpatient Medical As of and for the quarter ended December 31, 2023, dollars and square feet in thousands PORTFOLIO BY MARKET(1)(2) Total Square Feet On-campus Off-campus(3) Total MSA Property Count Portfolio Investment Portfolio Cash (Adjusted) NOI Occupancy % Multi-tenant Single-tenant Multi-tenant Single-tenant Multi-tenant Single-tenant % of Total Dallas, TX 33 $ 927,374 $ 19,900 93.2 2,067 1,472 209 54 2,276 1,526 16 Houston, TX 32 537,765 9,595 85.1 1,660 1,421 237 — 1,897 1,421 14 Nashville, TN 17 320,241 7,340 88.6 1,512 10 119 — 1,631 10 7 Seattle, WA 7 309,608 6,494 90.7 674 39 — — 674 39 3 Denver, CO 16 391,613 6,176 86.4 1,079 — 35 — 1,114 — 5 Louisville, KY 11 253,222 5,327 95.9 668 17 448 — 1,116 17 5 Philadelphia, PA 4 444,296 4,782 75.8 694 — 436 144 1,129 144 5 Phoenix, AZ 13 245,940 4,297 92.6 519 70 281 — 800 70 4 Miami, FL 11 153,570 3,101 89.3 543 — — 30 543 30 2 Kansas City, MO 6 130,640 2,801 92.1 349 89 — 8 349 97 2 Salt Lake City, UT 10 130,713 2,749 91.7 434 — 136 7 569 7 2 New York, NY 3 172,782 2,311 100.0 — — — 537 — 537 2 Greenville, SC 14 157,970 2,261 100.0 135 657 — 51 135 708 4 Minneapolis, MN 5 128,599 1,995 92.9 228 — — 81 228 81 1 Las Vegas, NV 5 109,863 1,779 95.5 342 — — — 342 — 1 Ogden, UT 8 92,008 1,638 90.6 338 — — 60 338 60 2 Washington, DC 4 103,496 1,557 90.6 55 29 186 — 242 29 1 Indianapolis, IN 4 117,216 1,514 100.0 180 46 39 — 219 46 1 Fresno, CA 1 59,689 1,370 100.0 — 56 — — — 56 — Los Angeles, CA 4 96,560 1,319 83.3 161 — 66 — 227 — 1 Remaining 86 1,518,018 26,127 92.8 2,338 1,477 636 716 2,974 2,193 22 294 $ 6,401,183 $ 114,432 90.7 13,977 5,383 2,828 1,687 16,805 7,070 100 (1) Properties that are held for sale are included in property count, Investment, Cash (Adjusted) NOI, and square feet but are excluded from Occupancy. One property is held for sale as of December 31, 2023. (2) Excludes three properties that are in Development. (3) Includes Outpatient Medical buildings that are off-campus, adjacent (within 0.25 miles of a hospital campus) and anchored (the asset is off-campus, but is 1/3 or more leased to a health system or large physician group).

32 Return to TOC Outpatient Medical Same-Store As of and for the quarter ended December 31, 2023, dollars and square feet in thousands SAME-STORE 4Q22 1Q23 2Q23 3Q23 4Q23 Year-Over-Year Growth Property Count 280 280 280 280 280 — Portfolio Investment $ 5,807,062 $ 5,844,114 $ 5,874,574 $ 5,911,347 $ 5,959,055 Square Feet 22,545 22,560 22,561 22,567 22,568 Occupancy % 91.4 91.1 91.2 91.2 91.6 20 bps Portfolio Real Estate Revenues $ 162,347 $ 163,836 $ 164,515 $ 168,770 $ 166,551 2.6% Portfolio Operating Expenses (54,947) (55,854) (56,295) (58,419) (56,685) 3.2% Portfolio NOI $ 107,400 $ 107,982 $ 108,220 $ 110,351 $ 109,866 2.3% Portfolio Cash Real Estate Revenues $ 157,000 $ 159,569 $ 160,160 $ 164,819 $ 163,154 3.9% Portfolio Cash Operating Expenses (54,291) (55,240) (55,651) (57,777) (56,047) 3.2% Portfolio Cash (Adjusted) NOI $ 102,710 $ 104,329 $ 104,510 $ 107,041 $ 107,107 4.3% Portfolio Cash (Adjusted) NOI Margin % 65.4 65.4 65.3 64.9 65.6 20 bps Pro Forma Portfolio Cash (Adjusted) NOI Margin %(1) 80.0 80.1 79.9 80.7 80.7 70 bps (1) Approximately 50% of operating expenses reported above are recoverable from tenants and are reported gross in both Portfolio Cash Real Estate Revenues and Portfolio Cash Operating Expenses. Pro Forma Portfolio Cash (Adjusted) NOI Margin % has been adjusted to remove recoverable expenses from both revenue and expenses. 32 Return to TOC Bolingbrook Outpatient Medical building Bolingbrook, IL

33 Return to TOC Outpatient Medical As of December 31, 2023, square feet in thousands SQUARE FEET BY HEALTH SYSTEM Total Square Feet Health System MSA Property Count Credit Rating On-Campus Adjacent(1) Anchored(1) Unaffiliated Off-Campus Total % of Total Outpatient Medical % Directly Leased by Health System Weighted Average Remaining Lease Term HCA Dallas TX, Nashville TN, Denver CO, Various 115 Baa3 9,550 183 318 — 10,052 42.1 24.8 7.4 Memorial Hermann Houston TX 16 Aa3 1,709 — 83 — 1,791 7.5 4.1 6.4 Norton Healthcare Louisville KY 10 — 685 329 — — 1,014 4.2 2.8 4.9 Community Health Systems Various 16 Caa2 976 — — — 976 4.1 4.7 6.2 Prisma Health System Greenville SC 14 A3 792 — 51 — 843 3.5 2.1 4.6 Thomas Jefferson Univ Hospital Philadelphia PA 1 A3 694 — — — 694 2.9 1.8 2.8 Providence Health & Services Seattle WA 6 A2 610 — — — 610 2.6 1.1 2.0 Atlantic Health New York NY 3 Aa3 — — 537 — 537 2.2 2.7 8.8 HonorHealth Phoenix AZ 9 A2 421 107 — — 528 2.2 0.7 4.3 CommonSpirit Various 8 Baa1 442 32 — — 474 2.0 1.7 2.6 UPENN Health System Philadelphia PA 1 Aa3 — 436 — — 436 1.8 1.0 6.1 Tenet Healthcare San Antonio TX, Phoenix AZ 4 B1 295 — 90 — 384 1.6 0.6 4.4 Encompass Health Various 4 Ba3 310 — — — 310 1.3 1.5 8.3 Orlando Health Tampa FL, Orlando FL 2 A2 289 — — — 289 1.2 0.3 5.0 Steward Health Houston TX, Phoenix AZ 2 — 268 — — — 268 1.1 0.2 5.1 Baylor Scott & White Health Dallas TX 4 Aa3 138 — 69 — 207 0.9 0.5 0.8 Bon Secours Mercy Health Richmond VA, Cincinnati OH 4 A2 60 — 134 — 194 0.8 0.5 3.7 Franciscan Alliance Indianapolis IN 2 Aa3 180 — — — 180 0.8 0.8 2.8 Ascension Health Pensacola FL, Indianapolis IN 4 Aa2 85 — 94 — 179 0.8 0.7 4.6 Medical Univ of South Carolina Florence SC 3 Aa3 172 — — — 172 0.7 0.9 8.0 Remaining - credit rated 36 1,008 292 717 — 2,017 8.4 Remaining - not credit rated 30 675 91 372 582 1,719 7.2 Total 294 19,360 1,470 2,464 582 23,875 100.0 53.6 5.4 % of Total 81.1 6.2 10.3 2.4 Total Healthcare Affiliated 97.6% (1) Denotes whether the Outpatient Medical building is adjacent (within 0.25 miles) to a hospital campus or anchored (the asset is off-campus, but is 1/3 or more leased to a health system or large physician group).

34 Return to TOC Outpatient Medical As of and for the quarter ended December 31, 2023, dollars and square feet in thousands LEASE EXPIRATION DATA(1) Total On-Campus Off-Campus Year Leased Square Feet % Annualized Base Rent(2) % Leased Square Feet Annualized Base Rent(2) Leased Square Feet Annualized Base Rent(2) 2024(2) 2,877 13.3 $ 85,517 15.6 2,272 $ 68,838 606 $ 16,679 2025 2,898 13.4 70,052 12.8 2,603 61,807 294 8,245 2026 2,055 9.5 57,412 10.5 1,745 49,155 311 8,258 2027 1,884 8.7 51,522 9.4 1,515 41,523 369 9,999 2028 2,554 11.8 57,173 10.4 2,294 50,515 260 6,658 2029 1,438 6.7 38,471 7.0 1,142 31,034 295 7,437 2030 1,310 6.1 36,069 6.6 934 26,530 376 9,539 2031 1,654 7.7 41,046 7.5 1,267 29,956 387 11,090 2032 1,376 6.4 28,376 5.2 685 14,687 691 13,688 2033 917 4.2 27,375 5.0 613 17,775 304 9,600 Thereafter 2,637 12.2 55,885 10.2 2,415 49,496 221 6,389 21,600 100 $ 548,900 100 17,486 $ 441,317 4,114 $ 107,583 (1) Excludes one asset held for sale at December 31, 2023. (2) Annualized Base Rent does not include expense recoveries, additional rent in excess of floors, and non-cash revenue adjustments. Month-to-month and holdover leases are included in 2024 expirations. (3) Reflects the earliest point at which the purchase option can be exercised. MATERIAL NEAR-TERM PURCHASE OPTIONS Maturity Year Option Date(3) Name Property Count MSA Property Type Cash (Adjusted) NOI Annualized Option Price 2026 10/2025 Innovation 1 San Diego, CA Outpatient medical $ 1,488 $ 31,700

35 Return to TOC Outpatient Medical (1) For comparative purposes, reflects adjustments for leases that converted to a different lease type upon renewal, amendment or extension of the original lease. Change in cash rents is based on renewals executed during the period and represents expiring rate compared to renewal rate. (2) Average cost per lease year. (3) Excludes a 1.3 million square foot lease renewal for which rents are percentage based. 35 Return to TOC FULL YEAR LEASING ACTIVITY Leased Square Feet Annualized Base Rent Per Sq. Ft. % Change in Cash Rents(1)(3) Tenant Improvements per Sq. Ft.(2) Leasing Costs per Sq. Ft.(2) Average Lease Term (Months) Trailing Twelve Month Retention Rate Leased Square Feet as of December 31, 2022 21,698 $ 26.04 Assets held for sale (35) 30.24 Dispositions (126) 28.67 Expirations (4,303) 28.20 Renewals, amendments and extensions 3,702 28.59 3.8 2.53 0.95 67 79.9% New lease commencements 726 28.42 5.72 1.65 83 Terminations (62) 26.82 Leased Square Feet as of December 31, 2023 21,600 $ 26.90 As of December 31, 2023, square feet in thousands, presented at 100% 4Q23 LEASING ACTIVITY Leased Square Feet Annualized Base Rent Per Sq. Ft. % Change in Cash Rents(1) Tenant Improvements per Sq. Ft.(2) Leasing Costs per Sq. Ft.(2) Average Lease Term (Months) Trailing Twelve Month Retention Rate Leased Square Feet as of September 30, 2023 21,482 $ 26.77 Expirations (641) 29.41 Renewals, amendments and extensions 554 29.34 3.6 $ 2.11 $ 0.89 73 79.9% New lease commencements 212 28.61 5.63 1.64 87 Terminations (7) 26.75 Leased Square Feet as of December 31, 2023 21,600 $ 26.90

36 Return to TOC Outpatient Medical PROVIDER SPECIALTY Healthpeak National Benchmark(4) Types of Specialties Orthopedics 10% 4% Obstetrics / Gynecology 8% 5% General / Specialty Surgery 8% 4% Ambulatory Surgery Center 7% N/A Cardiovascular 6% 4% Oncology 6% 3% Imaging / Radiology 4% 3% Neurology 4% 2% Gastroenterology 3% 2% Other 27% 40% Total Specialties 83% 67% Primary Care 17% 33% Total 100% 100% As of and for the quarter ended December 31, 2023, square feet in thousands LEASE TYPE Leased Square Feet On-Campus Adjacent Anchored Unaffiliated Off-Campus Total % of Total Triple-Net(1) 11,181 684 2,108 86 14,058 65.1 Base Year(2) 5,290 536 157 421 6,403 29.6 Gross(3) 1,016 9 100 14 1,139 5.3 Total 17,486 1,229 2,365 521 21,600 100.0 OWNERSHIP TYPE Total Square Feet On-Campus Adjacent Anchored Unaffiliated Off-Campus Total % of Total Weighted Average Remaining Lease Term Ground Lease 8,862 32 442 72 9,407 39.4 78 (5) Fee Simple 10,498 1,438 2,022 510 14,467 60.6 Total 19,360 1,470 2,464 582 23,875 100.0 CONTRACTUAL LEASE ESCALATORS Leased Square Feet % of Square Feet Escalator % Fixed 20,461 94.7 2.8 CPI 1,139 5.3 3.9 (6) Total 21,600 100.0 2.9 (1) Includes both triple-net lease structures, in which the tenant is directly responsible for all operating expenses of the property, and net lease structures, where the tenant is responsible for 100% of their pro rata share of operating expenses. (2) A lease structure in which the rental rate includes the tenant's pro rata share of operating expenses. The pro rata share of expenses in the first year of the lease is considered the “base year” and any increase in expenses beyond the “base year” is recoverable from the tenant. (3) A lease structure in which the tenant’s pro rata share of operating expenses is presumed to be included in the rental rate, with no variability for fluctuations in operating expenses. (4) U.S. physicians breakdown from AAMC, 2022 Physician Specialty Data Book. (5) Includes renewal options. (6) Includes both pure CPI leases, leases with a CPI floor averaging 2%, and certain leases containing CPI ceilings. The CPI escalator presented above is based on the average year-to-date year-over-year change in CPI, which will vary over time and is based on specific lease terms.

37 Return to TOC CCRC As of and for the quarter ended December 31, 2023, dollars in thousands, except REVPOR INVESTMENTS Property Count Net Portfolio Investment(1) Portfolio Real Estate Revenues, excluding NREFS NREF Amortization Portfolio Cash Opex Portfolio Adjusted NOI Units Occupancy % REVPOR CCRC NREF Cash Collections Operator Life Care Services 13 $ 1,305,926 $ 95,707 $ 19,080 $ (89,840) $ 24,947 6,045 85.9 $ 7,365 $ 25,295 Sunrise Senior Living 2 267,610 18,528 3,025 (16,582) 4,971 1,052 79.4 8,598 5,723 Remaining — — — — (438) (438) N/A N/A N/A — Total 15 $ 1,573,536 $ 114,235 $ 22,105 $ (106,860) $ 29,481 7,097 84.9 $ 7,536 $ 31,019 (1) Net Portfolio Investment is gross Portfolio Investment as defined in the Glossary less Non-Refundable Entrance Fees ("NREFs") and refundable Entrance Fees, which appear on our Consolidated Balance Sheet in the Deferred revenue line and Accounts payable, accrued liabilities and other liabilities line, respectively. As of December 31, 2023, the balances of NREFs and refundable Entrance Fees were $562.0 million and $251.9 million, respectively. TOTAL CCRC PORTFOLIO 4Q22 1Q23 2Q23 3Q23 4Q23 Property count 15 15 15 15 15 Gross Portfolio Investment $ 2,285,837 $ 2,305,971 $ 2,332,631 $ 2,353,693 $ 2,387,437 Net Portfolio Investment(1) 1,498,292 1,514,431 1,537,186 1,545,592 1,573,536 Units 7,183 7,107 7,108 7,112 7,097 IL, AL, and Memory Care Occupancy % 82.2 83.0 83.3 83.8 84.6 Skilled Nursing Occupancy % 83.4 83.7 84.1 84.6 86.7 Total Occupancy % 82.4 83.1 83.4 83.9 84.9 REVPOR CCRC $ 7,090 $ 7,179 $ 7,317 $ 7,477 $ 7,536 REVPOR CCRC excluding NREF Amortization 5,892 6,056 6,175 6,315 6,314 NREF Cash Collections $ 27,858 $ 28,791 $ 30,726 $ 36,117 $ 31,019 NREF Amortization 21,260 19,887 20,382 20,823 22,105 Portfolio Real Estate Revenues $ 125,920 $ 127,221 $ 130,231 $ 133,808 $ 136,340 Portfolio Operating Expenses before management fee (96,667) (97,206) (97,481) (100,454) (100,859) Management fee (3,444) (3,918) (4,174) (4,319) (5,061) Portfolio NOI $ 25,809 $ 26,097 $ 28,575 $ 29,036 $ 30,420 Portfolio Cash Real Estate Revenues $ 125,920 $ 127,221 $ 130,231 $ 133,808 $ 136,340 Portfolio Cash Operating Expenses before management fee (94,366) (97,156) (98,209) (100,454) (101,799) Management fee (3,444) (3,918) (4,174) (4,319) (5,061) Portfolio Adjusted NOI $ 28,109 $ 26,147 $ 27,848 $ 29,036 $ 29,481 Portfolio Adjusted NOI Margin % 22.3 20.6 21.4 21.7 21.6

38 Return to TOC CCRC As of and for the quarter ended December 31, 2023, dollars in thousands, except REVPOR SAME-STORE 4Q22 1Q23 2Q23 3Q23 4Q23 Year-Over-Year Growth Property count 15 15 15 15 15 — Net Portfolio Investment $ 1,498,292 $ 1,514,431 $ 1,533,060 $ 1,541,511 $ 1,570,388 Units 7,183 7,107 7,100 7,100 7,085 IL, AL, and Memory Care Occupancy % 82.2 83.0 83.3 83.8 84.6 240 bps Skilled Nursing Occupancy % 83.4 83.7 84.1 84.6 86.7 330 bps Total Occupancy % 82.4 83.1 83.4 83.9 84.9 250 bps REVPOR CCRC $ 7,090 $ 7,171 $ 7,314 $ 7,477 $ 7,535 6.3% REVPOR CCRC excluding NREF Amortization 5,892 6,049 6,173 6,315 6,315 7.2% Portfolio Real Estate Revenues $ 125,873 $ 127,084 $ 129,999 $ 133,603 $ 136,083 8.1% Portfolio Operating Expenses (99,769) (100,678) (101,210) (104,236) (105,416) 5.7% Portfolio NOI $ 26,104 $ 26,407 $ 28,789 $ 29,367 $ 30,667 17.5% Portfolio Cash Real Estate Revenues $ 125,873 $ 127,084 $ 129,999 $ 133,603 $ 136,083 8.1% Portfolio Cash Operating Expenses (97,469) (100,628) (101,938) (104,236) (106,356) 9.1% Portfolio Adjusted NOI $ 28,404 $ 26,457 $ 28,062 $ 29,367 $ 29,727 4.7% Portfolio Adjusted NOI Margin % 22.6 20.8 21.6 22.0 21.8 -80 bps Same-Store Cypress Village Jacksonville, FL 38 Return to TOC

39 Return to TOC (1) During the quarter, a property re-entered Occupancy and REVPOR following redevelopment. Excluding that property from 4Q23, Occupancy and REVPOR would have been 79.7% and $4,666, respectively. (2) Excludes $2.8 million of estimated reserves for loan losses under the current expected credit losses accounting standard in accordance with ASC 326, and resident loans on CCRC entrance fee contracts of $42.7 million. (3) Seller financing loans receivable have floating interest rates subject to certain floors. (4) In January 2024, a seller financing loan was extended, bringing the weighted average maturity in years to 0.4. Other DEBT INVESTMENTS Weighted Average as of December 31, 2023 Investment(2) Interest Income Yield(3) Maturity in Years(4) Seller financing loans $ 178,547 $ 4,979 11.7% 0.1 Total Debt Investments $ 178,547 $ 4,979 11.7% 0.1 As of and for the quarter ended December 31, 2023, dollars in thousands, except REVPOR SOVEREIGN WEALTH FUND SENIOR HOUSING JV AT SHARE 4Q22 1Q23 2Q23 3Q23 4Q23 Year-Over-Year Growth Property count 19 19 19 19 19 — Investment $ 464,068 $ 465,707 $ 467,765 $ 470,299 $ 471,413 Units 3,354 3,354 3,354 3,354 3,354 Occupancy % 78.3 78.0 78.3 79.3 78.6 (1) 30 bps REVPOR $ 4,250 $ 4,633 $ 4,584 $ 4,573 $ 5,005 (1) 17.8% Portfolio Real Estate Revenues $ 18,969 $ 20,574 $ 20,262 $ 20,572 $ 21,247 12.0% Portfolio Operating Expenses before management fee (13,927) (14,036) (13,652) (14,458) (14,762) 6.0% Management fee (901) (970) (966) (981) (987) 9.5% Portfolio NOI $ 4,140 $ 5,569 $ 5,644 $ 5,133 $ 5,498 32.8% Portfolio Cash Real Estate Revenues $ 19,024 $ 20,566 $ 20,278 $ 20,567 $ 21,167 11.3% Portfolio Cash Operating Expenses before management fee (13,935) (14,049) (13,679) (14,480) (14,256) 2.3% Management fee (901) (970) (966) (981) (987) 9.5% Portfolio Cash (Adjusted) NOI $ 4,188 $ 5,547 $ 5,634 $ 5,106 $ 5,924 41.4% Portfolio Cash (Adjusted) NOI Margin % 22.0 27.0 27.8 24.8 28.0 600 bps

40 Return to TOC 2024 Outlook Information(1) Projected full year 2024, dollars in millions, except per share amounts FY 2024 Outlook February 8, 2024 2024 Outlook Ranges and Supplemental Information(1) Diluted earnings per common share $0.07 - $0.13 Diluted Nareit FFO per common share $1.54 - $1.60 Diluted FFO as adjusted per common share $1.73 - $1.79 Diluted AFFO per common share $1.50 - $1.56 Total Portfolio Year-Over-Year Same-Store Cash NOI Growth(2)(3) 2.25% - 3.75% Other Key Assumptions General and administrative (excl. restructuring and severance-related charges) $95 - $105 Interest expense (net of capitalized interest)(4) $300 - $330 Sources and Uses(5) Transaction term loan $750 Sales / joint venture proceeds(6) $130 Seller financing repayments $0 - $100 Retained earnings $220 - $270 Total Sources $1,110 - $1,250 Development, redevelopment and revenue enhancing capex(7) $700 - $800 Debt repayments $210 Other / transaction costs $190 - $240 Total Uses $1,100 - $1,250 (1) These 2024 outlook ranges provide a framework for metrics of Healthpeak following the merger with Physicians Realty Trust. Assumes closing date of March 1, 2024 and weighted average share count of approximately 690 million for 2024. We expect to finalize 2024 guidance in late April once 1Q books are closed and GAAP merger adjustments are finalized. (2) Components of same-store outlook: Outpatient Medical 2.50% - 3.50%; Lab 1.50% - 3.00%; CCRC 4.00% - 8.00%. (3) Same-store outlook for Total Portfolio and Outpatient Medical includes properties acquired through the merger with Physicians Realty Trust as though the properties that meet our same-store definition had been owned for all of 2023 and 2024. (4) Initial outlook assumes approximately ($20) million debt mark-to-market assuming approximately 5% 5-year treasury rate. (5) High level cash sources and uses; excludes equity issued in merger and $1.9 billion of debt assumed in merger. (6) Includes the joint venture entered through the sale of a 65% interest in the Callan Ridge lab campus in January 2024. (7) Includes our share of unconsolidated JVs.

Return to TOC 41 Glossary Adjusted Fixed Charge Coverage* Adjusted EBITDAre divided by Fixed Charges. Adjusted Fixed Charge Coverage is a supplemental measure of liquidity and our ability to meet interest payments on our outstanding debt and pay dividends to our preferred stockholders, if applicable. Our various debt agreements contain covenants that require us to maintain ratios similar to Adjusted Fixed Charge Coverage and credit rating agencies utilize similar ratios in evaluating and determining the credit rating on certain of our debt instruments. Adjusted Fixed Charge Coverage is subject to the same limitations and qualifications as Adjusted EBITDAre and Fixed Charges. Adjusted Funds From Operations (“AFFO”)* See the “Adjusted Funds From Operations” definition included in the accompanying Discussion and Reconciliations of Non-GAAP Financial Measures for information regarding AFFO. Annualized Base Rent The most recent month’s (or subsequent month’s if acquired in the most recent month) base rent including additional rent floors, cash income from DFLs, and/or interest income annualized for 12 months. Annualized Base Rent includes the Company's share of unconsolidated JVs calculated on the same basis and excludes properties in our CCRC segment, properties sold or held for sale during the quarter, and noncontrolling interests' share of consolidated JVs calculated on the same basis. Further, Annualized Base Rent does not include expense recoveries, additional rents in excess of floors, and non-cash revenue adjustments (i.e., straight-line rents, amortization of market lease intangibles, DFL non-cash interest and deferred revenues). We use Annualized Base Rent for the purpose of determining Lease Expirations and Debt Investment Maturities. Completion Date - Development/Redevelopment For Developments, management’s estimate of the period the core and shell structure improvements are expected to be or have been completed. For Redevelopments, management’s estimate of the period in which major construction activity in relation to the scope of the project has been or will be substantially completed and excludes the completion of tenant improvements. Consolidated Debt The carrying amount of bank line of credit, commercial paper, term loans, senior unsecured notes, and mortgage debt, as reported in our consolidated financial statements. Consolidated Gross Assets* The carrying amount of total assets, excluding investments in and advances to our unconsolidated JVs, after adding back accumulated depreciation and amortization, as reported in our consolidated financial statements. Consolidated Gross Assets is a supplemental measure of our financial position, which, when used in conjunction with debt-related measures, enables both management and investors to analyze our leverage and to compare our leverage to that of other companies. Consolidated Secured Debt Mortgage and other debt secured by real estate, as reported in our consolidated financial statements. Continuing Care Retirement Community (“CCRC”) A senior housing facility which provides at least three levels of care (i.e., independent living, assisted living and skilled nursing). Debt Investments Loans secured by a direct interest in real estate and mezzanine loans. Development Includes ground-up construction. Newly completed developments, are considered Stabilized at the earlier of lease-up (typically when the tenant(s) controls the physical use of 80% of the space) or 24 months from the date the property is placed in service. Direct Financing Lease (“DFL”) Lease for which future minimum lease payments are recorded as a receivable and the difference between the future minimum lease payments and the estimated residual values less the cost of the properties is recorded as unearned income. Unearned income is deferred and amortized to income over the lease terms to provide a constant yield. EBITDAre and Adjusted EBITDAre* EBITDAre, or EBITDA for Real Estate, is a supplemental performance measure defined by the National Association of Real Estate Investment Trusts (“Nareit”) and intended for real estate companies. It represents earnings before interest expense, income taxes, depreciation and amortization, gains or losses from sales of depreciable property (including gains or losses on change in control), and impairment charges (recoveries) related to depreciable property. Adjusted EBITDAre is defined as EBITDAre excluding other impairments (recoveries) and other losses (gains), transaction and merger-related items, prepayment costs (benefits) associated with early retirement or payment of debt, restructuring and severance-related charges, litigation costs (recoveries), casualty-related charges (recoveries), stock-based compensation amortization expense, and foreign currency remeasurement losses (gains), adjusted to reflect the impact of transactions that closed during the period as if the transactions were completed at the beginning of the period. EBITDAre and Adjusted EBITDAre include our pro rata share of our unconsolidated JVs presented on the same basis. Enterprise Debt* Consolidated Debt plus our pro rata share of total debt from our unconsolidated JVs. Enterprise Debt is a supplemental measure of our financial position, which enables both management and investors to analyze our leverage and to compare our leverage to that of other companies. Our pro rata share of total debt from our unconsolidated JVs is not intended to reflect our actual liability or ability to access assets should there be a default under any or all such loans or a liquidation of the JVs. Enterprise Gross Assets* Consolidated Gross Assets plus our pro rata share of total gross assets from our unconsolidated JVs, after adding back accumulated depreciation and amortization. Enterprise Gross Assets is a supplemental measure of our financial position, which, when used in conjunction with debt-related measures, enables both management and investors to analyze our leverage and to compare our leverage to that of other companies. Enterprise Secured Debt* Consolidated Secured Debt plus our pro rata share of mortgage debt from our unconsolidated JVs. Enterprise Secured Debt is a supplemental measure of our financial position, which enables both management and investors to analyze our leverage and to compare our leverage to that of other companies. Our pro rata share of Enterprise Secured Debt from our unconsolidated JVs is not intended to reflect our actual liability or ability to access assets should there be a default under any or all such loans or a liquidation of the JVs. Entrance Fees Certain of our CCRC communities have residency agreements which require the resident to pay an upfront entrance fee prior to taking occupancy at the community. For net income, NOI, Adjusted NOI, Nareit FFO, FFO as Adjusted, and AFFO, the non-refundable portion of the entrance fee is recorded as deferred entrance fee revenue and amortized over the estimated stay of the resident based on an actuarial valuation. The refundable portion of a resident’s entrance fee is generally refundable within a certain number of months or days following contract termination or upon the sale of the unit. All refundable amounts due to residents at any time in the future are classified as liabilities.

Return to TOC 42 Glossary Net Operating Income (“NOI”) and Cash (Adjusted) NOI* NOI is defined as real estate revenues (inclusive of rental and related revenues, resident fees and services, income from direct financing leases, and government grant income and exclusive of interest income), less property level operating expenses; NOI excludes all other financial statement amounts included in net income (loss). Cash (Adjusted) NOI is calculated as NOI after eliminating the effects of straight-line rents, DFL non-cash interest, amortization of market lease intangibles, termination fees, actuarial reserves for insurance claims that have been incurred but not reported, and the impact of deferred community fee income and expense. NOI and Cash (Adjusted) NOI include the Company's pro rata share of NOI and Cash (Adjusted) NOI from its unconsolidated JVs and exclude noncontrolling interests’ pro rata share of NOI and Cash (Adjusted) NOI from consolidated joint ventures. See the "Net Operating Income ("NOI") and Cash (Adjusted) NOI" definition included in the accompanying Discussion and Reconciliation of Non-GAAP Financial Measures for further information regarding the impact of the Company's pro rata share on these measures. Occupancy For lab buildings and outpatient medical buildings, Occupancy represents rentable square feet where leases have commenced (certificate of occupancy received), including month-to-month leases, as of the end of the period reported divided by total rentable square feet. For senior housing facilities, Occupancy represents the facilities’ average operating Occupancy for the most recent calendar quarter (year-to-date for year-to-date SS) available based on units. The percentages shown are weighted to reflect our share and exclude facilities that are currently in Development, vacant square feet under lease-up in newly completed or recently redeveloped facilities, senior housing facilities acquired during the relevant period where a full calendar quarter is not available, and facilities held for sale. Senior housing occupancy was derived solely from information provided by operators without independent verification by us. Portfolio Adjusted NOI* Portfolio Adjusted NOI is Portfolio Cash Real Estate Revenues less Portfolio Cash Operating Expenses. Portfolio Operating Expenses and Portfolio Cash Operating Expenses* Portfolio Operating Expenses and Portfolio Cash Operating Expenses are non-GAAP supplemental measures. Portfolio Operating Expenses represent property level operating expenses (which exclude transition costs). Portfolio Operating Expenses include consolidated operating expenses plus the Company's pro rata share of operating expenses from its unconsolidated JVs less noncontrolling interests' pro rata share of operating expenses from consolidated JVs. Portfolio Cash Operating Expenses represent Portfolio Operating Expenses after eliminating the effects of straight-line rents, lease termination fees, actuarial reserves for insurance claims that have been incurred but not reported, and the impact of deferred community fee expense. Portfolio Income* Cash (Adjusted) NOI plus interest income plus our pro rata share of Cash (Adjusted) NOI from our unconsolidated JVs less noncontrolling interests' pro rata share of Cash (Adjusted) NOI from consolidated JVs. Management believes that Portfolio Income is an important supplemental measure because it provides relevant and useful information regarding our performance; specifically, it is a measure of our property level profitability of the Company inclusive of interest income. Management believes that net income (loss) is the most directly comparable GAAP measure to Portfolio Income. Portfolio Income should not be viewed as an alternative measure of operating performance to net income (loss) as defined by GAAP since it does not reflect various excluded items. Financial Leverage* Enterprise Debt divided by Enterprise Gross Assets. Financial Leverage is a supplemental measure of our financial position, which enables both management and investors to analyze our leverage and to compare our leverage to that of other companies. Fixed Charges* Total interest expense plus capitalized interest plus preferred stock dividends (if applicable). Fixed Charges also includes our pro rata share of the interest expense plus capitalized interest plus preferred stock dividends (if applicable) of our unconsolidated JVs. Fixed Charges is a supplemental measure of our interest payments on outstanding debt and dividends to preferred stockholders for purposes of presenting Fixed Charge Coverage and Adjusted Fixed Charge Coverage. Fixed Charges is subject to limitations and qualifications, as, among other things, it does not include all contractual obligations. Funds From Operations (“Nareit FFO”) and FFO as Adjusted* See the “Funds From Operations” definition included in the accompanying Discussion and Reconciliations of Non-GAAP Financial Measures for information regarding Nareit FFO and FFO as Adjusted. Healthcare Affiliated Represents properties that are on-campus or adjacent to a healthcare system and properties that are leased 1/3 or more to a health system or physician group. Initial Capital Expenditures (“ICE”) Expenditures required to bring a newly acquired property up to standard. The expenditures are typically identified during underwriting and incurred within the first year of ownership. Investment and Portfolio Investment* Represents: (i) the carrying amount of real estate assets and intangibles, after adding back accumulated depreciation and amortization and (ii) the carrying amount of DFLs and Debt Investments. Portfolio Investment also includes our pro rata share of the real estate assets and intangibles held in our unconsolidated JVs, presented on the same basis as Investment, and excludes noncontrolling interests' pro rata share of the real estate assets and intangibles held in our consolidated JVs, presented on the same basis. Investment and Portfolio Investment exclude land held for development. Metropolitan Statistical Areas (“MSA”) Metropolitan Statistical Areas are geographic entities delineated by the Office of Management and Budget for use by Federal Statistical agencies in collecting, tabulating, and publishing Federal statistics. A metro area contains a core urban area of 50,000 or more population, consists of one or more counties and includes the counties containing the core urban area, as well as any adjacent counties that have a high degree of social and economic integration (as measured by commuting to work) with the urban core. Net Debt* Enterprise Debt less the carrying amount of cash and cash equivalents, restricted cash, and expected net proceeds from the future settlement of shares issued through our equity forward contracts, as reported in our consolidated financial statements and our pro rata share of cash and cash equivalents and restricted cash from our unconsolidated JVs. Net Debt is a supplemental measure of our financial position, which enables both management and investors to analyze our leverage and to compare our leverage to that of other companies. Net Debt to Adjusted EBITDAre* Net Debt divided by Adjusted EBITDAre is a supplemental measure of our ability to decrease our debt. Because we may not be able to use our cash to reduce our debt on a dollar-for-dollar basis, this measure may have material limitations.

Return to TOC 43 Glossary Portfolio Real Estate Revenues* and Portfolio Cash Real Estate Revenues* Portfolio Real Estate Revenues and Portfolio Cash Real Estate Revenues are non-GAAP supplemental measures. Portfolio Real Estate Revenues include rental related revenues, resident fees and services, income from DFLs, and government grant income which is included in Other income (expense), net in our Consolidated Statement of Operations. Portfolio Real Estate Revenues include the Company's pro rata share from unconsolidated JVs presented on the same basis and exclude noncontrolling interests' pro rata share from consolidated JVs presented on the same basis. Portfolio Cash Real Estate Revenues include Portfolio Real Estate Revenues after eliminating the effects of straight-line rents, DFL non-cash interest, amortization of market lease intangibles, lease termination fees, and the impact of deferred community fee income. Projected Stabilized Yield Projected Cash (Adjusted) NOI at Stabilization divided by the expected total development costs. Redevelopment Properties that incur major capital expenditures to significantly improve, change the use, or reposition the property pursuant to a formal redevelopment plan. Newly completed redevelopments, are considered Stabilized at the earlier of lease-up (typically when the tenant(s) controls the physical use of 80% of the space) or 24 months from the date the property is placed in service. Retention Rate The ratio of total renewed square feet to the total square feet expiring and available for lease, excluding the square feet for tenant leases terminated for default or buy-out prior to the expiration of the lease and leases in assets designated as Held for Sale. REVPOR* The 3-month average Cash Real Estate Revenues per occupied unit for the most recent period available. REVPOR excludes newly completed assets under lease-up, assets sold, acquired or converted to a new operating structure during the relevant period, assets in redevelopment, assets that are held for sale, and assets that experienced a casualty event that significantly impacted operations. REVPOR cannot be derived from the information presented for the Other portfolio as units reflect 100% of the unit capacities for unconsolidated JVs and revenue is at the Company's pro rata share. All facility occupancy data was derived solely from information provided by operators without independent verification by us. REVPOR relates to our Other non-reportable segment. REVPOR CCRC* The 3-month average Cash Real Estate Revenues per occupied unit excluding Cash NREFs for the most recent period available. REVPOR CCRC excludes newly completed assets under lease-up, assets sold, or acquired during the relevant period, assets in redevelopment, assets that are held for sale, and assets that experienced a casualty event that significantly impacted operations. All facility occupancy data was derived solely from information provided by operators without independent verification by us. RIDEA A structure whereby a taxable REIT subsidiary is permitted to rent a healthcare facility from its parent REIT and hire an independent contractor to operate the facility. Same-Store (“SS”)* Same-Store NOI and Cash (Adjusted) NOI information allows us to evaluate the performance of our property portfolio under a consistent population by eliminating changes in the composition of our portfolio of properties, excluding properties within the other non-reportable segments. We include properties from our consolidated portfolio, as well as properties owned by our unconsolidated joint ventures in Same-Store NOI and Adjusted NOI (see NOI definition above for further discussion regarding our use of pro-rata share information and its limitations). Same-Store NOI and Adjusted NOI exclude government grant income under the CARES Act. Same-Store Adjusted NOI also excludes amortization of deferred revenue from tenant-funded improvements and certain non-property specific operating expenses that are allocated to each operating segment on a consolidated basis. Properties are included in Same-Store once they are stabilized for the full period in both comparison periods. Newly acquired operating assets are generally considered stabilized at the earlier of lease-up (typically when the tenant(s) control(s) the physical use of at least 80% of the space and rental payments have commenced) or 12 months from the acquisition date. Newly completed developments and redevelopments are considered stabilized at the earlier of lease-up or 24 months from the date the property is placed in service. Properties that experience a change in reporting structure are considered stabilized after 12 months in operations under a consistent reporting structure. A property is removed from Same-Store when it is classified as held for sale, sold, placed into redevelopment, experiences a casualty event that significantly impacts operations, a change in reporting structure or operator transition has been agreed to, or a significant tenant relocates from a Same-Store property to a non Same-Store property and that change results in a corresponding increase in revenue. We do not report Same-Store metrics for our other non-reportable segments. Secured Debt Ratio* Enterprise Secured Debt divided by Enterprise Gross Assets. Secured Debt Ratio is a supplemental measure of our financial position, which enables both management and investors to analyze our leverage and to compare our leverage to that of other companies. Share of Consolidated Joint Ventures ("JVs") Noncontrolling interests' pro rata share information is prepared by applying noncontrolling interests' actual ownership percentage for the period and is intended to reflect noncontrolling interests' proportionate economic interest in the financial position and operating results of properties in our portfolio. Share of Unconsolidated Joint Ventures Our pro rata share information is prepared by applying our actual ownership percentage for the period and is intended to reflect our proportionate economic interest in the financial position and operating results of properties in our portfolio. Stabilized / Stabilization Newly acquired operating assets are generally considered Stabilized at the earlier of lease-up (typically when the tenant(s) control(s) the physical use of at least 80% of the space and rental payments have commenced) or 12 months from the acquisition date. Newly completed developments and redevelopments are considered Stabilized at the earlier of lease-up or 24 months from the date the property is placed in service. Properties that experience a change in reporting structure are considered Stabilized after 12 months in operations under a consistent reporting structure. Total Market Equity The total number of outstanding shares of our common stock multiplied by the closing price per share of our common stock on the New York Stock Exchange as of period end, plus the total number of convertible partnership units multiplied by the closing price per share of our common stock on the New York Stock Exchange as of period end (adjusted for stock splits). Units/Square Feet/Capacity Senior housing facilities are measured in available units (e.g., studio, one or two bedroom units). Lab buildings and outpatient medical buildings are measured in square feet, excluding square footage for development or square footage removed from service for redevelopment properties prior to completion. * Non-GAAP Supplemental Measures Capacities are presented at 100% ownership share. Reconciliations, definitions, and important discussions regarding the usefulness and limitations of the Non-GAAP Financial Measures used in this report can be found at https://ir.healthpeak.com/quarterly-results.

44 Return to TOC (1) This amount includes the corresponding line on the Funds from Operations reconciliation of this Earnings Release and Supplemental Report excluding the related tax impact included in the adjustment for income tax expense (benefit) above. (2) Adjustment reflects the impact of transactions that closed during the period as if the transactions were completed at the beginning of the period. Debt Ratios Adjusted EBITDAre and Adjusted Fixed Charge Coverage Dollars in thousands NET INCOME TO ADJUSTED EBITDAre Three Months Ended December 31, 2023 Twelve Months Ended December 31, 2023 Net income (loss) $ 75,395 $ 334,757 Interest expense 52,784 200,331 Income tax expense (benefit) (11,842) (9,617) Depreciation and amortization 188,544 749,901 Other depreciation and amortization 1,168 6,269 Loss (gain) on sales of real estate — (86,463) Loss (gain) upon change of control — (234) Share of unconsolidated JV: Interest expense 834 1,987 Income tax expense (benefit) 150 648 Depreciation and amortization 6,723 24,800 EBITDAre $ 313,756 $ 1,222,379 Transaction and merger-related items(1) 11,202 14,300 Other impairments (recoveries) and other losses (gains)(1) (5,445) (4,539) Restructuring and severance-related charges — 1,368 Casualty-related charges (recoveries)(1) (3,462) (4,214) Stock-based compensation amortization expense 3,513 14,480 Impact of transactions closed during the period(2) 52 (3,927) Adjusted EBITDAre $ 319,616 $ 1,239,847 ADJUSTED FIXED CHARGE COVERAGE Interest expense, including unconsolidated JV interest expense at share 53,618 202,318 Capitalized interest, including unconsolidated JV capitalized interest at share 14,436 58,494 Fixed Charges $ 68,054 $ 260,812 Adjusted Fixed Charge Coverage 4.7x 4.8x

45 Return to TOC Debt Ratios As of and for the quarter ended December 31, 2023, dollars in thousands (1) For the three months ended, represents the current quarter Adjusted EBITDAre multiplied by a factor of four. For the twelve months ended, represents trailing twelve months Adjusted EBITDAre. FINANCIAL LEVERAGE December 31, 2023 Enterprise Debt $ 6,916,205 Enterprise Gross Assets 19,959,484 Financial Leverage 34.7% SECURED DEBT RATIO December 31, 2023 Enterprise Secured Debt $ 296,003 Enterprise Gross Assets 19,959,484 Secured Debt Ratio 1.5% NET DEBT TO ADJUSTED EBITDAre Three Months Ended December 31, 2023 Twelve Months Ended December 31, 2023 Net Debt $ 6,709,917 $ 6,709,917 Annualized Adjusted EBITDAre(1) 1,278,464 1,239,847 Net Debt to Adjusted EBITDAre 5.2x 5.4x

Return to TOC 46 COMPANY Information BOARD OF DIRECTORS KATHERINE M. SANDSTROM Chair of the Board, Healthpeak Properties, Inc. Former Senior Managing Director, Heitman LLC SCOTT M. BRINKER President and Chief Executive Officer, Healthpeak Properties, Inc. BRIAN G. CARTWRIGHT Former General Counsel, U.S. Securities and Exchange Commission JAMES B. CONNOR Former Chairman and Chief Executive Officer, Duke Realty Corporation EXECUTIVE MANAGEMENT SCOTT M. BRINKER President Chief Executive Officer PETER A. SCOTT Chief Financial Officer THOMAS M. KLARITCH Chief Operating Officer JEFFREY H. MILLER General Counsel CHRISTINE N. GARVEY Former Global Head of Corporate Real Estate Services, Deutsche Bank AG R. KENT GRIFFIN, JR. Managing Director, PHICAS Investors Former President, BioMed Realty Trust, Inc. DAVID B. HENRY Former Vice Chairman and Chief Executive Officer, Kimco Realty Corporation SARA GROOTWASSINK LEWIS Founder and Chief Executive Officer, Lewis Corporate Advisors, LLC SCOTT R. BOHN Chief Development Officer Head of Lab ADAM G. MABRY Chief Investment Officer SHAWN G. JOHNSTON Executive Vice President Chief Accounting Officer LISA A. ALONSO Executive Vice President Chief Human Resources Officer ANKIT B. PATADIA Executive Vice President Treasurer, Corporate Finance

Return to TOC 47 Forward-Looking Statements & Risk Factors Statements contained in this supplemental report that are not historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, among other things, statements regarding our and our officers’ intent, belief or expectation as identified by the use of words such as “may,” “will,” “project,” “expect,” “believe,” “intend,” “anticipate,” “seek,” “target,” “forecast,” “plan,” “potential,” “estimate,” “could,” “would,” “should” and other comparable and derivative terms or the negatives thereof. Examples of forward-looking statements include, among other things: (i) statements regarding timing, outcomes and other details relating to current, pending or contemplated acquisitions, dispositions, transitions, developments, redevelopments, densifications, joint venture transactions, leasing activity and commitments, financing activities, or other transactions; and (ii) the information presented in the section titled "2024 Outlook Information." Pending acquisitions, dispositions, joint venture transactions, leasing activity, and financing activity, including those subject to binding agreements, remain subject to closing conditions and may not be completed within the anticipated timeframes or at all. Forward-looking statements reflect our current expectations and views about future events and are subject to risks and uncertainties that could significantly affect our future financial condition and results of operations. While forward-looking statements reflect our good faith belief and assumptions we believe to be reasonable based upon current information, we can give no assurance that our expectations or forecasts will be attained. Further, we cannot guarantee the accuracy of any such forward-looking statement contained in this supplemental report, and such forward-looking statements are subject to known and unknown risks and uncertainties that are difficult to predict. These risks and uncertainties include, but are not limited to: macroeconomic trends, including inflation, interest rates, labor costs, and unemployment; risks associated with the proposed merger transactions with Physicians Realty Trust (the “Mergers”), including, but not limited to, our ability to consummate the Mergers on the proposed terms or on the anticipated timeline, or at all, potential loss or disruption of current and prospective commercial relationships due to the uncertainties about the Mergers, and the outcome of legal proceedings instituted against us, our Board of Directors, and others related to the Mergers; our ability to integrate the operations of the Company and Physicians Realty Trust successfully and realize the anticipated synergies and other benefits of the Mergers or do so within the anticipated time frame; changes within the industries in which we operate; significant regulation, funding requirements, and uncertainty faced by our lab tenants; factors adversely affecting our tenants’, operators’, or borrowers’ ability to meet their financial and other contractual obligations to us; the insolvency or bankruptcy of one or more of our major tenants, operators, or borrowers; our concentration of real estate investments in the healthcare property sector, which makes us more vulnerable to a downturn in a specific sector than if we invested across multiple sectors; the illiquidity of real estate investments; our ability to identify and secure new or replacement tenants and operators; our property development, redevelopment, and tenant improvement risks, including project abandonments, project delays, and lower profits than expected; the ability of the hospitals on whose campuses our outpatient medical buildings are located and their affiliated healthcare systems to remain competitive or financially viable; our ability to develop, maintain, or expand hospital and health system client relationships; operational risks associated with third party management contracts, including the additional regulation and liabilities of our properties operated through RIDEA structures; economic conditions, natural disasters, weather, and other conditions that negatively affect geographic areas where we have concentrated investments; uninsured or underinsured losses, which could result in significant losses and/or performance declines by us or our tenants and operators; our investments in joint ventures and unconsolidated entities, including our lack of sole decision making authority and our reliance on our partners’ financial condition and continued cooperation; our use of fixed rent escalators, contingent rent provisions, and/ or rent escalators based on the Consumer Price Index; competition for suitable healthcare properties to grow our investment portfolio; our ability to foreclose or exercise rights on collateral securing our real estate-related loans; any requirement that we recognize reserves, allowances, credit losses, or impairment charges; investment of substantial resources and time in transactions that are not consummated; our ability to successfully integrate or operate acquisitions; the potential impact on us and our tenants, operators, and borrowers from litigation matters, including rising liability and insurance costs; environmental compliance costs and liabilities associated with our real estate investments; ESG and sustainability commitments and requirements, as well as stakeholder expectations; epidemics, pandemics, or other infectious diseases, including Covid, and health and safety measures intended to reduce their spread; human capital risks, including the loss or limited availability of our key personnel; our reliance on information technology systems and the possibility of a cybersecurity incident or cybersecurity threat affect our information systems or the information systems of our tenants, operators or borrowers; volatility, disruption, or uncertainty in the financial markets; increased borrowing costs, including due to rising interest rates; Continued 101 CambridgePark Drive Boston, MA 47 Return to TOC

Return to TOC 48 cash available for distribution to stockholders and our ability to make dividend distributions at expected levels; the availability of external capital on acceptable terms or at all, including due to rising interest rates, changes in our credit ratings and the value of our common stock, bank failures or other events affecting financial institutions; our ability to manage our indebtedness level and covenants in and changes to the terms of such indebtedness; the failure of our tenants, operators, and borrowers to comply with federal, state, and local laws and regulations, including resident health and safety requirements, as well as licensure, certification, and inspection requirements; required regulatory approvals to transfer our senior housing properties; compliance with the Americans with Disabilities Act and fire, safety, and other regulations; laws or regulations prohibiting eviction of our tenants; the requirements of, or changes to, governmental reimbursement programs such as Medicare or Medicaid; legislation to address federal government operations and administrative decisions affecting the Centers for Medicare and Medicaid Services; our participation in the CARES Act Provider Relief Fund and other Covid-related stimulus and relief programs; our ability to maintain our qualification as a REIT; our taxable REIT subsidiaries being subject to corporate level tax; tax imposed on any net income from “prohibited transactions”; changes to U.S. federal income tax laws, and potential deferred and contingent tax liabilities from corporate acquisitions; calculating non-REIT tax earnings and profits distributions; ownership limits in our charter that restrict ownership in our stock; provisions of Maryland law and our charter that could prevent a transaction that may otherwise be in the interest of our stockholders; conflicts of interest between the interests of our stockholders and the interests of holders of Healthpeak OP common units; provisions in the operating agreement of Healthpeak OP and other agreements that may delay or prevent unsolicited acquisitions and other transactions; our status as a holding company of Healthpeak OP; and other risks and uncertainties described from time to time in our Securities and Exchange Commission (SEC) filings. Except as required by law, we do not undertake, and hereby disclaim, any obligation to update any forward-looking statements, which speak only as of the date on which they are made. The information in this supplemental report should be read in conjunction with our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other information filed with the SEC. The Reporting Definitions (and Reconciliations of Non-GAAP Financial Measures) are an integral part of the information presented herein. You can access these documents on our website, www.healthpeak.com, free of charge, as well as amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act, as soon as reasonably practicable after such material is electronically filed with, or furnished to, the SEC. The information contained on our website is not incorporated by reference into, and should not be considered a part of, this supplemental report. In addition, the SEC maintains a website that contains reports, proxy and information statements, and other information regarding issuers, including the Company, that file electronically with the SEC at www.sec.gov. This supplemental report also includes market and industry data that the Company has obtained from market research, publicly available information and industry publications. The accuracy and completeness of such information are not guaranteed. The market and industry data is often based on industry surveys and preparers’ experience in the industry. Similarly, although the Company believes that the surveys and market research that others have performed are reliable, such surveys and market research are subject to assumptions, estimates and other uncertainties and the Company has not independently verified this information. Continued Forward-Looking Statements & Risk Factors (continued) Callan Ridge San Diego, CA 48 Return to TOC

Return to TOC 49 Callan Ridge San Diego, CA Cambridge Park Boston, MA ADDITIONAL INFORMATION AND WHERE TO FIND IT In connection with the proposed transaction, on December 15, 2023, Healthpeak and Physicians Realty Trust filed with the SEC a registration statement on Form S-4 containing a joint proxy statement/prospectus and other documents regarding the proposed transaction. The joint proxy statement/prospectus contains important information about the proposed transaction and related matters. The Form S-4 was declared effective, and each of Healthpeak and Physicians Realty Trust commenced mailing of the joint proxy statement/prospectus included as part of the Form S-4, on January 11, 2024. STOCKHOLDERS ARE URGED AND ADVISED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS (INCLUDING ALL AMENDMENTS AND SUPPLEMENTS THERETO) AND OTHER RELEVANT DOCUMENTS FILED WITH THE SEC CAREFULLY BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT HEALTHPEAK, PHYSICIANS REALTY TRUST AND THE PROPOSED TRANSACTION. Investors and security holders of Healthpeak and Physicians Realty Trust are able to obtain free copies of the registration statement, the joint proxy statement/prospectus and other relevant documents filed by Healthpeak and Physicians Realty Trust with the SEC through the website maintained by the SEC at www.sec.gov. Copies of the documents filed by Healthpeak with the SEC are also available on Healthpeak’s website at www.healthpeak.com, and copies of the documents filed by Physicians Realty Trust with the SEC are available on Physicians Realty Trust’s website at www.docreit.com. PARTICIPANTS IN THE SOLICITATION Healthpeak, Physicians Realty Trust and their respective directors, trustees and executive officers may be deemed to be participants in the solicitation of proxies from Healthpeak’s stockholders and Physicians Realty Trust’s shareholders in respect of the proposed transaction. Information regarding Healthpeak’s directors and executive officers can be found in Healthpeak’s definitive proxy statement filed with the SEC on March 17, 2023. Information regarding Physicians Realty Trust’s trustees and executive officers can be found in Physicians Realty Trust’s definitive proxy statement filed with the SEC on March 23, 2023. Additional information regarding the interests of such potential participants is included in the joint proxy statement/prospectus and other relevant documents filed with the SEC in connection with the proposed transaction. These documents are available on the SEC’s website and from Healthpeak and Physicians Realty Trust, as applicable, using the sources indicated above. NO OFFER OR SOLICITATION This communication is for informational purposes only and is neither an offer to purchase, nor a solicitation of an offer to sell, any securities or the solicitation of any vote in any jurisdiction pursuant to the proposed transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended. For more information, contact Andrew Johns, Senior Vice President - Investor Relations, at (720) 428-5050. Forward-Looking Statements & Risk Factors (concluded)

healthpeak.com ________________________________________________________ Irvine, CA 1920 Main Street, Suite 1200 Irvine, CA 92614 _______________________________________________________ Nashville, TN 3000 Meridian Boulevard, Suite 200 Franklin, TN 37067 _________________________________________________________ Corporate HQ, Denver, CO 4600 South Syracuse Street, Suite 500 Denver, CO 80237 (720) 428 - 5050 _________________________________________________________ South San Francisco, CA 101 Oyster Point Boulevard, Suite 102 South San Francisco, CA 94080 ________________________________________________________ San Diego, CA 420 Stevens Avenue, Suite 170 Solana Beach, CA 92075 ________________________________________________________ Boston, MA 68 Moulton Street, Suite 200 Cambridge, MA 02138